Point-of-care testing for HIV and TB integration of services by Gous, Natasha
I | P a g e
POINT-OF-CARE TESTING FOR 
HIV AND TB INTEGRATION OF 
SERVICES 
Natasha Gous 
A thesis submitted to the Faculty of Health Sciences, university of the 
Witwatersrand, Johannesburg, in fulfilment of the requirements for the 
Degree of 
Doctor of Philosophy 
Johannesburg, 2015 
II | P a g e
DECLARATION 
I, Natasha Myrna Gous declare that this thesis is my own work. It is being submitted for the 
Degree, Doctor of Philosophy in the University of the Witwatersrand, Johannesburg. It has 
not been submitted before for any degree or examination at this or any other university. 
___________________________________________ 
______ day of __________________________, 2015 
III | P a g e
DEDICATION 
This work is dedicated to my parents, Myrna and Elmar Gous for your endless love, 
support and patience. 
“Our mission is to build a better world. To leave no one behind. To stand for the poorest 
and the most vulnerable in the name of global peace and social injustice.’ 
Ban Ki-Moon 
United Nations Secretary-General 
IV | P a g e
ABSTRACT 
The United Nations Programme on HIV/AIDS (UNAIDS) have recently released 
challenging new Human Immunodeficiency Virus (HIV) treatment targets to be achieved 
globally by 2020; all of which require concentrated efforts in scaling up laboratory testing 
capacity for HIV diagnosis, treatment initiation and treatment monitoring. The Global 
Tuberculosis (TB) Strategy have also put forth a list of ambitious goals which include 
reducing the number of deaths due to TB by 95% and the number of new TB cases by 
90%. 
In South Africa, which has the highest national prevalence of HIV described globally and 
ranks fifth in the world in terms of TB incident cases, further integration of HIV and TB 
services will be needed to achieve these targets. A major challenge to successful 
integration of these programs however, will be the ability to diagnose and monitor the 
progress of both infections, a process that in South Africa, is hampered by lack of access 
to laboratory testing. Although public pathology laboratory service providers, such as the 
National Health Laboratory Service (NHLS), are responding to increasing testing 
demands by scaling up centralised laboratory capacity, limitations such as the need for 
expertise, infrastructure, space, cold-chain, maintenance, logistics and cost, are 
challenging full implementation and scale up. 
Many international organisations believe that one of the ways to successfully achieve the 
global HIV ‘90-90-90’ and TB targets, will be through the development and scaling up of 
innovative, simpler and more affordable technology approaches such as Point-of-Care 
testing (POCT), a view shared by the South African National Department of Health 
(NDoH). POCT refers to testing that is performed near or at the site of the patient with the 
result leading to a possible or immediate change in patient management or outcome and 
holds promise as a strategy to extend laboratory testing capacity. Prior to large-scale POC 
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implementation efforts can begin, defining the difficulties and potential solutions which are 
likely to arise, particularly in high disease burden clinical settings need to be addressed.   
The main objective of this study was to investigate the feasibility, performance and 
operational considerations of multidisciplinary POCT in South Africa, including the 
development of a best practice framework to guide implementation efforts. This was 
achieved by performing a clinical needs assessment and engaging with government, 
evaluating POC technologies for HIV and TB diagnosis and/or monitoring and developing 
a framework for how to implement POCT in the field including quality, site and training 
requirements. The operational requirements for healthcare workers to perform multiple 
POCT in the South African clinical setting, was also determined. The assays required 
were based on the South African National Treatment guidelines in the period of review 
(2011-2014). 
In July 2013, the South African NDoH called a meeting with various stakeholders to 
provide the context for POCT in South Africa and strong emphasis was placed on HIV and 
TB and how POCT could expand on existing laboratory infrastructure for these diseases. 
Outcomes from this meeting prompted a thorough literature review on the challenges 
likely to be faced by large-scale POC implementation efforts.  
One of the key issues highlighted was the lack of evaluation data on numerous HIV and 
TB POC technologies available and/or in the pipeline. Even though viral load (VL) testing 
has been available in South Africa since 2004,  the global treatment guidelines (World 
Health Organization) now recommend a VL test for HIV antiretroviral treatment (ART) 
monitoring and there are talks around the possibilities of a ‘test and treat’ strategy. In light 
of this, two potential POC plasma-based VL technologies available at the time were 
evaluated in the laboratory. The Liat™ HIV-1 Plasma Quant (IQuum Inc, MA, USA; now 
Roche Molecular, Branchburg, MJ, USA) and the Xpert® HIV-1 VL (Cepheid, Sunnyvale, 
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CA) assays both demonstrated good performance and were proven to be interchangeable 
with existing in-country high-throughput VL laboratory platforms. Both however, require 
centrifugation to obtain the plasma sample and thus may be more suited to a district level 
facility as opposed to a ‘true’ POC environment. In light of these operational challenges, 
two further blood-based POC VL platforms were also evaluated, the Liat™ HIV-1 Blood 
Quant VL assay (IQuum, Inc) and the Alere™ q HIV-1/2 assay (Alere Technologies 
GmbH, Jena, Germany).  Both assays identified more patients as treatment failures at the 
1000 copies/ml treatment failure threshold (WHO and South African treatment guideline 
recommended threshold) compared to plasma VL, due to their total nucleic acid extraction 
protocols. Thus, if either were implemented at POC, one could expect a significant upward 
misclassification, increasing the number of HIV-positive patients requiring follow up VL 
testing and programmatic costs. Application therefore, could be niched VL testing; utilising 
a blood-based POC VL assay in maternity wards to diagnose HIV in new-borns; plasma-
based POCT for mothers to reduce risk of transmission.  
POCT may not be the only solution to increasing access to laboratory testing services, 
and thus alternative strategies for improving access were also investigated. Dried blood 
spots (DBS) and PrimeStore media (a sample transport media; Longhorn Vaccines and 
Diagnostics, San Antonio, TX, USA) were shown to be as valuable as plasma VL for 
detecting HIV-positive patients failing ART at the 1000 copies/ml threshold and both solve 
logistical issues around sample transport and maintaining sample integrity for centralized 
testing.   
For TB diagnosis, the Xpert® MTB/RIF assay (Cepheid, Sunnyvale, CA) was evaluated to 
determine its appropriate placement within the South African setting. Although Xpert® 
MTB/RIF proved superior in performance to smear microscopy, it was originally modelled 
as too costly for POC placement in South Africa and was implemented into smear 
microscopy centres nationally. Subsequently, the complexity of the analyser maintenance 
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and power issues has reinforced the original decision. Further potential POC TB 
technologies are in the development pipeline, but only one other was available for 
evaluation, namely the EasyNAT® detection kit (Ustar Biotechnologies, Hangzou, China). 
Initial laboratory evaluation results look promising but the technology is still a long way 
from clinical evaluation due to its laborious procedure.  
A further challenge identified for POCT is the lack of documented implementation science 
to ensure quality-assured multi-disciplinary POCT in the field. To address this, three key 
components of a quality testing framework were developed to ensure best practice for 
POCT; a clinic site readiness assessment tool, a POC training module and a quality 
monitoring program. The clinic site assessment checklist was developed to determine site 
readiness for POC placement. The POC training module included standard operating 
procedures, quick reference and workflow charts and a practical training component which 
was developed specifically with the non-laboratory trained user in mind. Both these 
components have been adopted and modified for use by the NHLS National Priority 
Program (NPP). 
Certain POC assays already have External Quality Assessment (EQA) material, while 
others had to be developed. For quality management of HIV VL technologies, a 
standardized plasma panel was developed to ensure molecular VL platforms are ‘fit-for-
purpose’ (verification, a requirement of the laboratory accreditation process). This panel, 
termed SAVQA, is being manufactured and supplied to aid POC assay developers in 
assessing their product for the South African market, and will also be further developed for 
use by healthcare workers at POC.  
Due to the hurdles encountered with the biosafety regulations for transporting TB external 
quality assessment (EQA) material, a quality assessment program using dried culture 
spots (DCS) was also developed for TB diagnostic technologies consisting of two 
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components; a verification and an EQA program. The DCS technology has become a 
global product and as of 2015 is being supplied to 20 different countries. DCS were 
successfully shown to be suitable for use at POC by non-laboratory trained staff. The 
versatility of the material has been confirmed by its expansion to other molecular TB 
diagnostic tests, most notably the Hain Genotype MTBDrplus assay for TB drug 
susceptibility testing (Hain LifeScience GmbH, Nehren, Germany). This work has been 
acknowledged through the Research and Development team involved in the development 
of the DCS program, winning three awards: the NHLS Top Award for Innovation 2013, the 
Gauteng Accelerator Program (GAP) Biosciences Award in 2014 and a special Social 
Impact award for Africa Innovations held in Morocco in 2015. 
Incorporating the quality components developed above, a clinical evaluation of nurse 
operated multidisciplinary POCT was performed. Although multiple POCT could be 
performed as accurately as laboratory testing on venepuncture specimens, it required 
dedicated staff and dramatically increased POC staff duties. It was further shown that 
multiple POCT could be accurately performed by a nurse on a single finger slice in order 
to obtain adequate blood volume to perform up to four POC tests, and that finger stick VL 
testing was also feasible by nurses at POC. Patients were also more willing to have up to 
three finger sticks performed than to have a single venepuncture specimen taken. The 
process of using finger sticks was further ratified by demonstrating that a single finger 
stick can provide up to 150µl of blood, which is sufficient to perform an array of POC tests. 
In spite of the feasibility of nurse based POCT, limitations of current technologies using 
finger stick were also realised, such as the performance of the Liat™ Quant blood assay 
which generated increased VL misclassification at the 1000 copies/ml treatment failure 
threshold (70% misclassification). This would impact programmatic costs, but this 
technology may have value as a diagnostic tool in key populations.  
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The work described shows that multi-disciplinary POCT within a South African setting is 
achievable with appropriate clinic infrastructure, dedicated staff, training and stringent 
quality monitoring measures in place. The HIV and TB POC technologies evaluated were 
found to be as accurate as laboratory-based testing however, few meet the criteria of a 
‘true’ POC device and thus further research and development is required. Based on South 
Africa’s testing needs, a tiered hybrid model which expands on centralized laboratory 
capacity through incorporating POCT into very remote, hard-to-reach areas and 
innovations around linkage to care efforts, may help meet ’90-90-90’ targets but will 
require costing/modelling and future assessments of the impact and outcome of the 
intervention. Much of this work presented contributed towards the development of a draft 
National POCT policy document in support of the national strategic plan for POCT for the 
management of HIV and TB in South Africa.  
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CHAPTER 1: INTRODUCTION AND RESEARCH 
OBJECTIVES 
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1.1 THE VISION FOR GLOBAL MANAGEMENT OF HIV AND TB 
The Joint United Nations Programme on HIV/AIDS (UNAIDS) has set an ambitious new 
Human Immunodeficiency Virus (HIV) treatment target for 2020, termed ’90-90-90’. This 
calls for 90% of all people living with HIV to know their HIV status, 90% of all HIV-positive 
persons to be placed on antiretroviral (ARV) treatment (ART) and 90% of all people on ART 
to have achieved viral suppression (2). All three of these goals place a strong emphasis on 
the need for scaling up laboratory testing capacity for HIV diagnosis, treatment initiation and 
treatment monitoring. Despite plans already underway globally to achieve these targets, it 
has been predicted that at the current pace of laboratory testing scale-up, the ‘90-90-90’ 
goals are unlikely to be reached by 2020 (Figure 1.1) (2).  
Figure 1.1: The Clinton Health Access Initiative (CHAI) performed data modelling to 
predict whether current scale up plans for laboratory testing capacity in 21 HIV high 
burden countries will be enough to meet global treatment demands. The graph shows 
that despite significant scale-up of viral load testing capacity, global demand for 
testing will not be met by 2020 (2). 
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The post-2015 Global TB Strategy has also set out a list of committed targets, which include 
reducing the number of deaths due to Tuberculosis (TB) by 95% and new cases by 90%, 
with the ultimate goal of ending the global TB epidemic (3). 
Many international groups such as the World Health Organisation (WHO), UNITAID, Bill and 
Melinda Gates Foundation and CHAI (to name a few), also including the South African 
National Department of Health (NDoH), now believe that one of the ways to successfully 
achieve these goals will be through the development and scaling up of innovative, simpler 
and more affordable technologies (4, 5). This is driving the development of Point-of-Care 
(POC) tests, which promise to expand access to testing services (6).  A strong focus is also 
being placed on collaborative HIV and TB activities, particularly in high-burden countries, in 
order to provide access through integrated services for prevention, diagnosis and treatment 
of both diseases (7). 
1.2 THE PROBLEM IN CONTEXT: THE BURDEN OF HIV AND TB GLOBALLY 
Identified over three decades ago, HIV infection, which leads to acquired immunodeficiency 
syndrome (AIDS), has been labelled the ‘modern-day plague’ (8). The global prevalence or 
number of persons living with HIV infection, increased from 34 million in 2011 [31.4 - 35.9 
million] (9) to an estimated 35 million [33.2 - 37.2 million] in 2013 (10, 11). Although 
estimates of prevalence vary by country and region, the epicentre of the disease burden 
occurs in sub-Saharan Africa, that by 2013 had 24.7 million [23.5 - 26.1 million] persons 
living with HIV infection, a staggering 70% of the global reported cases (12). Despite 
increasing prevalence, AIDS-related mortality decreased from 2.4 million [2.2 - 2.6 million] in 
2005, to 1.5 million [1.4 - 1.7 million] in 2013 (12), an effect which is largely attributable to 
the success of ART programs initiated in low- and middle-income countries (13).  
The number of new HIV infections (or incidence) reported globally has been on a steady 
decline over the past few years. The global HIV incidence reported in 2013 stood at 2.1 
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million [1.9 – 2.4 million], 13% less than that reported in 2010 (14). Of the total incidence, 
240,000 of those were reported in children deemed to be infected perinatally (12) which also 
represented a marked decline (58%) compared with that reported in 2002 (14).   
The linkage between HIV infection and TB is well known; the risk of developing TB is 26 to 
31 times greater in people infected with HIV (15). TB is therefore one of the most common, 
yet curable, opportunistic infections affecting people living with HIV. In 2013, the global 
estimate for TB prevalence stood at 11 million [10 – 13 million]; the majority of prevalent 
cases (81%) were reported in the 22 countries classified by the WHO as ‘high burden’ (16). 
TB incidence is defined as the number of new and relapse cases of TB over a certain period 
of time (usually a year) and as for HIV, is steadily declining. In 2013, 9 million [8.6 - 9.4 
million] people developed TB disease; most (56%) were reported in Asia and the Western 
Pacific region and 25% were reported in Africa (16). Of these 9 million cases, 1.1 million 
were reported in HIV/TB co-infected persons and 550,000 were in children under 15 years of 
age (15, 16) (Figure 1.2). Global TB mortality figures stood at 1.5 million in 2013; 24% of 
these deaths were in HIV co-infected persons (16).  
Although data is limited due to difficulty in diagnosis, it is estimated that 15-20% of all TB 
cases reported are actually of extra-pulmonary origin (EPTB) (17), meaning that TB has 
affected other organs of the body.  
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Figure 1.2: Diagram depicting the percentage of notified TB cases with known HIV 
status in 2013, based on data from the WHO (18).   
Against the backdrop of the global TB epidemic and increased case detection and treatment, 
multi-drug resistant TB (MDR-TB) is on the rise. MDR-TB is defined as tuberculosis that is 
resistant to at least two of the widely used first-line TB drugs, rifampicin (RIF) and isoniazid 
(INH). An estimated 3.7% of TB cases reported worldwide have MDR-TB (19) and there are 
currently 27 countries considered to have high MDR-TB burdens. In 2013, 480,000 new 
MDR-TB cases were reported (16), 60% of the burden occurring in Brazil, China, India, 
Russia and South Africa (19). This figure may be underestimated however, as globally many 
cases remain unreported. Considerably more alarming is the fact that an estimated 9.6% of 
all MDR-TB cases are actually extensively drug resistant (XDR) (20), a term which defines 
drug resistance to both of the first-line TB drugs, any of the fluoroquinolones and at least one 
of the three second-line injectables (21). This greatly restricts treatment options. One 
hundred countries have reported XDR-TB cases.   
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1.2.1 THE BURDEN OF HIV AND TB IN SOUTH AFRICA  
At the southern-most tip of Africa, South Africa had an estimated population of 54 million in 
2014 (22), representing only 0.73% of the world’s total population. South Africa nevertheless 
bears one of the highest HIV and TB burdens worldwide.  
The WHO reported an HIV prevalence of 6.3 million [6.0 - 6.5 million] (12.1%) in 2013, 5.9 
million of these cases occurring in persons 15 years and older (23). This was the highest 
national prevalence of HIV described globally. Women are the worst affected, carrying 
23.3% of the country’s burden (24) compared with 13.3% of men in the age group 15-49 
years (24).  
In terms of the number of TB incident case, South Africa currently ranks fifth behind India, 
China, Nigeria and Pakistan globally, with an approximate 1% of the population developing 
TB disease each year (16). In 2013, there were 328,896 new TB cases notified, 11.5% of 
which were of extra-pulmonary origin (25). South Africa also reports 40% of the global MDR-
TB cases (20). Certain population groups have been identified as highly vulnerable to TB, for 
example miners (occupational health risk, at highest risk are gold-miners who frequently 
have Silicosis, in addition to HIV and TB) and offenders in correctional services. Years of 
neglect with regards to the health of these populations have resulted in exceptionally high 
incidence rates of TB in mines (3,000/100,000) (26) and a TB prevalence of approximately 
3.5% -7.5% in correctional management centres (27).  
The South African NDoH estimates that 60% of all HIV-positive people are also co-infected 
with TB (28).  
1.3 THE ROLE OF LABORATORIES IN HIV AND TB DISEASE MANAGEMENT  
South Africa has put forward a broad list of goals in their National Strategic Plan (NSP) for 
2012-2016, which focuses on HIV and TB collaborative efforts such as reducing new HIV 
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infections by at least 50%, initiating at least 80% of eligible patients on ART and reducing the 
number of new TB infections, as well as deaths, from TB by 50% (29).  
A major challenge to successful implementation of both antiretroviral and anti-tuberculosis 
therapy, however, remains the ability to diagnose, treat and monitor both infections. This 
process is limited by lack of laboratory infrastructure, technical skill and poor integration of 
HIV and TB services. Each phase of the diagnostic and monitoring process for both 
diseases is facilitated by a number of laboratory tests based on country-specific guidelines. 
The specific diagnostic clinical algorithms followed for HIV and TB in many high-burden 
countries is largely dependent on disease prevalence and available resources (human and 
financial) in clinics and associated laboratories. The latter has two extremes for service 
provision, namely 
• high-throughput, centralized, placed testing, or
• low-throughput, decentralized POC testing (POCT).
1.3.1 CENTRALISED LABORATORY TESTING 
In South Africa, diagnostic testing in the public sector is currently the mandate of the 
National Health Laboratory Service (NHLS). To meet NSP goals and local testing demands 
of expanded access to testing and treatment, the need for maximization of testing and 
screening strategies for HIV and TB is driving the development of next-generation, high-
throughput diagnostic systems. The NHLS has provided significant investment in developing 
laboratory capacity through rapid expansion of a centralised laboratory infrastructure for 
CD4, Viral Load (VL), Early Infant Diagnosis (EID) and TB testing over the years.  
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1.3.1.1 CURRENT CENTRALISED TESTING STRATEGIES FOR HIV 
This section details two of the main laboratory tests used for the management of HIV- 
positive persons, namely a CD4 count and a VL test.  
Following on a positive HIV diagnosis, a CD4 count has traditionally been used to provide a 
measure of the immune system’s response to infection, i.e. assessment of immune status, 
establish eligibility for ART and monitor patients on treatment (30, 31). A VL test, or the 
measure of the amount of HIV virus in the body in ribonucleic acid (RNA) copies/ml, has 
been used alongside a CD4 count to monitor response to treatment and detect appropriate 
timing for treatment switches (32-36).  
The appropriate timing of ART initiation, based on the CD4 count threshold in HIV-positive 
people, has been hotly debated for the last 20 years. The CD4 treatment initiation threshold 
was initially set at less than 200 cells/µl by the WHO in 2002 (37). However, in 2009, results 
of a large clinical trial in Haiti (CIPRA HT 001) demonstrated alarming evidence suggesting 
that initiation of ART between a CD4 count of 200 and 350 cells/µl improved survival when 
compared with treatment initiation at less than 200 cells/µl (38).  In light of these findings, the 
WHO lowered the CD4 count threshold to less than 350 cells/µl in 2010 (39). Since then, 
other studies have provided evidence to suggest the benefits of even earlier treatment 
initiation. One of the most well-known of these is the NA-ACCORD (a ‘cohort of cohorts’) 
study which found that patients who started treatment at  greater than 350 or greater than 
500 cells/µl, had a significantly lowered risk of death than patients who deferred treatment 
(40). In addition, a large retrospective study of African patients (n=24,037) receiving ART for 
at least 9 months demonstrated that higher CD4 counts during treatment were associated 
with lower mortality rates (41). The odds of survival were found to be significantly better if 
patients had a CD4 count of  greater than 500 cells/µl than if they had a CD4 count of 
between 350 to 500 or between 200 to 349 cells/µl (41).  
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In 2013, the WHO advocated increasing the threshold for treatment eligibility to less than or 
equal to 500 CD4 cells/µl and recommended immediate treatment for sero-discordant 
couples, HIV-positive pregnant women, children younger than 5 years, and persons co-
infected with TB (42). A growing body of evidence suggests that once a patient is virally 
suppressed on ART, a CD4 count adds little value for monitoring (43, 44).  
HIV VL is becoming increasingly recognised and recommended by the WHO as the 
preferred measure for treatment monitoring, detection of treatment failure and prevention of 
inappropriate treatment switch (6, 45, 46). The 2013 guidelines made a recommendation for 
VL monitoring as more important than clinical monitoring using CD4 (42). In lieu of this, the 
guidelines were again updated in 2014 prompting a move towards VL monitoring as 
opposed to CD4 monitoring (6). The South African guidelines were also revised in 2015 to 
reflect these changes (47) (Figure 1.3). By mid-2014, more than 2.6 million people in South 
Africa were receiving treatment and requiring ongoing monitoring (48).  
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Figure 1.3: A graphical representation of the changing South African ART treatment 
guidelines from 2004 to 2015 (excludes assays other than CD4 and VL). 
The debate on when is considered best to start ART continues and some parties have been 
advocating for a ‘test and treat’ strategy (49) whereby persons diagnosed as HIV-positive 
would be placed on treatment immediately, regardless of CD4 count (50). This strategy, 
based on patient benefits, has already been adopted by the San Francisco Department of 
Health since 2010 (51). A population level study in Canada also demonstrated that an 
increase in ART coverage was significantly associated with decreased community VL over a 
15 year period (52). More recently, the START study (‘Strategic timing of ART’) showed a 
53% reduction in AIDS-related illness or death in participants who were started on ART 
immediately as opposed to those deferred for treatment until their CD4 count dropped to 
below 350 cells/µl (53). 
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Currently in South Africa, both CD4 count and VL measurement rely on laboratory-based 
testing. A CD4 cell count is performed using flow cytometry, a procedure that allows a 
measure of single cells in terms of size, complexity, content and membrane-bound proteins 
(30). Within the NHLS, which services more than 80% of the population in the public sector, 
the routine method employed for CD4+ T cell enumeration is the  PanLeucogating (PLG) 
technology, a cost-effective means of measuring CD4 cells in the total leucocyte population 
(54). PLG has the advantage of extending the window-testing period from six hours post-
venepuncture (as most CD4 technologies require), to five days and is a single platform 
technique that measures bead flow rate thus, ensuring each prepared CD4 test has an 
internal control (55). This technology is reliant on daily-maintained, bench-top equipment, an 
air-conditioned environment, stable electricity, well-trained laboratory personnel, 4°C storage 
of reagents and in South Africa, is located in 60 laboratories (56).  
VL testing in South Africa is currently performed in 17 centralised facilities due to the 
requirements for infrastructure, expensive equipment, technical skills and the need for a 
blood draw, all of which serve to limit its access in resource limited settings (56-59). Two 
high-throughput VL platforms are used routinely within the NHLS (through a highly-
competitive selection process), the COBAS® Ampliprep/COBAS® Taqman (CAP/CTM) 
version 2 (Roche Molecular Systems, Branchburg, NJ) and the Abbott RealTime HIV-1 
assay (Abbott Molecular, Des Plaines, Illinois) (60). Both instruments are fully automated, 
real-time platforms, have throughputs of up to 96 samples per run (61) and facilitate 
turnaround times within 24 hours. To cope with high testing demands, a new system has 
been released into market by Roche, namely the COBAS® 8800, which can generate results 
for 960 specimens in an eight-hour shift (62) by a single laboratory technician (Figure 1.4). In 
2014, Roche also announced their Global Access Program which will lower prices of VL 
tests in low- and middle-income countries in support of global goals (2, 63). Although this is 
a pivotal step towards achieving increased access to testing, many laboratories in Africa are 
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still underdeveloped (64). These technologies are reliant on phlebotomy and logistics around 
transport in order to maintain specimen integrity, which limits their geographic service 
catchment. Lack of available POC tests are therefore driving alternative ways to increase 
accessibility to laboratory testing for remote settings. Dried Blood Spots (DBS) can be 
collected from a finger or heel stick, thereby negating the need for phlebotomy skills and 
allows stable transport at ambient temperature to centralized testing facilities (45). Plasma 
preparation tubes (PPT) are also a simple and cost effective means of maintaining RNA 
integrity for transport of specimens to VL testing sites (65). 
Figure 1.4 shows the current, centralized, high throughput HIV VL and TB diagnostic 
systems in South Africa. On the left is the Roche COBAS® 8800 VL testing platform 
and on the right, the GeneXpert® Infinity-80 system for TB diagnosis and RIF 
susceptibility testing.  
Besides the two core tests mentioned, other diagnostic parameters such as haematology, 
chemistry and the diagnosis of opportunistic infections, are also required for management of 
HIV-positive persons in terms of treatment initiation and ongoing monitoring (Table 1.1). 
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Table 1.1: Tests required for initial HIV diagnosis, staging and treatment monitoring 
according to the current South African guidelines (47, 48). 
Tests required Purpose 
Diagnosis 
HIV rapid test HIV status 
CD4 To assess ART eligibility <500 cells/µl 
To assess priority cases <350 cells/ul 
To assess fast-tracking cases <200 cells/ul 
Pregnancy Screen for pregnancy for women needing Prevention 
of Mother to Child Transmission (PMTCT) 
Blood pressure and urine 
glycosuria 
To identify chronic diseases such as hypertension 
and diabetes 
Cryptococcus 
neoformans antigen 
(CrAg) screening 
To assess ART eligibility and  
in patients with a CD4 count <100 cells/ul 
Screen for Hepatitis B 
virus (HBV) 
To identify HBV infection 
Screening for sexually 
transmitted infections 
(STI’s) and syphilis 
To identify and treat STIs 
Active TB Following symptom screening to identify TB 
Haemaglobin (Hb) or full 
blood count 
To initially detect anaemia/neutropenia 
Creatinine (Cr) To asses renal sufficiency if requiring Tenofovir 
Alanine Aminotransferase 
(ALT) 
To exclude liver dysfunction if requiring Nevirapine 
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Treatment monitoring 
CD4 At initiation and 1 year to identify response 
Viral load AT 6months, 12 months on ART and then every 12 
months to monitor treatment failure and adherence  
Cr and calculated Cr 
clearance 
For monitoring Tenofovir toxicity 
 ALT For monitoring Nevirapine toxicity 
Full blood count To identify Zidovudine toxicity 
Fasting cholesterol and 
triglycerides 
For monitoring of second-line lopinavir/ritonavir based 
regimes 
1.3.1.2 CURRENT CENTRALISED TESTING STRATEGIES FOR TB 
The increasing burden of TB, need for scale-up in testing requirements as well as challenges 
with low sensitivity and diagnostic delays with conventional TB detection methods (66-69), 
led to the WHO endorsement of a new molecular TB diagnostic, which has revolutionized TB 
testing; the GeneXpert® technology using the Xpert® MTB/RIF assay (70). Prior to this, 
sputum smear microscopy was the most widely used diagnostic test for TB detection in 
resource-poor countries for over 100 years due to its simplicity, specificity, low cost and 
rapid turnaround time. The sensitivity of smear for diagnosing TB is less than 60% (71-74) 
and decreases to between 38-54% in HIV co-infected individuals (75, 76) due to low 
bacillary load (smear – negative TB). Culture, which is highly sensitive, is currently the gold 
standard method for confirmation of TB, but has prolonged turnaround times, biosafety 
requirements, technical skill and laboratory infrastructure requirements (67, 77) thus limiting 
its availability and timeous utility in clinical patient management. 
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The GeneXpert® MTB/RIF assay (Cepheid, Sunnyvale, CA) was therefore designed for 
rapid and sensitive detection of Mycobacterium tuberculosis complex (MTBC) and 
simultaneous detection of resistance to RIF, which is also used as a surrogate marker for 
MDR-TB (78). The assay incorporates automated sample extraction, amplification of the 81-
bp core region of the rpoB gene (a hot-spot for RIF mutations) and real-time detection, 
providing a result in just two hours once the cartridge is loaded into the instrument  (78, 79).  
In a multi-centre study involving South Africa, Peru and India, with a cohort of 6648 
participants, the Xpert® MTB/RIF assay showed a sensitivity of 76.9% in smear-negative, 
culture-positive patients and 98.3% in smear-positive, culture-positive patients (80). Use of 
the Xpert® MTB/RIF assay reduced the median time to TB treatment for smear-negative TB 
from 56 days to just 5 days (80). Based on these results and South Africa’s high HIV/TB co-
infection rates, the Xpert® MTB/RIF assay was implemented as the first-line TB screening 
diagnostic to replace smear microscopy in March 2011 by the NDoH and NHLS (81, 82). 
Based on a recent review of 27 studies, the pooled sensitivity of the Xpert® MTB/RIF was 
98% in smear-positive, culture-positive TB and 79% in HIV co-infected people (smear-
negative TB) (83). 
Since its implementation in South Africa in 2011, the average national TB positivity rates 
among presumptively infected individuals has decreased from 16-18% nationally in the first 
year, to an overall 9% in the fifth year of using the Xpert® MTB/RIF (84). In some high 
burden districts however, the TB positivity rates in 2014 were still as high as 15.5% 
(Western Cape) (84). Cepheid has now launched the GeneXpert®-80, which has a 
throughput of more than 2,000 specimens in a 24 hour period by a single operator, to cope 
with increasing testing demands (see Figure 4). Two new assays, the Xpert MTB/RIF® 
ULTRA, which will have similar sensitivity to culture, and the XDR assay, a reflex test for 
Xpert RIF positive results, are also in development.
According to the South African National TB algorithm (Appendix A), all persons with one or 
more of the classic screening symptoms for TB (persistent cough or fever for more than two 
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weeks, night sweats and weight loss) should have a sputum specimen tested by the Xpert® 
MTB/RIF assay to rapidly determine the presence of TB disease and drug susceptibility. 
Clinical symptom screening has, however, been shown to be a poor indicator of TB infection 
(85). Liquid culture or MGITs (mycobacterial growth indicator tube) are used for 
confirmation of MDR-TB and detection of resistance to first- and second-line drugs through 
drug susceptibility testing (DST) (86). Phenotypic DST is based on addition of critical 
concentrations of drugs to the growth medium and then measuring bacterial growth. One of 
the main limitations is that it takes approximately two to three weeks over and above the two 
to four weeks for a positive culture (87). 
A further molecular test for confirmation of first- and second-line drug resistant TB, 
assessing the need for triaging patients and as well as treatment initiation (86), is the 
Genotype® MTBDrplus line probe assay (LPA) version 1 and version 2 (Hain Lifescience, 
Gmbh). The LPA, endorsed by the WHO in 2008 (88), is a PCR-based probe hybridisation 
assay for use on smear positive specimens, liquid and solid culture isolates. The assay is 
able to simultaneously detect MTBC and resistance to the first-line TB drugs INH and RIF 
within 48 hours on direct sputum (89). The sensitivity of version 1 of the assay compared to 
culture was found to be 76%, but showed reduced sensitivity in HIV-positive persons (90). 
Version 2 can be used on smear-negative TB and has shown comparative sensitivity to 
MGIT (91).  
Since its implementation, use of the MTBDRplus assay on all culture confirmed TB cases 
has substantially increased the proportion of new MDR-TB cases confirmed in South Africa 
(92). A further LPA for second line drug resistance detection, the MTBDrsl is also available 
and is currently undergoing evaluations (93). As with any molecular-based test, limitations 
exist such that LPA also requires infrastructure (Biosafety level II and PCR laboratory), 
resources and highly trained personnel for both operation and interpretation.  
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For EPTB diagnosis, the algorithm is much the same as for pulmonary TB using the Xpert® 
MTB/RIF assay, except that the specimen type will differ to include gastric washing, gastric 
lavage, lymph node fine needle aspirate (FNA), pleural biopsy or cerebrospinal fluid (CSF) 
(94). 
1.3.2 DECENTRALISED POINT-OF-CARE TESTING 
Limitations to centralized testing are steering diagnostics closer to the patient. A POC test is 
defined as any test which can be performed outside of a central laboratory, including home-
based testing (95), and which provides rapid and accessible test results on minimally 
invasive specimen types, such as finger stick blood, sputum or urine (96). POCT can also be 
referred to as extra-laboratory or alternative site testing (97) as it may be seen as an 
extension of laboratory testing. One key difference between POCT and laboratory testing is 
that it allows the screening or diagnostic process to be potentially completed within a single 
clinical encounter (98) (Figure 1.5). More important than being simple and rapid, POCT 
should lead to increased access to testing and improved patient outcomes (98). Based on 
these criteria, the Clinical Laboratory Standards Institute (CLSI) defines the purpose of 
POCT as the provision of timely results that clinically and cost-effectively contribute to 
immediate patient management decisions (99). 
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Figure 1.5: Diagram showing the essential difference between conventional laboratory 
testing and POCT in terms of number of steps required to obtain a result (adapted 
from (100)). POC can encompass different test types or equipment such as non-
instrumental systems (disposable devices or strip-based testing) or small hand-held 
analysers and desktop analysers (101). 
1.3.2.1 RAPID HIV TESTING IN SOUTH AFRICA 
In a 2010 population survey of 10 sub-Saharan countries, the WHO found that more than 
69% of people were unaware of their HIV status and that gaps existed between testing and 
counselling needs and existing practice at the time (102). In light of this, the ‘National HIV 
counselling and testing policy guidelines’ were published in 2010 in which voluntary 
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counselling and testing (VCT) programs (now called HIV Counselling and Testing – HCT) 
were expanded to include provider initiated testing and counselling (PITC) in order to extend 
access to testing services (103). 
Currently, diagnosis of HIV in adults can be made on the basis of several different tests; the 
appropriate diagnostic test used depends largely on the stage of HIV infection and the age 
of the individual (61). In South Africa, HIV diagnosis in adults and children (more than 18 
months old) is conducted frequently at the primary health care (PHC) level, using two HIV 
rapid strip-based tests sequentially (one for diagnosis and one for confirmation) (Appendix 
B) (48). Discordant results between the rapid tests are reflexed to laboratory-based antibody
assays, namely enzyme-linked immunosorbant assay (ELISAs). HIV rapid testing, 
although fast and accessible, has many limitations and is plagued by quality assurance 
dilemmas (104). Rapid testing also does not address gaps, such as the need for 
detection of acute infection, diagnosis of babies born from HIV-positive mothers, and 
monitoring of treatment effectiveness and failures (105).  
1.4 THE PROMISE OF POINT-OF-CARE TESTING: BRIDGING THE DIVIDE 
An old approach to testing, POC has been available for several years in areas like hospitals, 
emergency rooms, doctors’ offices, clinics and even self-monitoring at home (106). The first 
POC device to be developed was a urine dipstick in 1957; a simple, instrument-free, rapid 
diagnostic test which was later followed by the development of a handheld glucose meter in 
1970 (107). Some of the most common and long established examples of POC tests 
available today include blood gas analysers, glucose meters (108, 109), urine analysers 
(108), HIV rapid tests and pregnancy tests. POC tests were initially used exclusively in the 
physician’s office or at home but have since expanded to four main areas; self-monitoring, 
community testing primarily in pharmacies, general practice, mobile vehicles and the 
emergency department (110). Due to their simplicity, users of POC tests can be laboratory 
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trained personnel, non-laboratory trained healthcare professionals or lay individuals, 
depending on the regulatory setting in which the testing is conducted.  
Initially, the ASSURED criteria, developed by the WHO, were used to describe first-
generation POC tests (strip or dipstick-based) as ‘affordable, sensitive, specific, user-
friendly, rapid and robust, equipment free and delivered’ (111). With advancements in the 
field of POC to hand-held devices and Nucleic Acid based Testing (NAAT), the Target 
Product Profile (TPP) is now being used to define POC tests based on the diversity of POC 
technologies available and the spectrum of users and settings in which they are used (112). 
The Clinical Laboratory Improvement Amendments of 1988 (CLIA88) which was introduced 
in the United States of America to ensure the accuracy, reliability and timeliness of patient 
results regardless of where the test is performed, distinguishes POC tests into two groups 
according to their degree of complexity: CLIA-waived and Food and Drug Administration 
(FDA) cleared POC tests which are suitable for home use, due to their simplicity and 
accuracy and limited risk of harm to the patient if performed incorrectly (95); and non-
waived tests which are more complex to perform and require training and increased 
responsibility (113). 
Today, a set of POC connectivity standards have also been developed, namely POCT01-A1 
and POCT01-A2, which consist of specifications for the manufacture of POC diagnostic 
devices to allow integration of the laboratory information system (LIS) to POC devices (114). 
1.4.1 GLOBAL DRIVERS FOR POINT-OF-CARE TESTING 
When POCT was first introduced, it was considered by central laboratories as supplemental 
testing which was seen as a competitor to laboratory services and of sub-standard quality to 
laboratory testing (115). This viewpoint is changing rapidly as POC developers continuously 
introduce advancements to the technology and improve required specifications. The main 
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driver for POC development in low resource settings where laboratory facilities may not be 
readily available, has been the need to diagnose high burden diseases such as HIV and TB 
(95). High rates of loss to follow up and poor retention in care are also driving funders, 
suppliers and users to seek alternatives to centralised testing (116).  
Strong advocacy for POCT is now emerging from various groups, such as the WHO, the Bill 
and Melinda Gates Foundation, Clinton Foundation, President’s Emergency Plan for AIDS 
Relief (PEPFAR) and African Society of Laboratory Medicine (ASLM), who maintain that 
universal access for HIV and TB care requires the use of POCT for earlier testing and 
improved retention in care. 
Today, POCT is one of the fastest growing segments of laboratory medicine, increasing by 
an average of 10-12% per year (up to 30% in some areas) (117) and accounts for 1 in 4 
tests used in the developing world (118, 119). But demand is set to grow even more, with an 
estimated worth of $27.5 billion by 2018 (120). This is mainly attributable to the increasing 
prevalence of infectious diseases and lifestyle-based diseases (for example diabetes) and a 
strong development pipeline (120). 
Additionally, new strategies by groups such as UNITAID are also being proposed to help 
reach the more than 50% worldwide who do not yet know their HIV status (6). There is now 
an increasing interest in oral self-testing, whereby a person wanting to know his/her HIV 
status can screen themselves using a rapid saliva-based HIV test using a saliva specimen, 
in the privacy of their own home (121). Some countries have already approved the sale of 
over-the-counter HIV rapid tests, whereas countries such as South Africa are considering its 
adoption into national policy in order to meet NSP goals (121, 122). Although this approach 
could potentially be beneficial in terms of increasing access and uptake of HIV testing, it 
also has many ethical implications which raise concerns (123).  
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1.4.2 POINT-OF-CARE TESTING PIPELINE FOR HIV  
An exciting developmental pipeline exists for POCT in the HIV arena and enormous leaps 
have been made in terms of the available POC diagnostic market (Table 2). Since 2009 the 
Pima™ Analyser (Alere Technologies GmbH, Jena, Gemany) has been used in many 
countries (124), and other promising analysers are  the CyFlow® CD4 miniPOC (Sysmex 
Partec GmbH, Germany) and the BD FACSPresto™ (BD Biosciences, San Jose, CA) (4). 
Numerous evaluation studies have been published detailing the performance of the Pima™ 
analyser against predicate technologies both on capillary samples (finger stick) (125-131) 
and venous blood (venepuncture) (125, 128, 131, 132). Limited performance data is 
available for other CD4 technologies in the pipeline (128, 131, 133-135) but all have shown 
good performance with predicate technologies, although capillary sampling shows increased 
variability as concluded in the Pima™ CD4 meta-analysis and summarized from this 
manuscript (124) in Table 1.2.  
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Table 1.2: Summary of CD4 meta-analysis results showing the misclassification, 
sensitivities and specificities for the Pima™ CD4 on venous and capillary samples 
[Adapted from (124)]. 
Overall 
N=11803 
Venous 
N=7648 
Capillary 
N=4155 
Reference technology 
Mean (absolute 
range 
428 (402–453) 436 (418–474) 411 (384–437) 
Median (IQR) 383 (249–555) 390 (254–565) 371 (241–537) 
Pima™ 
Mean (absolute 
range 
404 (373–425) 416 (388–444) 382 (351–412) 
Median (IQR) 363 (234–524 373 (242–534) 342 (221–507) 
Total 
Misclassification 
350 cells/µl 
11.0% (9.6 - 12.5%) 9.2% (7.5 - 11.1%) 13.8% (12.1 - 15.8%) 
Total 
Misclassification 
500 cells/µl 
9.5% (8.3 - 10.8%) 8.3% (7.0 - 9.8%) 11.3% (9.6 - 13.2%) 
Sensitivity at 
350 cells/µl 
93.3% (91.4 - 94.9%) 94.3% (92.1 - 95.9%) 91.8% (88.8 - 94.1%) 
Sensitivity at 
500 cells/µl 
96.1% (95.2 - 96.9%) 96.9% (95.8 - 97.7%) 95.0% (93.5 - 96.1%) 
Specificity at 
350 cells/µl 
86.3% (82.8 - 89.1%) 89.1% (85.4 - 92.0%) 82.1% (77.5 - 85.9%) 
Specificity at 
500 cells/µl 
78.2% (73.9 -82.0%) 81.3% (76.6 -85.2%) 73.7% (67.2 -79.3%) 
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Until recently, VL testing has been almost exclusively laboratory-based, as no POC 
device/assay existed. This is however, rapidly changing with the market release of the 
SAMBA (Simple Amplification Based Assay) by Diagnostics for the Real World, Ltd (DRW; 
Chesterford, UK) in 2014 (136) and many other fast followers undergoing external 
evaluations (Table 1.3). Due to challenges in the collection of clinical data, particularly in 
PHCs (frequently manual or paper-based), the need for new POC technologies to have 
connectivity capabilities has become imperative (137).   
Table 1.3: Current HIV POC VL technology landscape (4). 
Technology Description Time to 
result 
Connectivity 
capabilities 
SAMBA 
(Diagnostics 
for the Real 
World, Ltd.)  
A semi-quantitative measurement of 
HIV-1 RNA. Two systems, the semi-
automated SAMBA I system and the 
fully automated SAMBA II system. 
Both based on a single-use 
disposable cartridge (strip-
based detection).  
90 to 
120min 
Yes 
COBAS® Liat 
Analyser 
(Roche 
Molecular) 
Automated (extraction, amplification, 
detection) quantitative or qualitative 
measurement of HIV-1. Single-use 
disposable cartridge. 
15 to 35min Yes 
Alere q 
(Alere) 
Automated (extraction, amplification, 
detection) quantitative detection of 
HIV-1 and HIV-2. 
Based on a single-use disposable 
cartridge. 
55min Yes 
EOSCAPE-
HIV™ HIV 
Rapid RNA 
Assay 
System 
(Wave 80 
Biosciences 
A qualitative HIV-1 RNA test 
(EOSCAPE-HIV-D) and a 
quantitative viral load test 
(EOSCAPE-HIV-Q). 
Both based on a single-use 
disposable cartridge. 
Processing 
time = 
45min. 
Result read 
= 2 min. 
Yes 
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Truelab™ 
(Molbio 
Diagnostics 
Pvt Ltd) 
Quantitative HIV-1 viral load 
detection through a Truenat™ micro 
PCR chip. 
< 60min Yes 
GeneXpert® 
System 
(Cepheid) 
Automated (extraction, amplification, 
detection) quantitative HIV-1 viral 
load test. Based on a single-use 
disposable cartridge 
95 min Yes 
*Was previously called the Liat Analyser (IQuum, Inc).
The SAMBA I semi-q, a qualitative test which distinguishes patients as either above or below 
1000 copies/ml has been validated against the Roche COBAS® CAP/CTM version 2 (138). 
Initial results look promising with 99% overall accuracy on patient specimens (138).  When 
the SAMBA semi-q was tested on 284 specimens from patients on ART from Uganda and 
Malawi, the SAMBA incorrectly misclassified 2.5% as above the 1000 copies/ml treatment 
failure threshold (139). The SAMBA has already received in-county approvals in Uganda, 
Malawi and Kenya. Field experience using the SAMBA I (Malawi and Uganda) has 
suggested that a laboratory trained operator, such as a technician, will be needed due to the 
manual steps involved in testing; a single operator will be able to perform between 32 and 42 
samples in a 7 hour working day with a low invalid rate, but electricity is required (140). DRW 
are also developing a fully automated instrument, the SAMBA II that is suitable for operation 
by lay persons and is currently undergoing field evaluations.  
The Liat™ platform was originally developed by IQuum, Inc (Marlborough, MA, USA) but has 
recently been acquired by Roche Molecular Diagnostics and renamed the COBAS® Liat 
System, in order to take it to market (141). The Liat™ platform provides automated sample 
preparation, nucleic acid extraction, PCR amplification and real-time detection on a platform 
which weighs a mere 3.8kg and provides an interpreted result in 30 to 35 minutes. An initial 
laboratory evaluation of the platform showed a limit of detection of 57 copies/ml and high 
concordance with Siemens Versant HIV-1 RNA b-DNA (deoxyribonucleic acid) version 3.0 
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and Roche COBAS Amplicor high throughput VL platforms (92% and 88% respectively) 
(142). In its current ‘lab-in-a-tube’ format, the Liat™ reagent tube requires cold-
chain storage, which is less than ideal for POC, however, Roche are continuing 
research and development on the assay and anticipate market release by 2016 (143).  
Alere™ (Waltham, MA, USA), a company well known for their POC CD4 platform, is also 
evaluating a POC platform for VL that is currently only available for research use. The 
platform named the Alere™ q Analyser and HIV-1/2 assay, is a multiplex real-time PCR with 
fluorescence-based detection on competitive reporter probe hybridisation on an integrated 
microarray (144). The assay provides a quantitative VL result in 55 minutes on 25µl of whole 
blood making it ideal for finger or heel stick specimens. Performance studies are still ongoing 
and limited data is available, but the assay does seem to show better performance than DBS 
VL testing (145).   
Cepheid (Sunnyvale, CA, USA) (the company that developed the Xpert® MTB/RIF assay), is 
also in the process of evaluating a new qualitative and quantitative VL assay for their 
GeneXpert® platform. Performance data is also limited as external evaluation studies are 
ongoing, but interim results on 390 clinical specimens, show 100% specificity and a limit of 
detection of 21 copies/ml (146). 
In addition to the above mentioned assays which have limited evaluation data, there are a 
number of other POC VL assays still in various phases of development, such as the North 
Western Global Health Foundation (NWGHF, Chicago, Illinois) Savanna VL Test and 
Platform, EOSCAPE-HIV™ HIV rapid RNA Assay system (Wave 80 Biosciences, San 
Francisco, USA), Viral Load Assay using BART Technology (Lumora Ltd. Cambridgeshire, 
UK), RT CPA HIV-1 Viral Load Test (Ustar Biotechnologies, Hangzhou, Ltd), Gene-
RADAR® Platform (Nanobiosym® Diagnostics, Inc, Cambridge, MA), ZIVATM (Cavidi, 
Sweden), and the GenedriveTM (Epistem Ltd, Manchester, UK) (4, 143).  
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1.4.3 POINT-OF-CARE TESTING PIPELINE FOR TB 
Although the GeneXpert® platform has revolutionized TB testing globally, it is still a 
laboratory-based platform that requires computer literacy, electricity and some technical 
skill (147, 148). The POC molecular technology landscape for TB is still in development and 
a number of POC TB assays are now becoming commercially available such as the 
EasyNAT™ TB (Ustar Biotechnologies), GeneDriveTM Mycobacterium test kit (Epistem, UK) 
and Truelab™ Uno real time microPCR (MolBio Diagnostics Pvt, Ltd, India) (5), although 
limited data has been published on their use.  Others are in the early market entry phase 
(Table 1.4). The Foundation for Innovative New Diagnostics (FIND) are also leading efforts 
to develop a series of TTP's to better inform developers of the core requirements for TB 
dignostics.
Much interest is also now being placed on polyvalent POC platforms such as the 
GeneXpert® (149), which can detect multiple diseases on a single platform.  
Table 1.4: TB POC diagnostic landscape - early market entry products (5). 
Technology* Description Time to 
result 
Connectivity 
capabilities 
EOSCAPE TB 
and RIF-FQ 
(Wave-80) 
TB detection on a chip with 
Android phone operating 
system 
1 hour Yes 
Alere q Near 
TB assay 
(Alere) 
PCR based TB detection. 
Cartridge based 
30 minutes Yes 
TB assay 
(NWGHF) 
Fully automated Qualitative 
TB detection 
Not known Yes 
QuantuMDX Q-
TB 
Smartphone-like device to 
detect TB and drug resistance 
15-20minutes Yes 
*Not an exhaustive list
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1.4.4 ADVANTAGES AND DISADVANTAGES OF POINT-OF-CARE TESTING  
Many benefits have been reported after introduction of POCT into non-laboratory 
environments such as emergency departments, doctors’ rooms and patients’ homes in 
developed countries (Table 4). Self-monitoring of glucose and glycated haemoglobin levels 
(HbA1c) have long been described to provide significant benefits to patients with diabetes 
(150-152).  Several clinical studies are available that highlight advantages for assays such 
as blood gases, electrolytes, cholesterol and lipids (153), glucose (154), glycated 
haemoglobin (155) and haemoglobin in specific clinical scenarios (156-159). In general 
faster turnaround times, better patient management (160) and reduced patient length of stay 
(161) have all been documented.  Reduced hospital admissions have also been found with
POCT compared with laboratory testing due to the ability of POCT to provide a rapid result 
allowing faster decisions with regards to patient care and subsequent earlier discharge 
(162). As an example, implementation of a bedside hand-held lactate device for 
determination of sepsis in the emergency department reduced time to obtains results and 
administering of fluids in the intensive care unit, ultimately leading to a reduction in patient 
mortality (163). Similarly, use of a lateral flow strip-based assay for detection of cryptococcal 
infection (an opportunistic infection) was positively associated with predicting the 
development of meningitis in HIV infected hospitalized patients (164).  
Implementation of POCT may also improve resource utilization in PHC facilities (127, 165). 
A decrease in tests ordered per patient, reduced number of patient return visits and 
decreased phone calls, all resulted in improved efficiency and cost savings after POCT was 
introduced (166). 
Diagnosing TB at the POC also has advantages. Use of the Xpert® MTB/RIF as a POC test 
at a PHC facility has shown to increase the number of patients starting same day treatment 
and decrease time to treatment (167, 168). Provision of a rapid strip test namely the urine 
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LAM (lipoarabinomannan) assay, used to diagnose HIV-associated TB in adults about to 
initiate ARVs, was found to be a good predictor of poor prognosis and mortality risk (164, 
169). It was also a useful and rapid rule-in test for TB in patients with advanced 
immunosuppression (170).  
POCT also lowers the required skill of workers, as non- laboratory trained staff, such as 
nurses, have been shown to accurately and feasibly perform POCT (171-174). Most 
healthcare workers and POC operators report that POC tests are easy to perform (175) and 
lead to improved staff satisfaction (176). Management of HIV and TB will, however, require 
a multidisciplinary testing approach and few studies (177) have investigated the feasibility of 
a non-laboratory trained worker performing multiple POC tests simultaneously.  
Table 1.5: General listed advantages and disadvantages of POCT (115, 178). 
In general, the performance of POCT when compared to laboratory testing has been 
acceptable (179-182) despite some incidents and complaints involving patient harm by 
CLIA-waivered tests (183-185). There seems however to be a general distrust in POCT, 
which may lead to over-use of laboratory testing to confirm POC results or duplication of 
Advantages 
• Easy to obtain sample type
• Small sample volumes
• Limited pre-analytical processing
• Easy to use
• Rapid patient results
• Portable
• Negates sample transport
• Improved access to testing
• Patient satisfaction
• Healthcare worker satisfaction
• Convenience
Disadvantages 
• Reliability of results
• Increased errors
• Management of errors
• Potential increased workload
• Comparability to predicate methods
• Lack of standardised quality control
• Potential increased cost
• Management of results and
interfacing
• Potential over-use of tests due to
convenience
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POCT due to ease of access. A survey looking at the practices of clinicians using blood gas 
analysers found that more than half would wait for laboratory confirmation rather than use 
the obtained POC result (186). A further study in a busy Johannesburg hospital that provided 
critical care staff with a HemoCue (Hemocue AB, Angëlholm, Sweden) instrument for rapid 
haemoglobin measurements, showed similar results. During the study period, there was a 
sharp increase in laboratory haemoglobin testing which effectively doubled hospital testing 
volumes (187). 
This study highlights the need for strict control measures and quality assurance practice 
systems to be in place, which are often lacking or unsuitable for POCT (105, 188). This lack 
of quality control cannot be more apparent than the use of HIV rapid tests in South Africa. 
Although HIV rapid testing has been instrumental in ensuring wide-scale diagnosis and 
access to HIV care, it has also highlighted a number of issues around quality of testing. 
When a detailed evaluation of practices and processes for HIV rapid testing was conducted 
in 38 clinical sites, the testing process was found to be fraught with difficulties. Despite 
having over 10 years’ experience with HIV rapid tests in public sector clinics, fewer than 
13% of clinics followed recommended quality assurance testing guidelines (189).  
The widespread availability of POC tests in recent years has led to concerns over quality 
and reliability of results. Various factors in the pre-analytic, analytic and post-analytic testing 
cycle have the potential to affect results and their interpretation that the POC user may not 
be aware of (190). The current standard for quality testing in South African medical 
laboratories is governed by the South African National Accreditation system (SANAS, 
ISO15189, (191)). SANAS have released a further International Organisation for 
Standardisation (ISO) guideline governing the use of POC assays (ISO/FDIS 22870), 
entitled ‘Point-of -Care testing - Requirements for quality and competence’ (192), to be used 
in conjunction with ISO15189. Most POC platforms have built in Quality Control (QC) 
checks, such as checks for sample volume and integrity, extraction, amplification and 
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detection. Regardless, an external oversight will be needed as part of the QC procedure 
(193). This poses a unique challenge as traditionally, quality control material has been 
designed for laboratory-use with a technician or technologist in mind. Providing material 
which is simple, robust and cost effective should be the gold standard for designing a QC 
material for POC. 
To ensure quality, centralised data monitoring and the ability to interface with the LIS needs 
to also be taken into consideration (194). Centralised laboratory infrastructure relies heavily 
on data management systems for interfacing, quality monitoring and result reporting. With 
pressure from users, manufacturers of newer POC instrumentation now realise the 
importance of these systems and are attempting to automate the collection, review and 
transmission of patient data that is generated with computer-based software packages (195). 
As suppliers use their own propriety solutions and communication protocols, there is no 
common industry standard for interconnecting multiple POC platforms (195).  
Another disadvantage of POCT is that in general, it is considered expensive in terms of the 
cost per test, which is higher than that of laboratory testing costs, but may offer financial 
savings through rapid delivery of results and reduced facility costs (196). Most of the 
economic analyses for POCT come from costing and modelling projects. In South Africa for 
example, the cost of different placement models for GeneXpert® were investigated prior to 
wide scale implementation. Placing the GeneXpert® at the POC was found to be 51% more 
expensive than placing it into laboratories, mainly due to low test volumes, high human 
resource requirements and high number of POC sites required (197). The Xpert® MTB/RIF 
assay was also found to be more costly for healthcare providers compared to smear 
microscopy and culture, even though it was an effective tool for diagnosing smear-negative 
TB (198). The ‘XTEND’ trial in South Africa showed no reduction in initial loss to follow up or 
increase in patients initiating TB treatment following implementation of the Xpert® MTB/RIF 
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assay, although Xpert® did yield more confirmed positives versus smear microscopy (199, 
200). 
An Australian clinical trial to address clinical effectiveness, cost effectiveness and safety of 
POCT in diabetic patients, patients with hyperlipidaemia and patients receiving anticoagulant 
therapy, was conducted in a large number of general practices throughout Australia (201). 
Findings from this study concluded that POCT was non-inferior to laboratory-based testing 
but at a substantially higher cost, which would need to be weighed against overall health 
benefits (201). Numerous other studies have also found increased costs for POCT in self-
monitoring, emergency departments and general practice (202-204). Zarich and colleagues 
(205) however, found that providing a POC test to suspected myocardial ischemia patients in
an emergency department reduced overall hospital costs. 
A recent cost effectiveness analysis of POC CD4 versus laboratory CD4 testing in 
Mozambique, found that even though POC CD4 testing has higher costs, it had the potential 
to be more cost effective than laboratory CD4, if it improved linkage to care efforts (206). 
In addition, many challenges with POCT relating to poor regulatory control (207, 208), lack of 
policy documents and guidelines (187) have also been documented.  Even when POC 
technologies are developed and become available, regulatory and bureaucratic issues are 
delaying their uptake. Before POC implementation can happen, a policy needs to be 
developed detailing a single, strategic national plan for multi-disciplinary POCT, as was 
advocated by the Maputo declaration (209). Appropriate policy and guideline development 
will ensure that the most beneficial POC technologies can be rolled out on a wide scale to 
improve access to services (210).  
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1.4.5 FURTHER CONSIDERATIONS: THE ‘LEAKY’ CASCADE  
Besides the many advantages and disadvantages of POCT listed, and even though POCT 
will help alleviate many of the logistical problems faced by current centralised laboratory- 
based testing, translation into access to care is not always guaranteed (211). To be truly 
advantageous in terms of achieving successful treatment outcomes, the patient needs to 
successfully pass through each step of the treatment cascade: recruitment for testing, 
testing and diagnosis of infection, determining ART/TB treatment eligibility, linkage to clinical 
care and retention in care (122, 210, 212).  
In reality, laboratory testing frequently results in long turnaround times and delays in results, 
leading to attrition of patients in the testing and treatment pathway (112) at each stage of the 
treatment cascade (Figure 1.6) (212).  
Figure 1.6: The ‘leaky’ HIV treatment cascade through which patients are lost to follow 
up at different stages (213-215). Adapted from (216). 
HIV Diagnosis 
CD4 staging 
ART eligibility 
ART 
initiation 
Retention 
Loss to follow up 
41% 
Loss to follow up 
32% 
Loss to follow up 
45%-56% 
Loss to follow up 
23% 
Death 46% 
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 A review of pre-ART linkage to care studies showed that at every step of the process, from 
HIV testing to ART initiation, there is a substantial loss of patients, highlighting the need for 
enhanced, innovative linkage-to-care efforts (211, 217-221). Data from South Africa 
demonstrated that nearly half of patients diagnosed as HIV-positive at two clinic sites in 
Durban, failed to have a CD4 test within 8 weeks of diagnosis (222). Only 39% of patients, 
who had a CD4 test done and were eligible to start ART, did so within 12 months (223). 
More recently a ‘Links to Care’ program in Limpopo and Gauteng provinces was able to link 
only 51% of the 1,096 participants to care and the mean time to linkage was 31 days (224). 
An analysis of patient outcomes after the first year following HIV diagnosis at a PHC clinic in 
Johannesburg, South Africa, found that overall retention in care was only 37.9% (225). A 
systemic review quantifying the losses of patients in the continuum of care in sub-Saharan 
Africa estimated that of those patients eligible to start ART, only 66% initiated treatment and 
65% of these were retained in care after three years (226). Similar retention rates have been 
found in the United States (227) and India (228).  
POCT may improve loss to follow-up along this cascade: providing a CD4 test at HCT 
improves initiation rates (172, 229, 230) and ART eligibility assessment and allows 
immediate treatment initiation in HIV-positive pregnant women and youths (230-233). 
Placing a Pima™ CD4 analyser in a mobile van providing HCT demonstrated that patients 
who received an on-site CD4 test were more likely to complete their referral visits for HIV 
care, compared with those who were not offered a POC CD4 (234). Other studies however, 
have found little or no impact, with on-site CD4 testing not impacting on the uptake in HIV 
care and treatment or on retention in care (172, 229, 235). 
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1.5 THE ROLE OF POINT-OF-CARE TESTING IN SCALING UP TESTING 
SERVICES 
By the end of 2014, ART programs in low- and middle-income countries had placed a 
staggering 13.5 million people on life saving ARVs, although this represented only 37-45% of 
those globally in need at the time (236). Scaling up of ART programs will necessitate a 
similar scale up in laboratory testing capacity to meet demands (1). With talks around a ‘test-
and-treat’ strategy on the way, the numbers of persons requiring treatment will significantly 
increase, especially in low resource, high burden settings. This will require substantial speed 
in resource scale-up and health systems strengthening to meet increased testing demands 
(Figure 1.7). Many countries however, still cannot afford routine VL monitoring. 
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Figure 1.7: The WHO scenarios of treatment eligibility estimated in 2012. Even though 
numbers have increased, this diagram illustrates the sheer numbers of people 
requiring ART as guidelines have changed and potentially move to ‘test and treat’ 
strategy. Adapted from UNAIDS ‘90-90-90’ document (2).  
In South Africa, to cope with the increased testing burden needed to meet the NSP and ’90-
90-90’ goals, health system strengthening will be needed. To achieve this, both
decentralisation (moving laboratory services closer to the patient) of ART services to PHC 
clinics and integration with TB services (237) in a triaged fashion (bearing in mind infection 
control practices), together with innovation around linkage to care, will be needed. 
Integration of laboratory systems and services can be defined as a laboratory network, which 
Now 35 million! 
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can provide all the primary diagnostic services needed by a patient for their appropriate care 
and treatment, without requiring them to go to different laboratories for specific tests (238).  
South Africa has 3,991 public health facilities delivering HIV care (Figure 1.8) and in order to 
integrate HIV and TB services into a single one-stop facility (supermarket approach), 
significant restructuring of PHC facilities will be required (239). To this end, the South African 
NDoH has recently embarked on a new project called the ‘Ideal Clinics Initiative’, which aims 
to strengthen and improve service delivery at PHC clinics (240). The project will focus on 
certain key challenges faced by PHC clinics, one of which deals with laboratory service 
delivery. The vision is to integrate various new innovations such as extension of Short 
Message Service (SMS) printers and electronic gatekeeping, extending the use of 
phlebotomists, community based access to results and implementation of POCT to achieve 
health system strengthening (241).  
The latter, despite much interest and rapid growth globally, remains controversial in part 
because POCT challenges the conventional approach to laboratory testing, and specifically 
for South Africa, the prevailing paradigm. 
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Figure 1.8: Health care facilities and NHLS laboratory coverage throughout South 
Africa. There are 4576 health facilities serviced by the NHLS, of which 3991 provide 
ART. Within this network, there are 60 CD4 laboratories, 17 HIV viral load laboratories 
and 216 GeneXpert® testing sites. In 2014, 4 million CD4 tests, 2.8 million viral loads 
were performed. Since implementation of the GeneXpert® in March 2011, >5.7million 
Xpert® MTB/RIF tests have been conducted nationally (84, 242). 
1.5.1 POSSIBLE IMPLEMENTATION MODELS: THE TIERED HYBRID 
(LABORATORY/POCT) MODEL 
There are differing views on how POCT should be implemented on a national scale in South 
Africa. The NHLS laboratory testing network currently servicing 80% of the population with 
266 laboratories throughout the nine provinces of South Africa (1) (Figure 1.10). Despite the 
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advantages of centralised laboratory testing (high throughput, automation), the need for high 
level technical skill, infrastructure, space, cold chain requirements and instrument 
maintenance are limiting full implementation and scale up of this type of testing (60, 243). As 
mentioned previously, logistical issues also exist such as need for venous blood draw and 
proper transport of venous specimens to centralized facilities. Many patients are also lost to 
follow up due to increased result turnaround times and great distances between testing 
centres and patients’ homes (244). Services need to be brought closer to the patient or 
logistics for sample collection and transport to centralised laboratories (such as the use of 
DBS) need significant improvement (2). On the other end of the spectrum, a total 
decentralization model through POCT will not be possible due to the sheer volumes of 
testing required.  A hybrid model that includes both POCT and different tiers of laboratory 
testing may provide the best fit. 
The NHLS’s intent is to expand the three-tiered model to a hybrid model for CD4 testing 
which encompasses a six-tiered network in order to provide total coverage of services, even 
to areas where there is no access to laboratories (1) (Figure 1.9). Through this hybrid model 
which integrates both laboratory and POC-based testing, testing coverage is not only 
extended, but result turnaround times are decreased and programmatic costs are better 
contained (1).  
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Figure 1.9: The current NHLS CD4 tiered laboratory network. Tier 1 represents ‘true’ 
POC in remote areas; Tier 2 is a ‘POC Hub’ which consolidates POCT across clinics and 
provides low throughput laboratory testing; Tier 3 represents a community laboratory 
which services health clinics; Tier 4 is a district laboratory; Tier 5 is a centralized 
laboratory with high volume testing; Tier 6 represents coordinated national support 
from an expert team (1). 
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1.5.2 CHALLENGES FACING MULTIPLE POINT-OF-CARE TESTING FOR 
SOUTH AFRICA 
For implementation of POCT, South Africa will be faced with unique operational challenges 
due to the need for multi-disciplinary POCT that will require careful consideration.  
With the surplus of POC diagnostics in the pipeline for both HIV and TB, how will we go 
about ensuring that upcoming technologies are appropriate for our clinical setting? Prior to 
implementation of a POC test, evaluations need to be conducted in the population for which 
the test is intended. Many of the new POC technologies have limited evaluation data or are 
in the early stages of development. CHAI, UNITAID and especially the London School of 
Hygiene and Tropical Medicine (LSHTM) have been given funding to develop standardised 
protocols and conduct validations on new POC assays. With multi-disciplinary testing 
requirements for South Africa, the question of how multiple tests will be performed in the 
field by nurses on a single patient within the current clinic workflow is also pertinent and may 
require reengineering. In remote settings, phlebotomy skills are a limiting factor to increasing 
access to testing. In this context, the use of finger or heel sticks would be ideal, however, for 
an HIV-positive individual, this would translate to up to four finger sticks per single clinic visit 
as per national in-country guidelines (47), not to mention the two finger stick performed at 
HCT, potentially on the same day for the coming “test and treat” option.  
Infrastructure and operational requirements are also likely to be major barriers to scaling up 
POCT in South Africa (105) as it is unknown whether nurses at clinic sites have the available 
time or skills to perform multiple POCT appropriately or if clinics have the available 
resources. Studies have shown that certain POC tests may require additional human 
resource requirements. For the GeneXpert® MTB/RIF implementation in a PHC clinic in 
Johannesburg, 2.5 staff members were required for every 15 patients receiving same day 
treatment (245). Implementation of POCT may also require additional infrastructure, often 
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lacking from PHC clinics such as stable electricity, waste disposal and temperature 
control (112).  
Although POC tests are designed to be simple and easy to use, the need for training should 
not be underestimated. The skill set of the local workforce to operate the tests also needs to 
be taken into account (207). In an ideal world, POC systems should be easy to operate by 
non-laboratory staff with minimal training and require very little sample manipulation. 
However, besides operation of the test device, training also needs to include other aspects 
such as good laboratory practice, quality control, safety and maintenance as well as how the 
test fits into the prevailing clinical algorithm (207).  
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1.6 RESEARCH OBJECTIVES 
The South African NDoH requires a concrete recommendation for the country on laboratory 
and POCT for HIV and TB, incorporating either a centralised, decentralised or hybrid model. 
During 2011, a Grand Challenges Canada (GCC) Grant (grant # 0007-02-01-01-01) (246) 
was awarded to Professor Wendy Stevens with the aim of assessing the feasibility of 
implementing multidisciplinary POCT for HIV and TB service integration in South Africa. The 
main objective of this project was to determine whether multidisciplinary POCT for HIV and 
TB diagnosis and monitoring could be performed in remote settings, by non-laboratory 
personnel; that it was cost effective and could impact positively on patient treatment 
outcomes. This was an ambitious, global project requiring a multidisciplinary team to 
execute; scientists, bioengineers, nurses, health economists and various clinical partners.  
The current PhD candidate’s work is embedded within the objectives of the GCC project 
(Figure 1.10) and focused on investigating operational requirements for POC implementation 
and ensuring best practice guidelines to ensure POCT not only integrates with the existing 
laboratory testing network, but also complements it without disrupting patient care. 
This was achieved by taking the core requirements for a quality diagnostic laboratory testing 
framework (247) and adapting and developing it specifically for POCT, as detailed in the 
objectives below. 
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Figure 1.10: Outline showing the main objectives of the GCC project, with red 
highlighted boxes indicating the contribution of work from the PhD candidate. 
Objectives: 
1. To identify the key challenges and potential solutions for multiple POCT in South
Africa through
a. assessment of clinical needs for POCT, and
b. engaging with government to develop the basis for standards and guideline
documents to inform the use of POCT in future.
2. To determine standard acceptance criteria for evaluating new HIV and TB POC
technologies:
a. Establish analytical acceptance of POC technologies through laboratory
evaluations;
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b. Establish field acceptance for POC technology performance through clinical
evaluations.
In parallel with objective 2: 
3. To develop best practice guidelines for clinical implementation of multi-disciplinary
POCT in terms of:
a. Site, training and quality requirements.
4. To determine the performance and operational requirements of multiple POCT for
HIV and TB service integration in South Africa.
The abovementioned objectives are addressed by subsequent chapters. 
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CHAPTER 2: ASSESSING CLINICAL NEEDS FOR POCT AND 
ENGAGING GOVERNMENT 
The clinical needs for POCT and potential approaches to implementing POCT were 
highlighted in the following manuscript and a summary presented as an oral abstract at the 
following conference: 
a) Natasha Gous on behalf of Wendy Stevens. 2013. Point of Care diagnostics: South
Africa’s experience. In: Laboratory Medicine Congress, Cape Town, South Africa, 28th-
31st July.
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2.1 FEASIBILITY OF HIV POINT-OF-CARE TESTS FOR RESOURCE-LIMITED 
SETTINGS: CHALLENGES AND SOLUTIONS 
Medicine for Global Health
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http://www.biomedcentral.com/1741-7015/12/173REVIEW Open AccessFeasibility of HIV point-of-care tests for
resource-limited settings: challenges and solutions
Wendy Stevens1,2*, Natasha Gous1, Nathan Ford3 and Lesley E Scott1Abstract
Improved access to anti-retroviral therapy increases the need for affordable monitoring using assays such as CD4
and/or viral load in resource-limited settings. Barriers to accessing treatment, high rates of loss to initiation and poor
retention in care are prompting the need to find alternatives to conventional centralized laboratory testing in
certain countries. Strong advocacy has led to a rapidly expanding repertoire of point-of-care tests for HIV. point-of-
care testing is not without its challenges: poor regulatory control, lack of guidelines, absence of quality monitoring
and lack of industry standards for connectivity, to name a few. The management of HIV increasingly requires a
multidisciplinary testing approach involving hematology, chemistry, and tests associated with the management of
non-communicable diseases, thus added expertise is needed. This is further complicated by additional human
resource requirements and the need for continuous training, a sustainable supply chain, and reimbursement
strategies. It is clear that to ensure appropriate national implementation either in a tiered laboratory model or a
total decentralized model, clear country-specific assessments need to be conducted.
Keywords: Anti-retroviral therapy, CD4, Challenges, HIV, Implementation, Point-of-care, Viral loadIntroduction
Globally, the number of persons living with HIV has in-
creased from 34 million (31.4 to 35.9 million) in 2011 to
an estimated 35.3 million (32.2 to 38.8 million) in 2012;
approximately 69% of the global HIV burden resides in
sub-Saharan Africa [1]. In response to anti-retroviral
therapy (ART) programs, a concurrent drop in AIDS-
related deaths from 2.3 million (2.1 to 2.6 million) in
2005 to 1.6 million (1.4 to 1.9 million) in 2012 has been
recorded [1]. In order to reach the expected 2020
goals, a massive increase in HIV testing capacity will
be required.
The expansion of ART programs can only be des-
cribed as a huge success in low- and middle- income
countries. Estimates reached 9.7 million on ART at the
end of 2012, representing some 60% of those in need at
that time [2]. With the new World Health Organization
(WHO) guidelines changing the CD4 test threshold for* Correspondence: wendy.stevens@nhls.ac.za
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unless otherwise stated.113 | P  a g  etreatment initiation from mid-2013, the number of indi-
viduals infected with HIV potentially requiring access to
treatment has increased to an estimated 28.6 million [1].
Challenges to continued ART scale-up remain, and in-
clude improving access to HIV testing, ensuring universal
access to testing, earlier initiation of treatment by im-
proved access to HIV testing, ensuring subsequent linkage
to care, and finally long-term retention in care. Each phase
of HIV diagnosis and monitoring is supported by a num-
ber of tests conducted according to different algorithms in
many high-burden countries, each with human and tech-
nical resource requirements. HIV rapid tests, used in
adults in serial or parallel algorithms using one to three
different assays, have been instrumental in ensuring
wide-scale diagnosis and access to care, albeit with on-
going challenges to ensure quality. A recent estimate from
President's Emergency Plan for AIDS Relief (PEPFAR)
countries suggests over 80 million HIV rapid assays were
performed in 2013 and that 11% of all assays were
conducted as point-of-care tests (POCTs) (Jason Williams,
personal communication).
CD4 testing has been the gatekeeper for assessing im-
mune status and establishing eligibility for treatment and
care. Treatment eligibility threshold levels have changedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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2010 [4]. More recently, the new consolidated WHO rec-
ommendations suggest initiation at CD4 counts of <500
cells/μl [5]. Further suggestions of universal access and
test and treat strategies are also being evaluated and hotly
debated [6]. The latter approach is already occurring
for certain high-risk population groups such as those
co-infected with tuberculosis (TB), pregnant women, and
children under 5 years of age. CD4 count has also been
used for regular monitoring of immunological recovery on
treatment, generally at six-monthly intervals. CD4 testing
can be done at different tiers of the laboratory service [7]
and the frequent delay in linking this assay to the initi-
ation of patient care can result in significant loss to
follow-up [8]. CD4 testing is also recommended by WHO
and used in South Africa as a benchmark for estab-
lishing the risk of cryptococcal infection, where testing for
cryptococcal antigen can now be done at point-of-care
(POC) and the onset of meningitis can be prevented if
treated with fluconazole [9].
The HIV viral load (VL) assay, a nucleic-acid-based
test, is used to monitor response to treatment; an unde-
tectable viral load defines treatment success. VL testing
is frequently done in centralized facilities and currently
requires expensive instrumentation, technical skill, and
has relatively high costs per assay. Despite these chal-
lenges, this assay has gained its rightful place in guide-
lines and clinical practice and is thought to be the most
reliable marker for treatment success [10,11]. The deve-
lopment pipeline of POC VL assays promises to deliver
a number of options to improve access and facilitate
earlier identification of treatment failure. This will allow
clinicians to avoid premature switching of regimens,
particularly in regions with limited drug availability, po-
tentially improving patient adherence and reducing the
development of drug resistance [12]. Also, the percent-
age of failures using this assay can provide a monitor of
both individual and program success [13]. As access to
VL testing is improving, the role of CD4 measurements
is being reassessed. Numerous studies have demon-
strated that for the vast majority of people living with
HIV who are receiving ART and are virally suppressed,
CD4 cell count does not decline over time [14]. Other
studies have shown that one third of individuals whose
CD4 count was greater than 350 cells/μl had viral loads
greater than 100,000 HIV RNA copies/ml [15]. A meta-
analysis of seven studies assessing the accuracy of clin-
ical or CD4 tests in predicting virological failure found a
poor sensitivity of 26.6% and a positive predictive value
of 49.4% [11]. This suggests that in situations where viral
load is available routinely, CD4 monitoring can be re-
duced in frequency or stopped altogether. Recognizing
this opportunity to save resources, the South African
ART guidelines in 2013 recommended stopping routine114 | P  a  g  eCD4 monitoring in people who are stable on ART and a
number of other countries are considering moving in
this direction [16].
In addition to the core assays described in individuals
with HIV, there are also hematology and biochemistry
assays that remain important, including hemoglobin,
creatinine (especially for tenofovir initiation) and liver
transaminase tests as well as assays for the diagnosis of
opportunistic infections such as TB and cryptococcal in-
fection. The diagnosis and treatment of TB is critical in
low- and middle- income countries where a significant
proportion of individuals with HIV infection are
co-infected with TB. In South Africa as an example,
co-infection rates are as high as 65% to 70% [17].
To address all the needs described above and in the
face of the successes of rapid tests such as those for
HIV, malaria and, more recently, cryptococcal antigen,
there is a drive now towards using POCT for the non-
communicable diseases such as diabetes, cardiovascular
disease and cancer, many of which are associated with
long-term management of people living with HIV. Thus,
there is an expanded list of multidisciplinary testing
needs at primary health clinics (PHC). Performing and
interpretation of these tests will potentially require
significantly more expertise than a single rapid HIV
antibody test.
History of point-of-care testing
POCT is an old approach to testing that has been around
for decades and remains as controversial today as it was
when first introduced. POCT refers to testing that is
performed near to or at the site of patient care, with the
result leading to a possible or immediate change to patient
care [18]. The rationale is largely based on a need for
shortening the time to decision making. The literature
provides a myriad of different definitions such as the
Clinical Laboratory Standards Institute in the USA, which
defines the purpose of POCT being the provision of timely
results that clinically and cost-effectively contribute to
management decisions [19]. The first references to POCT
date back to the early 1990s and focused largely on glu-
cose testing for diabetes and blood gas analyzers in ICUs
and operating theaters [20]. The controversy around man-
agerial, quality and regulatory ownership remains a prob-
lem and it has been suggested that this is still a ‘work in
progress’ [21]. Despite this, POCT is the fastest growing
segment of the diagnostic industry (10% to 14% annually),
accounting for one in four tests within the developing
world [22,23]. A recent review reported that POCT ac-
counts for 25% of total laboratory revenue [24]. New diag-
nostics into which POCT has expanded include cardiac
markers, coagulation assays, substance abuse and home-
based HIV testing, to name a few [25]. Interestingly, POC
devices include not only ex vitro but also in vitro and
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[26]. Technological advances such as microfluidics [27],
miniaturization [28], microfabrication, simple power and
affordable light sources, electromagnetic actuation of
fluids using microelectronics and, more recently, nano-
diagnostics [29,30] have facilitated the development of
more complex assays capable of placement at the POC
[28]. Thus, rapid tests described for HIV diagnosis have
been described as first-generation POC assays, involving
antigens and antibodies and simple biochemistry and
hematology; the second generation is infinitely more
complex and based on cell detection or nucleic acid
amplification and detection; the third generation will
involve complex analyzers that could have multiplexing
capabilities [31].
Global perspective on point-of-care testing
The unmet laboratory needs for assays to address com-
municable diseases such as HIV, TB and malaria appear
to have assisted in catalyzing the POC diagnostics industry
as a whole. Both communicable and non-communicable
diseases will in future reap the benefits as appropriate im-
plementation strategies are developed [31]. This is particu-
larly important when predictions for the future suggest
that diabetes may well be a more important risk factor for
TB than HIV. Global market assessments have suggested
that the increase in diabetes and thus glucose testing com-
prises at least 10% of the global POCT market [32]. The
growth in POC HIV testing has been further reinforced by
strong advocacy from groups such as the WHO (One
pillar of Treatment v2.0 {WHO Department of HIV/AIDS,
2011 #99}guideline [33], WHO 2013 treatment guide-
lines [34]), UNITAID (market catalysts; Geneva), the Bill
and Melinda Gates Foundation, the Clinton Foundation,
PEPFAR and the African Society of Laboratory Medicine,
who have been tasked with promoting guidance and im-
plementation in field sites. This drive has begun to address
many of the factors mentioned above, such as the absence
of laboratories or access to assays such as CD4 and VL
testing for the diagnosis and monitoring of HIV in remote
sites. Alternatives to conventional centralized testing are
being driven by the high rates of loss to initiation for both
HIV and TB, as well poor retention in care [35]. These
activities have catalyzed funders, suppliers, users and
patients in galvanizing the POC diagnostics industry into
action. In addition, POCT has been incorporated into the
Global Health Strategy on HIV/AIDS [36]. Both the
WHO and the London School of Tropical Medicine
and Hygiene have been tasked with bringing forward
multi-center laboratory-based validations of POC assays
followed by an evaluation of their implementation in the
field [37]. Strong emphasis has also been placed on the
need for monitoring the impact and cost of the interven-
tions across the entire continuum of care. By nature of the115 | P  a  g  elow throughput of these technologies and the additional
human resources required in the field for testing and
maintenance, the total assay costs can be as expensive, or
more expensive, than laboratory testing. A strong em-
phasis needs to be placed on innovative strategies to en-
sure quality for tests that are being conducted in volumes
far beyond that covered by conventional laboratory quality
assurance plans and accreditation status. In South Africa,
there is an ISO standard (ISO22789) that has been imple-
mented for accredited laboratories to follow if they are
conducting and supporting POC testing [38]. Perhaps
a similar approach to accreditation of clinic sites con-
ducting POC testing with a simpler standard and checklist
could be used to ensure quality is maintained in field-
testing sites.
The pipeline for HIV diagnosis and monitoring
There is an ever-expanding pipeline associated with the
strong advocacy for POCT from global players, who main-
tain that universal access for HIV and TB care requires
the use of POCT for earlier testing and improved re-
tention in care. Cited advantages of POCT include im-
proved turnaround time, greater accessibility, potentially
improved patient retention and possible reduction in over-
all healthcare costs. However, despite the rapid growth
and interest in POCT, many aspects remain controversial,
in part because this approach challenges the conventional
approach to laboratory testing, which remains the prevail-
ing paradigm in many countries. In addition, while nu-
merous early or near market entry products are available,
at the time of writing few could be purchased on a large
scale, outside of rapid HIV and malaria strip-based tests,
and a monopoly exists of one or two suppliers with a
proven track record for CD4 testing, such as the PIMA
assay (Alere Inc., Waltham, MA, USA). In the VL arena,
many early market entry products are available and devel-
opment has been heavily funded, yet only three were avail-
able for clinical validation as of April 2014 - the LIAT™
Analyzer (IQuum, Inc., Roche) [39], Alere™ q HIV-1/2
Detect (Alere) [40] and Samba (Diagnostics for the
Real-World, Ltd.) [41] - and manufacturing track records
for scale-up were not available. The upcoming pipeline
for HIV CD4 and VL testing with their performance
characteristics are summarized in the landscape document
produced annually by UNITAID [12]. A plethora of fast
followers are in various stages of research, development
and evaluation and include the MBio POC CD4 (MBio
Diagnostics, Inc)(Co,USA) [42], Daktari CD4 Counter
(Daktari Diagnostics, Inc.)(MA, USA), FACSPresto™ (BD
Biosciences)(NJ, USA) [43], Visitect® (Omega Diagnostics),
Zyomyx CD4 (Zyomyx, Inc.) and EMD Millipore® Muse™
(Merck)(Darmstadt,Germany) [12]. For VL testing, these
include the GeneXpert® Viral Load system (Cepheid,
Sweden), the EOSCAPE-HIV™ Rapid RNA Assay system
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Time micro PCR system (MolBio Diagnostics, Ltd.),
Goa, India Savanna VL test and platform (Northwestern
Global Health Foundation in collaboration with Quidel
Corporation) and Bioluminescent Assay in Real Time tech-
nology (Lumora, Ltd.)(cambridgeshire,UK) [45], amongst
others [12].
In countries where significant laboratory infrastructure
currently exists in both the public and private sectors,
the sheer volumes of testing may make total decentra-
lization prohibitive in terms of instrumentation and
human resource requirements. In these instances, POC
assays may and do have a role to play where gaps in
service are noted, which can be identified by approaches
such as geographic information systems mapping to en-
sure a national ‘total coverage model’. The total coverage
model is a new term being used in laboratory testing cir-
cles which refers to a tiered implementation model that
includes both POC testing and different tiers of labora-
tory testing to ensure access for the entire national po-
pulation. POCTs are also used heavily in specific niche
areas such as hemoglobin in emergency rooms or renal
clinics. A particular niche for the VL assay could, for ex-
ample, be in maternity wards and antenatal care clinics
where pregnant women infected with HIV could be
monitored for risk of transmission and success of treat-
ment strategies, and exposed infants could be tested at
birth for HIV and then treatment initiated as soon as
possible.
Major issues surrounding the implementation of POCT
exist and include poor regulatory control, difficulties in
ongoing monitoring of quality, and limited availability of
guideline documents for the safe implementation of POC
devices. In addition, there are few studies that report data
on full economic costing for POC [46], which is likely to
vary depending on tests used, diseases investigated and
model input parameters.
There is a dearth of well-designed randomized
controlled clinical trials (RCTs) to evaluate the outcomes
and impact of the implementation of POCT. Most
notable for their contributions to the POC literature are
a group led by Shephard in Australia [47,48]. Although
evaluating other assays in a general practitioner setting
in Australia, the final study conclusions were that POCT
was not inferior to laboratory-based testing, but came at
a substantially higher cost that needs to be weighed
against overall health benefits. Various clinical experi-
ences were presented at a recent forum held in South
Africa, with a number of studies reporting progress in
RCT studies such as the Home-based Care Plus trial in
Kwazulu-Natal, Rapid Initiation of Anti-retrovirals in
Pregnancy (RAP) study in Cape Town, the Grand Chal-
lenges Canada RCT, and RapIT (Midrand PHC, South
Africa). Results are still awaited eagerly and will help116 | P  a  g  eform policy but have shown clearly that POCT is just
one step in a multi-step process along the continuum of
care [49]. Other experiences show that POCT has great
potential for certain high-risk populations such as mi-
grants or adolescents where loss to follow-up is high and
where immediate results would add value [49].
Pilot studies on the implementation of PIMA CD4
POC testing in South Africa and Mozambique have
demonstrated that time to initiation is reduced; however,
challenges were identified in that nurses perceived POC
implementation as additional workload, and patients
migrated from facilities before staff were able to track,
record and file the results in patients’ folders [49]. Expe-
riences from Mozambique showed that after the intro-
duction of POC CD4, the loss to follow-up before CD4
staging dropped, ART initiation rate increased, and time
to ART initiation was reduced from 48 days to 20 days
[50]. Retention rates in care, however, remained the
same. It was recommended by this group that deploying
POC should be done in in conjunction with conven-
tional testing as part of a total laboratory network and
there was acknowledgement that POC testing is far from
error-proof. Only 20% of Mozambique’s CD4 counts are
conducted at POC. High invalid rates were noted using
POC CD4 tests in this study. The authors warned that
simple implementation is not always efficient - access
does not necessarily mean that the patient gets care
(approximately 25% of patients did not get CD4 testing
even with POCT on site). They also highlighted that
significant health systems strengthening is needed and
clinic workflow re-engineering. A meta-analysis of the
performance of PIMA is underway and preliminary
analysis have revealed that the performance of the in-
strument on venous specimens is as good as current
gold standard technology. However, the performance
on capillary-derived specimens showed increased vari-
ability at the 350 cells/μl threshold, resulting in higher
false-positive rates that would lead to more patients being
placed on ART (unpublished results, Lesley Scott personal
communication).
Approaches to ensuring quality testing
The US Food and Drug Administration requirements for
defining a simple test are that it should be rapid, easy to
perform, require minimal training and no specialized
laboratory setup, and reagents should be stable and tem-
perature independent. However, few assays actually meet
these requirements. It should be noted that assay trans-
fer from the laboratory to POC is not synonymous with
improved quality of care. Implementation at the POC
will require facilitation in a step-wise fashion with care-
ful monitoring and evaluation at each step. The approach
to quality of rapid lateral flow-based assays will be diffe-
rent to those that are device based. Several guidelines for
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uptake of these recommendations has been poor in
most resource-limited settings. In fact, many of these
assays are considered Clinical Laboratory Improvement
Amendment-waived because they are simple tests with
a low risk for an incorrect result and are thus not
quality assured in developed countries such as the USA.
While programs such as the WHO pre-qualification
process [51] have provided guidance by conducting
product and supplier evaluations and validations, and
the Centers for Disease Control and Prevention (CDC)
has done similar work for PEPFAR-related programs,
there is a need for harmonization of approaches and stan-
dardization of protocols with greater co-operation be-
tween stakeholders. There needs to be co-ordination
between and a review of all strategies and guidelines
so that a simple, single guidance can be provided for
countries. Quality needs to be addressed, within the
laboratory and at the pre-analytic, analytical and post-
analytical phases [22]. For rapid assays, the sheer vol-
umes of assays conducted make conventional internal
and external quality approaches extremely difficult to
implement. Strategies employed have included the use
of external quality assurance (EQA) material using dried
tube spots for various HIV rapid assays [52] or dried
culture spots for near POCT for TB [53,54]. Innovative
strategies are required for material distribution and data
collection across large programs. Regular training and
re-training, competency assessments, and ongoing super-
vision and mentoring of staff conducting assays are all
critical to ensuring continuous maintenance of quality.
For device-based assays, an approach that is under
scrutiny is the use of real-time continuous monitoring
using various connectivity systems linked to analyzers in
the field [55,56]. Connectivity provides a means not only
to ensure analyzer performance meets requirements, but
also of collecting programmatic data, distribution of re-
sults and identifying the need to intervene should prob-
lems arise. Data ownership and data security are issues
that need to be addressed. Each analyzer, however, fre-
quently connects to the middleware or software solution
via a different mechanism and there is thus a need for
industry standards for POCT connectivity [57]. Several
middleware programs have been evaluated that link to
laboratory information systems in South Africa with
success, although approaches differ in different regions
depending on wireless availability, internet access and
computer literacy. Thus solutions may need to be con-
textualized within different geographic regions. Simpler
approaches may include the use of bi-directional short
message service printers with additional capabilities
for data collection and acknowledgement of receipt of
results [58]. To improve retention in care, patients can
be recalled for results, and this makes for a reasonably117 | P  a  g  esuccessful means of improving adherence [59]. The role
of secondary and tertiary laboratories in the management
of quality in PHCs is essential and many believe POCT
should be a natural extension of the laboratory [60].
Supply chain management and procurement strategies
need to be well planned. Global procurement and global
forecasting may play a larger role than for other assays
because the production lines for new assays entering the
market are frequently unable to meet the demand of
rapid recommendations that lead to rapid global uptake.
Engagement with industry in the pre-market phase may
help to ensure quality features are built into the system,
connectivity is considered, and production meets the
needs based on information provided on disease preva-
lence and likely test numbers. UNITAID, as an organiza-
tion that funds approaches to catalyze and effect market
changes, can stimulate additional approaches improving
access. Advocacy for quality assured, appropriately
selected assays used in settings where impact can be
demonstrated is strongly needed.
Ownership and accountability
There is a general consensus that ownership should be
at the level of in-country ministries of health. A POCT
policy needs to be embedded within national strategic
laboratory plans, the development of which was strongly
advocated for by the Maputo declaration [61]. A single
strategic national plan for the introduction of POCT in
a country is likely to solicit donor funding or that of
local treasuries in a far more effective manner. It is
imperative that technical task teams are established to
support decision making. The composition of the team
should include clinicians; laboratorians; health econo-
mists; procurement, supply and distribution workers;
and funders. Strong partnerships with industry need to
be facilitated because the ongoing procurement, main-
tenance of analyzers and product failures need to be
addressed. As a result of recent product failures in the
HIV arena impacting many countries, a task team was
established with expertise from organizations such as
the WHO, CDC and other partners. This may be useful
going forward to urgently address product failures as
this body is formalized. This brings in the concept of a
far more active reporting to support post-market sur-
veillance, currently poorly coordinated the world over.
Ownership of the POCT process, however, needs to
extend to users of the assays and the communities that
are tested, with creative ways developed for incentiviz-
ing healthcare workers conducting the tests to maintain
high quality standards.
Conclusions
POCT will improve access to needed HIV and associated
diagnostics, but these assays are not without limitations
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tegrate these technologies cost-effectively and efficiently
into clinical algorithms and existing laboratory networks.
In costing, it should be emphasized that context matters,
particularly human resources and test volumes. There is
much to be done in this field. Notably, large randomized
studies measuring the impact of a diagnostic interven-
tion along the entire continuum of care are currently an
exception and need to be encouraged and supported.
Standardization of assay evaluation and development of
appropriate internal and external quality control are im-
portant activities that need support. Regulatory hurdles
need to be overcome and developed in many countries.
Global harmonization of all stakeholder activities is es-
sential to get the product from an idea to the bench and
ultimately to the patient bedside. The likelihood is that
in many countries POCT will be strategically deployed
in a hybrid model with support from the conventional
tiers of in-country laboratories.
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CHAPTER 3: THE EVALUATION OF NEW TECHNOLOGIES 
FOR THE DIAGNOSIS AND/OR MONITORING OF HIV AND TB 
Several new technology evaluations for HIV and TB were performed, with a particular focus 
on potential POC technologies, two of which are featured in subsequent publications.  
Further HIV and TB technology evaluations were also presented in the following list of 
conference abstracts: 
HIV technology evaluations: 
a) Gous N. 2015. Experience with a polyvalent molecular platform: The Xpert® MTB/RIF
assay and the Xpert® HIV-1 Quant assay. In: Cepheid Satellite Session on Your
GeneXpert® Can Do So Much More!! 7th SA AIDS Conference, Durban, SA, 9-12 June.
b) Scott LE, Gous N, Carmona S, Stevens WS. 2014. HIV viral Load Monitoring: Introducing
New Technologies. In: Cepheid Lunch and learn. ASLM, Cape Town, South Africa, 30th
November – 4th December.
c) Scott LE, Gous N. 2014. Alere Q whole blood viral load assay (prototype) evaluation for
ART monitoring. Symposium. In: ASLM, Cape Town, South Africa, 30th November - 4th
December.
d) Gous N, Scott LE. 2015. Longitudinal cohort analysis of dried blood spots for viral load
monitoring. In: 7th SA AIDS Conference, Durban, SA, 9th-12th June.
TB technology evaluations 
e) Stevens W, Gous N, Erasmus L, Coetzee G, Cunningham B, Scott L. 2011.Taking the
first steps in national GeneXpert® implementation: lessons learned from South Africa. In:
IAS, Italy, 17th – 20th July.
f) Gous N, Scott LE, Khan S, Reubenson G, Coovadia A, Cunningham B, Stevens W. 2012.
The Reality of Xpert® MTB/RIF at Point of Care (POC) for the Diagnosis of Childhood TB
using Raw Sputum. In: CROI, Seattle, USA, 5th – 8th March.
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g) David A, Gous N, Stevens W, Scott LE. 2014. Laboratory validation of Ustar EasyNAT™
Diagnostic test compared to GeneXpert® MTB/RIF for qualitative detection of
Mycobacterium tuberculosis using Dried Culture Spots. In: ASLM, Cape Town, South
Africa, 30th November - 4th December.
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3.1 LABORATORY EVALUATION OF THE LIAT HIV QUANT (IQUUM) 
WHOLE-BLOOD AND PLASMA HIV-1 VIRAL LOAD ASSAYS FOR POINT-
OF-CARE TESTING IN SOUTH AFRICA 
Laboratory Evaluation of the Liat HIV Quant (IQuum) Whole-Blood
and Plasma HIV-1 Viral Load Assays for Point-of-Care Testing in
South Africa
Lesley Scott,a Natasha Gous,a Sergio Carmona,a,b Wendy Stevensa,b
Department of Haematology and Molecular Medicine, School of Pathology, Faculty of Health Science, University of Witwatersrand, Johannesburg, South Africaa; National
Health Laboratory Services, National Priority Program, Johannesburg, South Africab
Point-of-care (POC) HIV viral load (VL) testing offers the potential to reduce turnaround times for antiretroviral therapy moni-
toring, offer near-patient acute HIV diagnosis in adults, extend existing centralized VL services, screen women in labor, and
prompt pediatrics to early treatment. The Liat HIV Quant plasma and whole-blood assays, prerelease version, were evaluated in
South Africa. The precision, accuracy, linearity, and agreement of the Liat HIV Quant whole-blood and plasma assays were com-
pared to those of reference technologies (Roche CAP CTMv2.0 and Abbott RealTime HIV-1) on an HIV verification plasma panel
(n 42) and HIV clinical specimens (n 163). HIV Quant plasma assay showed good performance, with a 2.7% similarity coef-
ficient of variation (CV) compared to the Abbott assay and a 1.8% similarity CV compared to the Roche test on the verification
panel, and 100% specificity. HIV Quant plasma had substantial agreement (pc [concordance correlation] 0.96) with Roche on
clinical specimens and increased variability (pc 0.73) in the range of<3.0 log copies/ml range with the HIVQuant whole-
blood assay. HIV Quant plasma assay had good linearity (2.0 to 5.0 log copies/ml; R2 0.99). Clinical sensitivity at a viral load of
1,000 copies/ml of the HIV Quant plasma and whole-blood assays compared to that of the Roche assay (n 94) was 100% (confi-
dence interval [CI], 95.3% to 100%). The specificity of HIV Quant plasma was 88.2% (CI, 63.6% to 98.5%), and that for whole
blood was 41.2% (CI, 18.4% to 67.1%). No virological failure (downwardmisclassification) was missed. Liat HIV Quant plasma
assay can be interchanged with existing VL technology in South Africa. Liat HIV Quant whole-blood assay would be advanta-
geous for POC early infant diagnosis at birth and adult adherence monitoring and needs to be evaluated further in this clinical
context. LIAT cartridges currently require cold storage, but the technology is user-friendly and robust. Clinical cost and imple-
mentationmodeling is required.
HIV viral load (VL) testing is used to monitor the effectivenessof antiretroviral therapy (ART) after initiation, identify early
virological failure and targeted adherence, and finally to provide
guidance on when to switch therapy in late failures (1). VL testing
has been used in the diagnosis of HIV acute infection (2) and early
infant diagnosis (EID; 18 months of age) (3, 4); however,VL
testing may be limited in the developing world, and EID still is
widely performed with a qualitative test and VL is used as a sec-
ondary test (5). Several well-established VL technologies are avail-
able (6) in high-throughput and, more recently, ultrahigh-
throughput platforms designed for centralized laboratories with
good quality control. There is a dire need to increase access to VL
testing in resource-limited settings (7) and to simplify and im-
prove efficiency in diagnostics to ensure patient care is not com-
promised. Complexities related to logistics and sample transport
to ensure RNA integrity in blood specimens is one limitation to
providing full access to VL testing (8). Solutions to increasing
access to VL testing being investigated are the use of dried blood
spots (9–11), which are easy to transport and appear to extend
sample RNA integrity (12), and on-site (point-of-care [POC]) VL
testing (without requiring specimen transport and potential loss
of specimen integrity) (13). POC VL testing, however, has been
slow in commercialization, especially for large-scale implementa-
tion programs, such as that in South Africa. In spite of a rich
diagnostic development pipeline and ample global support, in-
cluding the Liat (laboratory-in-a-tube) analyzer (Roche Molecu-
lar Systems, NJ, USA), Alere q HIV-1/2 (Alere, Jena, Germany),
SAMBA (Diagnostics for theRealWorld, Ltd., Cambridge,United
Kingdom), GeneXpert viral load system (Cepheid, Sunnyvale,
USA), and the EOSCAPE-HIV rapid RNA assay system (Wave 80
Biosciences, San Francisco, CA), among others (14, 15), few HIV
VL POC tests have been evaluated and are commercially available
(16, 17).
One such promising technology is the LiatHIVQuant POCVL
assay (IQuum, Inc., Marlborough, MA, which was recently ac-
quired by Roche Molecular Systems, Inc., Branchburg, NJ, USA)
(18 and http://www.roche.com/media/media_releases/med-cor
-2014-04-07.htm). A validation of this technology’s initial plasma
assay, requiring 200l plasma, showed good performance against
theHIV-1 real-time test (AbbottMolecular, Des Plaines, IL, USA)
(17). The current Liat HIV Quant molecular assay is a fully auto-
mated POC test that generates a quantitative HIV VL within 30 to
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35min using either 150l plasma (Liat HIV plasma Quant assay)
or 75l whole blood (Liat HIV blood Quant assay). The ability to
rapidly performVL testing on both plasma andwhole-blood spec-
imens using the same instrument is an attractive feature, particu-
larly where specialized skill is required for performing phlebot-
omy on infants, and it is not available for POC HIV VL testing in
South Africa.
MATERIALS AND METHODS
Specimen collection and study site description. Ethics approval was ob-
tained from the University of the Witwatersrand, Johannesburg
(M110139), for an additional 4 ml to 16 ml anticoagulated (EDTAK3)
venous derived blood from adult patients attending two primary health
clinics in Johannesburg for their routine antiretroviral therapy (ART) and
tuberculosis (TB) monitoring between June 2012 and September 2012.
The two clinics were Hillbrow Community Health Centre, Johannesburg
(approval for 4 ml [1 tube] blood collection), and Themba Lethu HIV
Clinic,Helen JosephHospital, Johannesburg (approval for 16ml [4 tubes]
blood collection). The blood specimens were couriered (30 min trans-
port time) to the University of the Witwatersrand Research Diagnostics
testing laboratory on the same day that venesection was performed.
Whole-blood testing on the Liat HIV Quant assay was performed first,
and then residual whole blood was centrifuged at 3,000  g for 15 min
using a Hettich EBA-20 centrifuge (Hettich AG, Germany), followed by
plasma Liat HIV Quant assay testing. Residual plasma was tested on the
Roche COBAS AmpliPrep/COBAS TaqMan (CAP/CTMv2) (Roche Mo-
lecular Systems, Inc., Branchburg, NJ, USA), and residual plasma with
sufficient volume was tested with the Abbott RealTime HIV-1 assay (Ab-
bott Diagnostics Abbott Molecular Inc., Des Plaines, IL, USA) using
m2000sp and m2000RT. The Liat HIV whole-blood Quant assay was
tested on the sameday as blooddraw, followedby plasma testing either the
same or the next day (overnight storage at 4°C). Residual plasma was
stored at 70°C, and batch testing on the comparator assays was per-
formed in the accredited National Health Laboratory Service HIV PCR
laboratory of the same department.
LiatHIVQuant assay VL testing.Three Liat analyzers were couriered
from the supplier (in Massachusetts, USA) to the University of the Wit-
watersrand in Johannesburg, where they were self-installed by the labora-
tory scientist using the manufacturer’s package insert instructions. The
Liat analyzer is a quantitative, fully automated instrument that performs
silica magnetic bead sample extraction, multiplex real-time PCR amplifi-
cation, and detection of HIV in a single assay tube and has a barcode
reader and digital screen display with integrated keypad. The lower limit
of detection is reported as 81 copies/ml in 150l plasma, and the dynamic
range is 102 to 1.5 106 copies/ml. Both LiatHIVQuant assays (one assay
tube for plasma and one assay tube for whole blood) have an internal
control and require 75l whole blood or 150l plasma to generate results
within 30 to 35 min. The testing cartridges require a cold chain (4°C).
Evaluation protocol and statistical methodology. The blood speci-
mens (whole blood and plasma) were tested on the Liat HIV Quant
plasma and the Liat HIV Quant whole-blood assays to determine quanti-
tative precision, accuracy (including misclassification), and linearity as
well as the qualitative performance (ease of use, number of invalids and
errors, and number of tests per day). An evaluationmatrix is presented in
Table 1 outlining the various evaluation components. A 42-member fro-
zen plasma verification panel (termed the South African viral quality as-
sessment [SAVQA], developed by the South African National Priority
Program in Johannesburg using HIV subtype C plasma for verifying
newly installed Roche CAP/CTMv2 and Abbott RealTime HIV-1 plat-
forms), which included several confirmedHIV-negative blood specimens
obtained from SANBS (South African Blood Transfusion Services) (19),
also was included in the evaluation matrix. The panel is designed to mea-
sure precision (intra- and intervariability) as well as carryover (instru-
ment contamination) and the limit of the blank (i.e., to correctly identify
all HIV-negative specimens). Due to a limited number of Liat plasma
cartridges available, 10 of 17 HIV-negative panel members were tested,
and all (n 25) of the quantifiable panel members were tested on a Liat
analyzer. The results generated by the Liat HIV Quant plasma assay were
compared to published criteria (35% coefficient of variation on un-
transformed data; 0.19 log copies/ml standard deviations [SD]; 0.3
log copies/ml bias; 2.9% similarity coefficient of variation [CV] [21])
determined previously for the Roche CAP/CTMv2 and Abbott HIV-1
RealTime HIV-1 platforms on this panel (19).
Liat HIV Quant plasma assay precision was determined for all three
Liat analyzers and encompassed intra- and interinstrument precision and
total precision [the square root of (intrainstrument SD2  interinstru-
ment SD2)]. The latter was established for both the whole blood and
plasma Liat HIV Quant test cartridges for three VL log ranges (3.0 log
copies/ml, 4.0 log copies/ml, and 5.0 log copies/ml). Intravariability was
calculated using the means and SD across six replicate specimens per Liat
analyzer. The intervariability was calculated from one (the same) speci-
men tested on each Liat analyzer.
To determine the Liat HIVQuant plasma assay linearity, three clinical
plasma specimens with VL values of 5.0 log copies/ml were selected and
serially diluted (1:10) in HIV-negative plasma down to 3.0 log copies/ml
(Table 1). A further dilution of 1:2 was performed to obtain samples of 2.0
log copies/ml, and 9 repeats were prepared. Liat HIV Quant plasma assay
and the reference testing (Roche CAP/CTMv2) were performed over 1
day on all instruments. Linearity was determined by linear regression
(including R2).
Agreement (accuracy) was determined between the Liat HIV Quant
plasma and the Roche CAP/CTMv2 and Abbott RealTime HIV-1 plat-
TABLE 1 Evaluation matrix of the specimen numbers, specimen type, and comparator VL tests performed
Purpose Material No. and type of specimens Comparator assay
Platform verification Assessment-quality frozen plasma
from 42-member panela
10 HIV, 25 HIV Roche CAP/CTMv2; Abbott
RealTime HIV-1
Precision (intra- and
intervariability)
4 ml whole blood (and plasma) 3 patient specimens (3, 4, and 5 log copies/ml) repeated
6 times; all tested on 3 instruments
Not applicable
Linearity and variability
of LDL
Clinical specimen plasma diluted
into HIV-negative plasma
3 patient specimens (	5.0 log) serially diluted 1:10
down to 3.0 log copies/ml and then diluted 1:2 to 2.0
log copies/ml (repeated 9 times); all tested on 3 Liat
HIV Quant assay instruments
Roche CAP/CTMv2
Accuracy and misclassification HIV clinical specimens 157 clinical specimens tested on the CAP/CTMv2 and
Liat HIV Quant assay plasma assays; 94 (of 157)
tested by Liat HIV Quant assay whole blood and 63
(of 157) tested by RealTime HIV-1
Roche CAP/CTMv2
a Ten of 17 HIV-negative panel members were tested, and all (n 25) of the quantifiable panel members were tested on a Liat analyzer due to limited numbers of cartridges being
available at the time of study.
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forms, as well as between the Liat HIV Quant whole-blood assay and the
Liat HIVQuant plasma assay on paired specimens. This was measured by
concordance correlation (pc) (22), Bland-Altman difference plots (23),
and percent similarity (24). Concordance correlation was calculated as a
measure of agreement strength (accuracy and precision) between a new
assay and a referencemethod (22, 25). The formula applied is pc pCb
(22, 25), where p is the Pearson correlation (a measure of precision) and
Cb is the bias correction factor (a measure of accuracy). The value of pc
(strength of agreement) is suggested to be0.9 (poor), 0.90 to 0.95 (mod-
erate), 0.95 to 0.99 (substantial), and 	0.99 (almost perfect) (22). Any
paired Liat HIV Quant whole-blood or plasma assay value of 	1.0 log
copies/ml difference from the reference was considered clinically relevant
(i.e., the point at which patient management may change).
Clinical sensitivity, specificity, andmisclassification. The sensitivity
and specificity (including the 95% confidence interval [CI]) at a clinical
threshold of 1,000 copies/ml of the Liat HIV Quant plasma and whole-
blood assays was determined using Roche CAP/CTMv2 as the reference.
Detection by the Liat HIV Quant whole-blood and plasma assay quanti-
fiable test results was compared to that of the Roche CAP/CTMv2 plasma
VL as the reference method. The Roche CAP/CTMv2 results were sorted
into 4 categories (1, TND [target not detected]; 2, lower detection limit
[LDL; 1.59 log copies/ml]; 3, 2.0 to 2.99 log copies/ml; 4, 3.0 to	6.99
log copies/ml). Any paired Liat HIV Quant whole-blood or plasma assay
value outside these reference categories were consideredmisclassified and
were represented as a percentage (rate) of the number of reference test
results in each category. Statistical analyses were performed using STATA
version 12 (StataCorp, College Station, TX).
RESULTS
Performance of the Liat HIV Quant plasma assay using a stan-
dard verification panel. The Liat HIV Quant plasma assay re-
ported all HIV-negative and HIV-positive specimens correctly
(100% concordance), with no carryover between specimen tests
on the SAVQA (19) plasma panel. The Liat HIV Quant plasma
assay had increased assay variability (reduced precision) in the
low-VL ranges (3.0 log copies/ml). However, this increased
variability was within the acceptable clinically relevant difference
(bias) of 1.0 log copies/ml, and patient management would not
have been changed. The Liat HIV Quant plasma assay demon-
strated acceptable bias of 0.3 log copies/ml for the majority of
VL values of 	3.0 log copies/ml, with an overall acceptable per-
centage similarity CV of 2.7% compared to that of the Abbott
RealTimeHIV-1 assay and even better performance of 1.8% com-
pared to that of RocheCAP/CTMv2. These are below the expected
limit of 2.9% CV reported for the comparison between Roche
CAP/CTMv2 and Abbott RealTime HIV-1 on the SAVQA panel
(19). Twenty confirmed HIV-negative specimens all were re-
ported as undetectable on both the Liat HIV Quant whole-blood
and plasma assays.
Performance of the LiatHIVQuant plasma andwhole-blood
assay precision on clinical HIV-positive specimens. The Liat
HIV Quant whole-blood and plasma assay precision (variability)
on clinical specimens shows overall good intravariability and in-
tervariability, with median SD of 0.19 log copies/ml for whole
blood and median SD of 0.22 log copies/ml for plasma across
values of 3.0 log copies/ml to 5.0 log copies/ml. Increased variabil-
ity, however, was noted with the Liat HIV Quant whole-blood
assay in the category of 3.0 log copies/ml. The Liat HIV Quant
plasma assay generated acceptable linearity (R2 0.99) for three
analyzers across the range (5.0 log copies/ml to 2.0 log copies/ml).
The variability at 2.0 log copies/ml for two analyzers (11%CV and
12% CV) was similar to that of the CAP/CTMv2 assay (12% CV),
with one analyzer showing somewhat increased variability to 23%
CV. The quantifiable results generated by the assays were the fol-
lowing: 94% (59/63) quantified by Abbott RealTime HIV-1, with
a median of 4.2 log copies/ml; 93% (88/94) quantified by the Liat
HIVQuantwhole-blood assay, with amedian of 4.5 log copies/ml;
88% (138/157) quantified by Roche CAP/CTMv2, with a median
of 4.3 log copies/ml; and 82% (128/157) quantified by the Liat
HIVQuant plasma assay, with amedian of 4.3 log copies/ml.Of all
HIV-positive clinical specimens analyzed by the Liat HIV Quant
whole-blood, plasma, and comparator assays, the Liat HIVQuant
plasma assay values cluster with those of Roche CAP/CTMv2,
whereas the Abbott RealTime HIV-1 assay generates lower viral
load values than both the Liat HIVQuant plasma assay and Roche
CAP/CTMv2. Overall, the Liat HIV Quant assays align more with
the Roche CAP/CTMv2 than Abbott RealTime HIV-1 assay (Fig.
1A and B).
The Liat HIV Quant whole-blood assay has more variability
FIG 1 Modified Bland-Altman difference plots comparing the Liat HIV Quant plasma to the Roche CAP/CTM v2 reference comparator method (A) and the
Abbott RealTime HIV-1 (HIV-1RT) reference comparator assay (B). Mean difference and SD lines are present, as well as an additional legend containing the
concordance correlation, absolute bias, and percent similarity values for each comparison. The vertical axes are the paired differences, and the horizontal axes are
the log copies/ml VL values for the reference technology.
Scott et al.
1618 jcm.asm.org May 2015 Volume 53 Number 5Journal of Clinical Microbiology
 o
n
 August 4, 2015 by UNIVERSITY O
F W
ITW
ATERSRAND
http://jcm.asm.org/
D
ow
nloaded from
 
D
iff
er
en
ce
 L
ia
t H
IV
 Q
ua
nt
 - 
re
fe
re
nc
e 
m
et
ho
d 
(lo
g 
cp
/m
l)
126 | P  a g  e
than the LiatHIVQuant plasma assay (Fig. 2), because it generates
overall higher viral load values and has several outliers in the viral
load range of 4.0 log copies/ml. Overall, the Liat HIV Quant
whole-blood assay misclassified 16% and the Liat HIV Quant
plasma assay misclassified 5% of samples compared to the refer-
ence Roche CAP/CTMv2 (Table 2). The misclassified specimens
tested by the Liat HIV Quant plasma assay all had values of3.0
log copies/ml (1,000 copies/ml) and would not result in treat-
ment switching. Testing on the Liat HIV Quant whole-blood as-
say, however, did misclassify 10 of 94 (10.6%) specimens that
would have resulted in a change in patient management through
upwardmisclassification. Neither the Liat HIVQuant plasma nor
the Liat HIV Quant whole-blood assay generated any downward
misclassification (i.e., virological failure [	1,000 copies/ml] clas-
sified by the reference) that would have beenmissed by either Liat
HIV Quant assay. The sensitivity and specificity of the Liat HIV
Quant plasma andRocheCAP/CTMv2 assays (n 94)were 100%
(CI, 95.3%, 100%) and 88.2% (CI, 63.6%, 98.5%), respectively.
The sensitivity and specificity of the Liat HIV Quant whole-blood
and Roche CAP/CTMv2 assays (n  94) were 100% (CI, 95.3%,
100%) and 41.2% (CI, 18.4%, 67.1%), respectively.
Figure 1A and B further show that the assays with the most
agreement between their paired viral load results are the Liat HIV
Quant plasma assay and the Roche CAP/CTMv2. Their paired
viral load values have substantial strength of agreement (pc 
0.96) with overall good accuracy and precision (5.4% CV) and
acceptable variability in their bias (0.35 log copies/ml). The agree-
ment between the Liat HIV Quant plasma and the Abbott Real-
Time HIV-1 is less (pc  0.87) due to an increased variability in
their bias (0.41 log copies/ml). The agreement between the Liat
HIV Quant whole-blood assay and the Liat HIV Quant plasma
assay (Fig. 2) shows all outliers occur in the plasma viral load range
of3.0 log copies/ml, with the LiatHIVQuantwhole-blood assay
generating higher viral load values with a concordance correlation
of 0.81.
Qualitative analysis of the Liat HIV Quant assays. The staff
who performed this evaluation reported that the Liat analyzer
installation was easy to perform, and no supplier support was
necessary. This installation and self-training (familiarity with the
assay features and testing procedures) were performed within 2 h,
and no adverse events were experienced by the operators. The Liat
analyzer had a small footprint (approximately 11.4 cm by 19 cm
by 24.1 cm) with a touchscreen user interface. Throughout the
testing period (n  437 Liat HIV Quant assay tubes tested),
seven errors were reported (1.6% error rate). These all were due to
a scanning error; after rescanning, no specimen results were lost. A
total of 12 to 14 specimens could be tested on a single Liat analyzer
using either the HIVQuant whole-blood or plasma assay within a
single 8-h day. As the assay cartridge is a closed system, no special
safety precautions were required, and standard biohazardous
waste disposal was needed. Data could be exported byUSB port or
Ethernet cable (however, no connectivity was used for this evalu-
ation).
DISCUSSION
POC VL testing offers a solution to improved access, decreased
result turnaround time, reduced patient return visits for results,
immediate adherence counseling, and reduced concerns around
TABLE 2 Liat HIV Quant plasma and whole-blood assay detection of
HIV compared to detection by Roche CAP/CTMv2 on HIV-positive
clinical specimens
Category of plasma VL
(n 94)
Result bya:
CAP/CTMv2
Liat HIV
Quant
plasma
assay
Liat HIV
Quant
whole-blood
assay
TND (log copies/ml) TND TND 2.77
TND TND 4.10
LDL (1.60) (log copies/ml) TND TND 4.83
TND TND 3.29
1.30 TND 3.70
1.30 TND 4.08
1.38 TND 3.38
1.60 2.61 3.46
1.60 2.37 4.17
2.0–2.99 log (log copies/ml) 2.17 1.86 TND
2.19 TND TND
2.30 2.41 3.83
2.48 2.92 TND
2.92 3.01 4.13
2.99 3.03 TND
3.0–6.99 log (n) 79 79 79
Overall misclassification (%) NA 5.3 (5/94) 15.9 (15/94)
Misclassification resulting in
a change in patient
management (%)
NA 0 10.6 (10/94)
a Underlined results indicate clinical relevance for ART monitoring (	1.0 log copies/ml
difference at values of	1,000 copies/ml) compared to the reported comparator results
(1,000 copies/ml).
FIG 2 Modified Bland-Altman difference plot of the Liat HIV Quant plasma
assay (considered the reference in this comparison) compared to the Liat HIV
Quant whole-blood assay. The mean difference and SD lines are present, as
well as an additional legend containing the concordance correlation, absolute
bias, and percent similarity values for each comparison. The vertical axis is the
paired difference, and the horizontal axis is the log copies/ml VL values for the
reference technology.
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sample integrity. The Liat HIV Quant assay has several features
that are attractive to POC testing, such as a 30- to 35-min sample
input to result time, ease of use by nonlaboratory personnel, and a
small footprint. However, plasma testing would require the added
step of centrifugation, and the current reagent has a short shelf life
of 6 months and requires cold storage. The latter requirement,
however, is not unachievable in areas where both assays and drugs
use similar conditions in the clinic pharmacy. If used at the POC,
however, viral load testing will require ongoing quality monitor-
ing, which currently is accessible only to high-throughput labora-
tories and will require development for POC.
Overall, the Liat HIV Quant whole-blood and plasma assays
show good precision and accuracy compared to existing technol-
ogies, such as the Roche CAP/CTMv2 and Abbott RealTime
HIV-1. This was evident on the frozen plasma verification panel
and fresh clinical specimens and also shows that the Liat HIV
Quant whole-blood and plasma assays are well suited to HIV sub-
type C specimens representative of the South African HIV-in-
fected population (although no sequencing was performed) (26).
Overall, the agreement of the Liat HIV Quant assays are aligned
more with that of Roche CAP/CTMv2 than that of Abbott Real-
Time HIV-1. The Liat HIV Quant assays and analyzer appear to
have good reproducibility between and within repeat specimen
testing for both whole blood and plasma and good linearity be-
tween 2.0 log copies/ml and 5.0 log copies/ml. However, increased
variability was found in the viral load range of 2.0 log to 3.0 log
copies/ml, which is similar to that for testing dried blood spots.
Compared to the Roche CAP/CTMv2, Liat HIVQuant plasma
assay testing did not generate any clinically misclassified results
that would have resulted in a change in patientmanagement at the
1,000-copies/ml threshold. The Liat HIV Quant whole-blood as-
say testing, however, did yield 10.6% clinical misclassification on
these same specimens, but these all were upward misclassified
(i.e., identified higher viral load values than reference testing), and
no specimens identified by reference testing as virological failure
were missed. This is due to the assay’s total nucleic acid extraction
protocol, with amplification fromwhole-blood specimens of cell-
associated HIV-1 DNA and RNA. This indicates repeat testing on
plasma of all whole-blood specimens with Liat HIVQuant whole-
blood values of4.5 log copies/ml but is advantageous in assess-
ing HIV-1 infection among newly infected persons receiving pre-
or postexposure prophylaxis, where plasma HIV-1 RNA levels
may be suppressed, and for newly infected neonates whose moth-
ers had received ART at parturition. The sensitivity and specificity
of the Liat HIV Quant whole-blood assay (100% [CI, 95.3%,
100%] and 41.2% [CI, 18.4%, 67.1%], respectively) compared to
those of the Roche CAP/CTMv2 platform (n  94) is not too
dissimilar fromvalues reported for dried-blood-spotVLmonitor-
ing (11); however, this study is limited by a small sample size.
Analysis of a national program’s patient’s HIV VL data has
value inmeasuring a program’s treatment performance (commu-
nity VL) (27). However, this is possible only with central collec-
tion of VL results, such as through a laboratory information sys-
tem (LIS). In South Africa, this is very well managed through the
use of Abbott link, Roche Ampli-link (28), and Axeda systems;
therefore, the introduction of new HIV VL technology must en-
sure connectivity in this context. The Liat analyzer does have full
connectivitywithHL7 communication protocols andwireless and
Ethernet capabilities.
Positioning such an assay at POC in South Africa (currently
performing 2 million VL analyses through centralized testing
laboratories) would be best in underserviced areas and niche set-
tings to extend access to VL testing. The goal of the South African
national HIV treatment program was to add 500,000 new people
toARTper year in their 3,540 clinics, which are staffed by23,000
trained nurses (29). Areas where sample integritymay be compro-
mised (	4-h specimen transport times), and where rapid turn-
around of VL results is required (maternity wards to identifyHIV-
positive mothers and babies at birth), would benefit from using
the Liat HIV Quant assays and ensure equity of access. The Liat
HIV Quant plasma assay, as shown in this study, performs well
against the two existing in-country VL plasma technologies, mak-
ing it an ideal candidate for implementing in this existing pro-
gram. Concerns would be minimal for cross-platform VL plasma
test reporting, leading to clinical differences and unnecessary (or
undetected) changes in patient management. Although the Liat
HIV Quant assay was not evaluated on infant specimens in this
study, whole-blood testing in thematernity settingwould have the
benefit of its total nucleic acid extraction protocol. However, both
scenarios require further clinical evaluation (especially finger
stick-derived whole-blood specimen testing), cost analyses (sin-
gle-use specimens versus high throughout), procurement, and
implementation modeling.
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3.2 COMPARISON OF XPERT MTB/RIF WITH OTHER NUCLEIC ACID 
TECHNOLOGIES FOR DIAGNOSING PULMONARY TUBERCULOSIS IN A 
HIGH HIV PREVALENCE SETTING: A PROSPECTIVE STUDY  
Comparison of Xpert MTB/RIF with Other Nucleic Acid
Technologies for Diagnosing Pulmonary Tuberculosis in
a High HIV Prevalence Setting: A Prospective Study
Lesley E. Scott1*, Kerrigan McCarthy2, Natasha Gous1, Matilda Nduna3, Annelies Van Rie4, Ian Sanne5,
Willem F. Venter2, Adrian Duse3,6, Wendy Stevens1,3
1Department of Molecular Medicine and Hematology, University of the Witwatersrand, Johannesburg, South Africa, 2Wits Reproductive Health and HIV Institute,
University of the Witwatersrand, Johannesburg, South Africa, 3National Health Laboratory Service, Johannesburg, South Africa, 4Department of Epidemiology, University
of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 5Clinical HIV Research Unit, Department of Medicine, University of the
Witwatersrand, and Right to Care, Johannesburg, South Africa, 6Department of Clinical Microbiology and Infectious Diseases, University of the Witwatersrand,
Johannesburg, South Africa
Abstract
Background: The Xpert MTB/RIF (Cepheid) non-laboratory-based molecular assay has potential to improve the diagnosis of
tuberculosis (TB), especially in HIV-infected populations, through increased sensitivity, reduced turnaround time (2 h), and
immediate identification of rifampicin (RIF) resistance. In a prospective clinical validation study we compared the
performance of Xpert MTB/RIF, MTBDRplus (Hain Lifescience), LightCycler Mycobacterium Detection (LCTB) (Roche), with
acid fast bacilli (AFB) smear microscopy and liquid culture on a single sputum specimen.
Methods and Findings: Consecutive adults with suspected TB attending a primary health care clinic in Johannesburg,
South Africa, were prospectively enrolled and evaluated for TB according to the guidelines of the National TB Control
Programme, including assessment for smear-negative TB by chest X-ray, clinical evaluation, and HIV testing. A single sputum
sample underwent routine decontamination, AFB smear microscopy, liquid culture, and phenotypic drug susceptibility
testing. Residual sample was batched for molecular testing. For the 311 participants, the HIV prevalence was 70% (n= 215),
with 120 (38.5%) culture-positive TB cases. Compared to liquid culture, the sensitivities of all the test methodologies,
determined with a limited and potentially underpowered sample size (n= 177), were 59% (47%–71%) for smear microscopy,
76% (64%–85%) for MTBDRplus, 76% (64%–85%) for LCTB, and 86% (76%–93%) for Xpert MTB/RIF, with specificities all
.97%. Among HIV+ individuals, the sensitivity of the Xpert MTB/RIF test was 84% (69%–93%), while the other molecular
tests had sensitivities reduced by 6%. TB detection among smear-negative, culture-positive samples was 28% (5/18) for
MTBDRplus, 22% (4/18) for LCTB, and 61% (11/18) for Xpert MTB/RIF. A few (n= 5) RIF-resistant cases were detected using
the phenotypic drug susceptibility testing methodology. Xpert MTB/RIF detected four of these five cases (fifth case not
tested) and two additional phenotypically sensitive cases.
Conclusions: The Xpert MTB/RIF test has superior performance for rapid diagnosis of Mycobacterium tuberculosis over
existing AFB smear microscopy and other molecular methodologies in an HIV- and TB-endemic region. Its place in the
clinical diagnostic algorithm in national health programs needs exploration.
Please see later in the article for the Editors’ Summary.
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Introduction
The tuberculosis (TB) and HIV epidemic in sub-Saharan Africa
continues to pose enormous challenges to public health. South
Africa alone has 1 million people currently receiving HIV
antiretroviral treatment [1,2], the TB incidence is 941 per
100,000 individuals [3], and 9,070 cases of multidrug-resistant
(MDR) TB were reported in 2009 [4]. A recent post-mortem study
from KwaZulu-Natal observed that TB is still the leading cause of
death in HIV+ individuals [5], suggesting that the diagnosis of TB
is made too late to avert mortality. Early diagnosis and
management of TB is also critical to reduce TB transmission in
communities and health care facilities. In 2009, 3 million smears
and 740,000 cultures were performed in South Africa public sector
health care facilities (excluding the KwaZulu Natal province) [6,7].
In recent years, the South African National Health Laboratory
Service scaled up its infrastructure to 249 sites for smear
microscopy and 16 laboratories for Mycobacteria Growth
Indicator Tube (MGIT) culture. While culture remains the most
sensitive method for confirmation of TB, the prolonged turn-
around time, biosafety requirements, and laboratory operational
requirements [8] limit its contribution to clinical decision making
[9]. In 2009, the World Health Organization (WHO) approved
the MTBDRplus assay (Hain Lifescience) for use in smear-positive
specimens and Mycobacterium tuberculosis (M.tb) isolates [10]. To
hasten diagnosis of drug-resistant TB, 20 National Health
Laboratory Service laboratories were earmarked for implementa-
tion of the MTBDRplus assay in South Africa in 2010. The assay
is limited in its application because laboratory infrastructure must
accommodate PCR technology, the assay is not approved for use
in smear-negative cases, and in high-throughput laboratories, it
can take up to 7 d from sample receipt to result reporting [6]. All
these factors limit its potential to contribute to the control of drug-
resistant TB.
The diagnostic development pipeline for both high-throughput
and point-of-care laboratories has seen rapid innovations in the
last decade [11,12] through WHO, Stop TB Partnership, and
Foundation for Innovative New Diagnostics partnerships [13,14].
The most recently WHO-endorsed [15] diagnostic tool, the Xpert
MTB/RIF (Cepheid) assay, has been reported in a multi-country
study to have sensitivities of 98.2% among smear-positive, culture-
positive patients and 72.5% among smear-negative, culture-
positive patients on a single direct Xpert MTB/RIF test compared
to three smears and four culture results [16]. Two sites from South
Africa (Durban and Cape Town) with average HIV infection rates
of 73% were included in this multi-center study. The sensitivity of
the Xpert MTB/RIF assay (three tests performed per participant)
among smear-negative, culture-positive individuals compared to
standard testing (three smears and four culture results per
participant) was 87% (95% CI 62%–96%) for samples from
Durban and 90% (95% CI 79%–96%) for samples from Cape
Town. Other studies have also recently reported the performance
and clinical role of the Xpert MTB/RIF test for detecting TB in
extrapulmonary specimens, with sensitivities of 69% to 85.7% for
tissue specimens and up to 100% in urine and stool specimens
[17,18].
Our study aims to (1) further assess the performance of a single-
sputum Xpert MTB/RIF test against culture-confirmed and
clinically defined cases of TB in a cohort of adults being
investigated for TB with high prevalence of HIV infection from
South Africa (Johannesburg region) and (2) to compare this nucleic
acid amplification technology (NAAT) to two existing molecular
TB assays, the LightCycler Mycobacterium Detection (LCTB)
assay (Roche) and the MTBDRplus assay (Hain Lifescience), for
use directly on sputum.
Methods
Ethics Approval
The study was approved by the University of the Witwatersrand
Human Ethics Review Committee (M070826).
Study Design for Investigation of Potential TB Patients
and Data Management
This prospective study investigated consecutive adults present-
ing with suspected pulmonary TB to a primary health care clinic
in Johannesburg, South Africa, over a 9-mo period between 3
August 2009 and 28 May 2010. Individuals were eligible if they
were$18 y of age and presented with a cough of$2 wk duration,
with or without fever, night sweats, loss of weight, chest pain, and
signs of extrapulmonary involvement (such as lymph nodes,
pleural effusions, or abdominal TB), independent of a history of
TB treatment and acceptance of HIV testing. Persons were
excluded if they were not able to produce sputum, had symptoms
only of extrapulmonary TB, were already on TB treatment, or
required hospital admission.
TB and HIV diagnosis and management were performed
according to South African guidelines [1,19]. As part of routine
care, participants on first presentation were asked to provide two
sputum specimens for smear microscopy. On return (within 1 wk)
for results, participants were invited to participate, and written
informed consent was obtained by the study nurse. At this visit, all
participants were asked to provide a third sputum specimen for
routine smear and culture, and investigational tests. Smear-
positive patients were started on TB treatment. AFB-smear-
negative patients underwent chest radiography and were pre-
scribed amoxicillin. One week later, response to antibiotic therapy
was evaluated, the chest X-ray was read, and the case was assessed
by the study physician. Smear-negative participants with no
response to antibiotics and chest X-ray findings compatible with
TB were initiated on TB treatment. Participants without these
criteria were deemed not to have TB. When in doubt, participants
were referred to a tertiary center for further investigation. For all
participants, data were collected on history of TB, HIV status,
most recent CD4 count, antiretroviral therapy, weight, and oral
temperature at baseline, and a follow-up visit was conducted
approximately 60 d after enrolment. The third sputum sample
underwent routine and immediate N-acetyl-L-cysteine-sodium
hydroxide (NALC)–NaOH decontamination for AFB smear and
MGIT culturing. Residual processed specimen was stored at
270uC, batched, and later used for the three NAAT tests. The
NAAT tests were performed by a scientist, blinded to smear,
culture, and clinical evaluations in an off-site laboratory. All
culture-positive specimens underwent routine MTBDRplus testing
for rifampicin (RIF) and isoniazid (INH) resistance, and where one
or other of these was found present, phenotypic drug sensitivity
testing (DST) was performed. These routine smear and culture
DST results were reported to clinicians and used for patient
management and clinical decision making. The sensitivity,
specificity, and positive and negative predictive values for the
NAAT tests compared to MGIT culture and clinical case
definition were calculated from the results generated from this
single processed sputum sample.
Patient data were recorded using a standardized case report
form, entered periodically into MS Access and exported into
STATA 10 (StataCorp) for analysis. Characteristics between
Xpert MTB/RIF TB Diagnosis Evaluation in an HIV Setting
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groups were compared using chi-square and t-tests as appropriate.
Sensitivity, specificity, and positive and negative predictive values
were calculated using either MGIT culture (excluding contami-
nated cultures and non-tuberculous mycobacteria [NTM]) or any
TB (definite, probable, and possible TB) as a gold standard.
NAAT test performance was established for those specimens
where sufficient sample allowed all tests to be done on each
specimen. Analysis was stratified by HIV status and smear
microscopy.
Definitions for TB Case Classification
Participating individuals were classified as ‘‘definite TB’’ if
sputum culture yielded M.tb (with or without positive smears);
‘‘probable TB’’ if M.tb culture was negative/contaminated and at
least one smear was positive for AFB; ‘‘possible TB’’ if smear was
negative for AFB, M.tb culture was negative or contaminated, but
the patient had TB-compatible chest X-ray and any documented
weight gain in response to TB treatment; and ‘‘no TB’’ if smear
was negative for AFB, M.tb culture was negative or contaminated,
symptoms resolved without TB treatment, or if the culture grew
NTM. Individuals who were smear-negative, had a culture that
was negative or contaminated, had a chest X-ray suggestive of TB,
and were initiated on TB treatment, but in whom weight gain was
not documented, were classified as ‘‘indeterminate TB.’’ Partic-
ipants who were not started on TB treatment and were lost to
follow-up or died were also classified as indeterminate TB. The
clinical classification of TB status was performed blinded to the
NAAT results.
Laboratory Methods
The single sputum sample was processed and analyzed using
standard operating procedures in an accredited biosafety level 3
laboratory. Following decontamination using NaOH (1%)–NALC
[20], the specimen was centrifuged and resuspended in approx-
imately 2 ml of phosphate buffer (pH 6.8) to ensure maximum
recovery of bacteria and easy homogenization before aliquots were
removed for testing methodologies. The reconstituted pellet was
used fresh for smear microscopy (,50 ml) and culture (0.5 ml), and
the residual sample was stored at 270uC for NAAT processing.
The MTBDRplus and the LCTB assays were the first NAATs to
be performed in batches of 12 per day (extraction protocols
performed on day 1 followed by amplification the following day).
Once the Xpert MTB/RIF became available (June 2009), 4–5
residual frozen (270uC) specimens stored after completion of the
MTBDRplus and LCTB assays were tested daily. Use of residual
pellet for Xpert MTB/RIF (0.5 ml), MTBDRplus (0.5 ml), and
LCTB (0.1 ml) depended on availability of residual sample after
smear and culture. Any specimen yielding an invalid NAAT result
was re-tested if there was sufficient residual material. This latter
result was used in the sensitivity and specificity calculations.
The sputum smear was stained using standard auramine
reagent and 100 high-power fields examined using a fluorescent
microscope (Olympus CX31 with LED attachment, Wirsam).
Culture was performed using MGIT containing modified Mid-
dlebrook 7H9 broth base, supplemented with MGIT Growth
Supplement and PANTA (BD) and incubated at 37uC up to 42 d
in a BACTEC cabinet (Becton Dickinson). Positive cultures were
subjected to Ziehl-Neelsen staining to confirm the presence of
AFB, and to routine MTBDRplus assay to confirm identity as M.tb
and establish INH and RIF susceptibility profiles. Routine
phenotypic MGIT DST was performed when MTBDRplus assay
detected genotypic resistance. All cultures were preserved and
stored. At completion of the study MGIT DST was performed as
per manufacturer’s instructions on additional isolates when this
had not been done before.
All NAAT methods were performed according to the
manufacturer’s instructions and are detailed below. The LCTB
assay is a real-time PCR assay, with bacterial nucleic acid
extracted using the COBAS Amplicor Respiratory Specimen
Preparation kit (Roche Diagnostics) by adding a wash and lysis
solution to the pellet followed by 45 min incubation at 60uC and
addition of a neutralization buffer before the PCR step. PCR is
performed using the LCTB amplification kit (Roche Diagnostics)
designed to amplify a 200-bp fragment of the 16s rRNA gene
containing the hypervariable region A using fluorescent resonance
energy transfer hybridization probes designed for the LightCycler
instrument (Roche Diagnostics). Melting curve analysis is
performed for species differentiation (positive control, 5961.5uC;
negative control not defined; M.tb, 55.961.5uC; M. kansasii,
5961.5uC; M. avium, 47.561.5uC).
The MTBDRplus assay in this study was performed directly on
sputum (irrespective of smear result) and routinely on positive
cultures. In this assay, bacterial nucleic acid extraction is performed
by heat followed by sonication. The PCR is a multiplex
amplification using biotinylated primers, followed by reverse
hybridization onto nitrocellulose strips. A strip contains 17 probes,
including five sample and hybridization controls [21]. The targets
amplified are (1) the core region of the rpoB gene, positions 505–533,
analyzed for RIF resistance based on eight wild-type probes and
four mutant probes (D516V, H526Y, H526D, and S531L), (2) the
katG gene, analyzed for high-level INH resistance based on the wild-
type S315 and two mutants (AGC to ACC and AGC to ACA, both
producing S315T mutations), and (3) the inhA gene, analyzed for
low-level INH resistance based on the wild-type 1 probe spanning
positions 9–22 and wild-type 2 probe spanning positions 1–12, as
well as four mutation probes (C15T,1A6G, T8C, and T8A) [21].
After several washes and chromogenic substrate reaction, the bound
probes are visually inspected for the presence or absence of control,
wild-type, and mutant bands. Omission of a wild-type band or the
appearance of a mutant band in the resistance-determining region
of a gene indicates the existence of a resistant strain.
The Xpert MTB/RIF assay is a hemi-nested real-time PCR
method that amplifies the 81-bp region of the RIF-resistance-
determining region of the rpoB gene, positions 507–533. A sample
reagent buffer containing NaOH and isopropanol is added in a 2:1
ratio to the processed sputum ensuring a final volume of at least
2 ml. After 15 min of incubation with intermittent hand mixing,
2 ml of the liquefied inactivated sample is added to the cartridge
that contains the wash buffer, reagents for lyophilized DNA
extraction and PCR amplification, and fluorescent detection
probes (five for the rpoB gene and one for an internal control,
Bacillus globigii spores). After the cartridge is placed in the
instrument module, the automated processes include the following:
specimen filtering, sonication to lyse the bacilli and internal
control spores, released DNA collection and combination with the
PCR reagents, amplification, target detection by five-color
fluorescence of overlapping molecular beacon probes, and one-
color fluorescence for the internal control. Results are automat-
ically generated within 2 h and reported as M.tb-negative or -
positive (with semi-quantification) and RIF sensitive or resistant.
The former determination is based on the amplification of any two
rpo gene regions, and the latter determination is based on a
difference of .3.5 amplification cycles of any probe. The Xpert
MTB/RIF assay definition files versions 1.0 and 2.0 were used in
this study. Data analysis for RIF resistance detection, however,
reports results with both the 3.5 and 5.0 cycle threshold differences
as per the manufacturer’s suggestion.
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Results
Patient Population and TB Case Classification
During the study period, 402 potential adults with suspected TB
presented to the clinic, and 319 agreed to participate (Figure 1).
Participants’ mean age was 32.4 y (range 19–75 y); 188 (59%)
were male (Table 1). Most participants (274, 86%) accepted HIV
counseling and testing, among whom 220 (70%) were HIV
positive. Eight patients did not provide a sputum sample for study
procedures and were excluded from the analysis. Among the 311
patients included in the analysis (Figure 1), 88 (28.2%) were smear-
and culture-positive TB cases, 32 (10.2%) had smear-negative,
culture-positive TB, and three (0.9%) had smear-positive, culture-
negative TB. Culture was contaminated for 19 (6.1%) participants.
Among the 188 (60.4%) participants without bacterial confirma-
tion, 50 (26.5%) had possible TB, 58 (30.9%) were classified as not
TB (including five patients with NTM), 31 (16.4%) who started TB
treatment were classified as indeterminate TB because of failure to
gain weight on treatment or because weight at follow-up was not
documented, and 50 (26.6%) were classified as indeterminate TB
because they were not started on treatment and were lost to follow-
up or died.
Case Detection by NAAT Assay
Sufficient sputum sample was available to perform NAAT
analysis using Xpert MTB/RIF in 205 (64%) participants,
MTBDRplus in 283 (89%) participants, and LCTB assay in 280
(88%) participants. There was no significant difference in mean
age, gender, smear microscopy, culture, and HIV status between
patients in whom the different NAAT assays were performed (all
comparative p-values.0.05). Overall, NAAT analysis yielded a
positive result for M.tb in 33% (67/205) by Xpert MTB/RIF, 29%
(83/283) by MTBDRplus, and 31% (88/280) by the LCTB assay.
Among smear-negative participants (n=227), the proportion of
NAAT tests yielding a positive result for M.tb was 11.8% (17/143),
6.7% (13/194), and 6.1% (12/199) for Xpert MTB/RIF,
MTBDRplus, and LCTB, respectively.
Amongst the NAAT tests, the highest rate of indeterminate or
invalid test results was observed for Xpert MTB/RIF (12/205,
5.9%) due to power failures during instrument performance before
an uninterrupted power supply was installed (n=2), inability to
determine presence or absence of M.tb due to improper sample
processing (cartridge error) or PCR inhibition (reported as ‘‘invalid
results’’) (n=5), probe check failure (reported as ‘‘error’’) (n=4),
and operator error (n=1). Of these invalid results there was
sufficient residual material to re-analyze seven samples, which
were then included in the sensitivity and specificity calculations.
Only 2.3% of MTBDRplus assays were indeterminate (due to
positive M.tb control [TUB] band detection issues). None of the
LCTB tests results were indeterminate.
NAAT Sensitivity and Specificity
As detailed in Table 2, compared to MGIT culture, the lowest
sensitivity was observed for smear microscopy (59%, 95% CI
47%–71%), followed by MTBDRplus and LCTB with identical
performance (76%, 95% CI 64%–85%), and Xpert MTB/RIF
(86%, 95% CI 76%–93%), with the highest sensitivity. Sensitivity
estimates did not differ for each NAAT when test results were
included for specimens not having been tested on all NAAT
formats. These results were as follows: smear microscopy, n=289,
sensitivity 59% (95% CI 49%–68%); MTBDRplus, n=254,
sensitivity 74% (95% CI 64%–81%); LCTB, n=236, sensitivity
75% (95% CI 67%–84%); Xpert MTB/RIF, n=182, sensitivity
86% (95% CI 76%–93%). Specificity was 100% for smear
microscopy and .96% for all three NAAT assays. Among
culture-negative TB cases, clinical classifications for participants
with positive NAAT results were as follows: Xpert MTB/RIF,
possible TB (n=1), not TB (n=1), and indeterminate TB status
(n=1); MTBDRplus, indeterminate TB status (n=3); and LCTB,
indeterminate TB status (n=2).
NAAT test performance amongst the cohort of HIV-uninfected
participants had similar sensitivities to test performance on the
entire cohort, although the confidence intervals were wide on
account of the small numbers. However, amongst HIV-infected
participants MTBDRplus and LCTB sensitivities dropped, while
that of Xpert MTB/RIF assay remained similar to that of test
performance in the entire cohort. As expected for all three NAAT
assays, sensitivity was higher among smear-positive than among
smear-negative patients (Table 2). Amongst smear-negative,
culture-positive cases, Xpert MTB/RIF had the highest sensitivity,
61%, detecting 11/18 cases.
The sensitivity for diagnosis of any TB (smear- and/or culture-
positive TB plus possible TB), was 40%, 66%, 51%, 51%, and
58% for smear, culture, MTBDRplus, LCTB, and Xpert MTB/
RIF, respectively.
Detection of Drug Resistance by NAAT
Phenotypic DST results were available for 89 participants, and
identified two MDR strains, five INH mono-resistant strains, and
three RIF mono-resistant strains. Resistance was detected by
MTBDRplus (on sputum or culture) and/or Xpert MTB/RIF in
23 patients (Figure 2). Xpert MTB/RIF identified RIF resistance
in nine patients (using the amplification cycle threshold maximum
3.5 of Xpert MTB/RIF software version 1), of which three were
not reported as RIF-resistant by other DST methods. These are
likely false-positive RIF resistance results, as these samples were
reported as RIF-sensitive by Xpert MTB/RIF when using a
maximum 5.0 amplification cycle threshold (as per Xpert MTB/
RIF software versions 2 and 3). The MTBDRplus test directly on
sputum identified eight patients with RIF-resistant TB, seven of
these had AFB-smear-positive TB. Two were confirmed by MGIT
DST, three were sensitive by MGIT DST, one was culture-
negative, one culture was not done, and one culture was
contaminated. MTBDRplus directly on sputum did not identify
three smear-negative isolates with RIF resistance on phenotypic
MGIT DST. MTBDRplus performed on culture isolates identified
six patients with RIF resistance, of which five were confirmed by
MGIT DST.
INH resistance was detected in ten patients using the
MTBDRplus test directly on sputum. Of these, four were also
resistant on MGIT DST and MTBDRplus on cultured isolates,
four were INH-sensitive by MGIT DST and MTBDRplus done
on cultured isolates, while one was negative for M.tb on MGIT.
MTBDRplus directly on sputum missed INH resistance identified
by MGIT DST in two cases, one of which was AFB-smear-
negative.
Discussion
This is a real-world comparison of different TB sputum
detection technologies, integrated within a national TB screening
guideline. The sensitivity of a single NAAT test compared to a
single MGIT culture in our cohort of South African outpatients
with suspected pulmonary TB (70% HIV-co-infected) was higher
for Xpert MTB/RIF 86% (76%–93%) than MTBDRplus 76%
(64%–85%) and LCTB 76% (64%–85%). This difference in
sensitivities was especially prominent for the diagnosis of
pulmonary TB in HIV-infected individuals (84% versus 70%
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Figure 1. Study algorithm. ART, antiretroviral therapy; contam, contaminated; CXR, chest X-ray; ind, indeterminate; neg, negative; pos, positive;
res, resistant; Rx, drug treatment.
doi:10.1371/journal.pmed.1001061.g001
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and 70%, respectively) and among smear-negative, culture-
positive patients (61% versus 28% and 22%, respectively). The
potential underpowering of this limited sample size should be
noted, and it should be clarified that the confidence intervals for all
three NAATs do overlap (even with the sample size increased to
289 by including samples not tested by all assays); however, there is
Table 1. Demographics, clinical characteristics, and results of TB diagnostics in 311 adults with suspected pulmonary TB.
Characteristica
All Participants
(n=319)
Smear Microscopy,
MGIT Culture, and
Susceptibility
(n=311) NAAT Performed Directly on Sputum
MTBDRplus (n=283) LCTB (n=280)
Xpert MTB/RIF
(n=205)
Demographics
Age in years, mean (range) 32 (19–75) 32 (19–75) 32 (19–57) 32 (19–57) 32 (19–56)
Male gender, number (%) 188 (59) 185 (59%) 165 (58) 161 (58) 115 (56)
Clinical signs and symptoms at presentation
Duration of cough in weeks, mean (range) 4.1 (0–12) 4 (0–12) 3.9 (0–12) 4.0 (0–12) 3.9 (0–12)
Night sweats 287 (90) 281 (90) 256 (90) 253 (90) 186 (90)
Loss of weight 314 (98) 307 (98) 278 (98) 275 (98) 202 (99)
Chest pain 314 (98) 307 (98) 278 (98) 275 (98) 201 (98)
Concurrent extrapulmonary TB symptoms 31 (10) 30 (10) 26 (9) 26 (9) 25 (12)
Pyrexial at presentation 53 (17) 52 (17) 45 (16) 47 (17) 37 (18)
HIV-related information
Agreed to HIV testing 274 (86) 269 (86) 244 (86) 243 (86) 175 (85)
Tested positive 220 (70) 215 (69) 197 (70) 195 (70) 143 (70)
Tested positive: on ART at presentation 17 (5) 17 (5) 12 (4) 11 (4) 8 (4)
Tested positive: mean CD4 count, cells/ml (n, range) 214 (166, 0–818) 217 (162, 0–818) 215 (151, 0–818) 214 (149, 0–818) 221 (109, 0–818)
Refused testing 43 (14) 42 (13) 38 (14) 36 (13) 30 (15)
Tested negative 54 (17) 54 (17) 47 (17) 48 (17) 32 (16)
Bacteriological classificationb
Smear- and culture-positive 88 (28) 88 (28) 82 (29) 81 (29) 54 (26)
Smear-negative, culture-positive 32 (10) 32 (10) 28 (10) 28 (10) 19 (9)
Smear-negative, culture-negative 166 (52) 166 (53) 150 (53) 148 (53) 115 (56)
Smear-negative, culture contaminated 17 (5) 17 (5) 16 (6) 16 (6) 11 (5)
Clinical classification
Definite TB 120 (38) 120 (39) 110 (39) 109 (39) 73 (36)
Probable TB 4 (1) 3 (1) 2 (1) 2 (1) 1 (1)
Possible TB 51 (16) 50 (16) 45 (16) 44 (16) 40 (20)
No TB 57 (17) 58 (19) 50 (18) 48 (17) 37 (18)
Indeterminate TB status (on TB drugs) 31 (10) 30 (10) 29 (10) 29 (10) 22 (11)
Lost to follow-up, not on TB drugs 56 (18) 50 (16) 47 (17) 48 (17) 32 (15)
M.tb case detection
Percent with indeterminate resultsc, number/total
(percent)
NA 19/311 (6.1) 10/283 (3.5) 0/280 (0) 12/205 (5.9)
Percent positive among those with valid results,
number/total (percent)
NA 120/292 (41) 83/273 (30) 88/280 (31) 67/195 (34)
Detection of RIF and/or INH resistanced
RIF resistance, number/total done (percent) NA 5/89 (6) 8/273 (3) NA 7/195 (4)
INH resistance, number/total done (percent) NA 7/89 (8) 10/273 (4) NA NA
MDR (INH+RIF resistance), number/total done (percent) NA 2/89 (1.0) 3/273 (1)e NA NA
aValues are number (percent) unless otherwise indicated.
bOne case was smear-positive, culture-negative, and two cases were smear-positive, culture contaminated.
cNo indeterminate smear results; for MGIT culture, indeterminate = contaminated; for Xpert MTB/RIF, indeterminate = error or other result.
dMGIT susceptibility testing done on selected isolates including all cultures where NAAT tests detected resistance.
eTwo cases were culture-positive with phenotypic-confirmed MDR; a third case was culture-negative.
NA, not applicable.
doi:10.1371/journal.pmed.1001061.t001
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no confidence interval overlap between the Xpert MTB/RIF
assay (76%–93%) and smear microscopy (47%–71%). This
therefore supports the WHO policy that the Xpert MTB/RIF
should be the initial test in adults with HIV infection suspected of
having TB and can replace smear microscopy. The sensitivity of a
single Xpert MTB/RIF assay in our Johannesburg cohort was
slightly lower than in the landmark multi-country study (86%
versus 92.2% overall and 61% versus 72% for smear-negative,
culture-positive specimens) by Boehme et al. [16]. This may be
due to differences in study population, as HIV infection rates
reported in the multi-country study ranged from 1.7% to 76%
across sites [16]. Although the two South African sites (Durban
and Cape Town) involved in the multi-center Xpert MTB/RIF
study [16] reported HIV infection rates (71.4% and 76.1%,
respectively) similar to that found in our Johannesburg population
(70% HIV-infected), breakdown of a single Xpert MTB/RIF test
compared to a single culture result from these sites was not
provided. A recent study [22] performed in a East African 
(Tanzania) population using a single Xpert MTB/RIF test
reported sensitivities of 84.1% overall and 61% for smear-
negative, culture-positive isolates, similar to the results in our
study. A more recent study also from South Africa in the Cape
Town population reports even lower sensitivities of 78.1% overall
(performed on raw or processed sputum stored at 220uC) and 
55% for smear-negative, culture-positive samples (1 ml unpro-
cessed archived sputum) [23]. This latter study further reported a
sensitivity of the Xpert MTB/RIF assay among HIV-infected
individuals of 69.6% (n = 46), which, although lower than our
study findings (84%, n = 124), was not significantly different
(p = 0.09) from the sensitivity reported for the HIV-uninfected
group in their study (82.9%, n = 82) [23]. All together, these studies
and our findings provide evidence of the much improved
Table 2. Test performance (including comparison to clinical case definitions) for smear microscopy, MGIT culture, MTBDRplus
directly on sputum, LCTB, and Xpert MTB/RIF assays stratified by smear microscopy and HIV status.
Test Performance Measurea Smear Microscopy MGIT Culture NAAT Performed Directly on Sputum
MDRTBplus LCTB
Xpert MTB/
RIF
Comparison to MGIT culture (n=177)
Sensitivity 59 (47–71) NA 76 (64–85) 76 (64–85) 86 (76–93)
Specificity 100 (96–100) 97 (92–99) 98 (93–99) 97 (92–99)
PPV 100 (91–100) 94 (84–98) 92 (87–99) 95 (86–99)
NPV 80 (72–86) 87 (79–92) 87 (79–92) 92 (85–96)
Comparison to MGIT culture (HIV-positive
cohort only, n=124)
Sensitivity 54 (38–69) NA 70 (54–83) 70 (54–83) 84 (69–93)
Specificity 100 (95–100) 96 (89–99) 98 (93–100) 96 (89–99)
PPV 100 (85–100) 91 (76–98) 97 (83–100) 92 (79–98)
NPV 80 (70–87) 85 (76–92) 86 (77–92) 92 (84–97)
Comparison to MGIT culture (HIV-negative
cohort only, n=26)
Sensitivity 66 (35–90) 75 (43–95) 75 (42–94) 83 (52–98)
Specificity 100 (70–100) 100 (76–100) 100 (76–100) 100 (76–100)
PPV 100 (63–100) 100 (66–100) 100 (66–100) 100 (69–100)
NPV 79 (52–93) 82 (56–96) 82 (56–96) 88 (62–98)
Comparison to clinical case definition ‘‘Any
TB including definite, probable, and possible
TB’’ (n=177)
Sensitivity 40 (30–50) 66 (56–75) 51 (40–60) 51 (40–60) 58 (48–68)
Specificity 100 (95–100) 100 (95–100) 96 (88–99) 97 (91–99) 97 (91–99)
PPV 100 (91–100) 100 (94–100) 94 (84–98) 96 (87–99) 97 (88–99)
NPV 56 (47–64) 69 (59–77) 59 (50–68) 60 (51–68) 63 (54–72)
Percent detectionb
Smear-positive, culture-positivec, number/total (percent) 40/49 (81) 49/49 (100) 46/49 (94) 47/49 (96) 47/49 (96)
Smear-negative, culture-positived, number/total (percent) 0/18 (0) 18/18 (100) 5/18 (28) 4/18 (22) 11/18 (61)
Smear-negative, culture-negative, number/total (percent) 0/107 (0) 0/107 (0) 3/107 (3) 1/107 (1) 3/107 (3)
All tests performed on the same 177 sputum specimens. Confidence intervals 95%.
aAll values are percent (95% CI) unless otherwise indicated.
HIV status distribution was as follows: HIV-positive, 124; HIV-negative 26; HIV status unknown, 27.
bAmongst 177 cases where all tests were done, 49 were smear-positive, culture-positive; 18 were smear-negative, culture-positive; 107 were smear-negative, culture-
negative; in three cases NTM was isolated.
cWhere any of the three smears taken during the study period were positive.
dWhere all of the three smears taken during the study period were negative.
doi:10.1371/journal.pmed.1001061.t002
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performance of the Xpert MTB/RIF test compared to smear
microscopy. Our findings further show the superior sensitivity of
the Xpert MTB/RIF compared to the MTBDRplus and the
LCTB assays, especially in the context of HIV co-infection. Some
studies have reported Xpert MTB/RIF performance compared to
other NAATs not evaluated in our study: the sensitivity of the
Xpert MTB/RIF is reported to be higher than that of COBAS
Amplicor MTB (Roche) (94% versus 86.8%) and similar to that of
ProbeTec ET MTB Complex Direct Detection Assay (BD) (83.7%
versus 83.9%) [16]; the sensitivity of the Xpert MTB/RIF assay is
reported to be 79%, compared to an in-house IS6110-TaqMan
real-time PCR assay with 84% sensitivity [24]; the Xpert MTB/
RIF is suggested to be as good as the Gen-Probe MTB (Gen-
Probe), but no data are available [25].
In our study, the decreased sensitivities of all tests (smear,
culture, and NAATs) when using ‘‘clinical TB’’ as a gold standard
instead of MGIT culture reflect the paucibacillary nature of
pulmonary TB in a community of high HIV seroprevalence and
the preference of clinicians to potentially overtreat than undertreat
TB in HIV-infected individuals. Amongst these cases, confirma-
tion of TB could be improved through additional MGIT cultures
or additional Xpert MTB/RIF assays [16]. However, we elected
to remain with this study design (one specimen sample for all
investigational NAATs and MGIT culture) as it more closely
Figure 2. Heat map showing drug susceptibility profiles from 23 samples based on Xpert MTB/RIF, MTBDRplus on sputum,
MTBDRplus on cultured isolates, and phenotypic culture (MGIT DST). The 23 samples were from a cohort of 311 participants. The heat map
shows samples represented in rows and assigned numerical patient identifiers and testing methodologies in columns. Three colors are used to
indicate the results: red, resistant; green, sensitive; yellow, not done, negative for M.tb, contaminated, or inconclusive. The samples are sorted into
AFB-negative or -positive, with RIF and INH profiles in blocks side by side. Two columns are shown for the RIF results generated from the Xpert MTB/
RIF using the amplification cycle threshold maximums 3.5 and 5.0. MDR TB was identified in two patients.
doi:10.1371/journal.pmed.1001061.g002
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resembles current South African National TB Control Programme
guidelines, and may remain practicable should Xpert MTB/RIF
be implemented into routine diagnostic algorithms.
We further compared the assays’ performances for the diagnosis
of drug-resistant TB. Xpert MTB/RIF can detect mutations in the
rpoB gene which occur in 95%–99% of RIF-resistant isolates [26–
29] and are considered a good indicator for MDR TB [30]. The
MTBDRplus assay is able to detect katG and inhA gene mutations
that confer INH resistance in phenotypically resistant INH isolates,
in addition to rpoB gene mutations. The LCTB assay does not detect
mutations in resistance-determining regions ofM.tb. Regarding RIF
resistance, over-reporting has previously been described for the
Xpert MTB/RIF assay compared with phenotypic DST [16].
Boehme et al. [16] further investigated isolates reported by Xpert
MTB/RIF as RIF-resistant, and established by gene sequencing the
presence of resistance-associated rpoB mutations or mixed infection
with wild-type and mutant strains in the same culture. We did not
genotype our resistant isolates further but initially observed a higher
yield of the Xpert MTB/RIF assay for diagnosis of RIF resistance
compared to MTBDRplus or MGIT DST. On re-evaluation using
the new recommended software amplification cycle threshold of
maximum 5.0, no discrepancies with MTBDRplus were found. We
also observed a loss of detection of RIF and INH resistance between
MTBDRplus directly on sputum and MTBDRplus on culture
isolate. This difference could be due to the presence of a mixed-
drug-susceptible and drug-resistant population with different
growth potentials [31].
Overall, of 23 resistant samples detected by any methodology
amongst 311 patients, we found nine discrepancies between
phenotypic and genotypic results. In practice, discrepancies may
lead to inappropriate management of TB, with unnecessary exposure
to potentially toxic drugs or suboptimal treatment; however, the
small sample size limits the full powering for DST accuracy testing.
In addition to the investigation of the Xpert MTB/RIF and
MTBDRplus NAAT tests, this study also investigates the new LCTB
NAAT assay, which may find place in laboratory settings for cost-
effective high-throughput rapid screening (76% sensitive) in place of
smear microscopy (59% sensitivity), with similar turnaround times.
A limitation of our study is that NAAT assays were performed
on frozen aliquots, while smear microscopy and MGIT culture
were performed on fresh samples. This may have impaired M.tb
detection, and reduced the sensitivity of the NAATs in comparison
to culture. In addition, the resuspension of the single processed
sputum in ,2 ml of buffer, as opposed to the recommended
1.5 ml, increased the sample volume, resulting in a dilution and
possibly reduced NAAT sensitivities. Freezing of sample aliquots
may have caused bacterial disintegration, and consequent
suboptimal performance of Xpert MTB/RIF, which relies on
capturing whole (intact) bacteria. Several other studies too have
recently reported Xpert MTB/RIF assay performance using
stored samples: 217 samples from three sites within the western
United States processed by NALC-NaOH and then stored at
280uC showed sensitivities of 98% for smear-positive and 72% for
smear-negative samples [25]; 125 smear-negative clinical speci-
mens processed by NALC-NaOH and then stored at 280uC for
up to 10 y had reported sensitivities (on 1 ml) of 75.3% on the
Xpert MTB/RIF assay [32]; 97 clinical specimens processed by
NALC-NaOH and then stored at280uC before Xpert MTB/RIF
testing had reported sensitivities of 79% [24]; and the Cape Town
study also tested the Xpert MTB/RIF assay using archived
specimens, as mentioned above [23]. Despite these limitations,
Xpert MTB/RIF still showed superior performance among all
NAATs. In favor of the Xpert MTB/RIF assay design is the
sample input volume of processed sputum of 500 ml, compared to
100 ml used for the LCTB assay, and product detection using
automated, more sensitive fluorescence, not visual detection as
with the MTBDRplus assay. Although the Xpert MTB/RIF assay
invalid rate appeared higher than previously documented, the use
of an uninterrupted power supply did improve result reporting,
and should therefore be considered during field implementation.
It has been estimated that the diagnosis of active TB with a
sputum-based assay with a sensitivity of 85% and specificity of 97%
has the potential to save more than 400,000 lives per year [33]. The
only NAAT assay that achieved these targets in our study was Xpert
MTB/RIF. Combined with the fast turnaround time and the
potential for point-of-care implementation (latter not evaluated in
this study), the assay could revolutionize TB diagnosis. Already in a
first implementation study of the Xpert MTB/RIF assay [34] in
sites in South Africa, Peru, and India, and totaling 6,648
participants, use of the Xpert MTB/RIF assay reduced the median
treatment duration for smear-negative TB from 56 d to 5 d. Further
research is needed to determine how best to integrate this assay into
current TB diagnostic algorithms and to improve our understanding
of the prevalence and causes of discrepant drug resistance profiles.
The implementation of point-of-care testing including NAATs
such as the Xpert MTB/RIF will need to be assessed for
appropriate management of quality assurance, the adequacy of
clinic resources (infrastructural and human), data collection,
acceptance by patients and health care providers, and affordabil-
ity, especially in resource-constrained settings.
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Editors’ Summary
Background. Tuberculosis (TB)—a contagious bacterial
infection that mainly affects the lungs—is a global public
health problem. In 2009, 9.4 million people developed TB,
and 1.7 million people died from the disease; a quarter of
these deaths were in HIV-positive individuals. People who
are infected with HIV, the virus that causes AIDS, are
particularly susceptible to TB because of their weakened
immune system. Consequently, TB is a leading cause of
illness and death among people living with HIV. TB is caused
by Mycobacterium tuberculosis, which is spread in airborne
droplets when people with the disease cough or sneeze. Its
characteristic symptoms are a persistent cough, night
sweats, and weight loss. Diagnostic tests for TB include
sputum smear analysis (the microscopic examination of
mucus brought up from the lungs by coughing for the
presence of M. tuberculosis) and mycobacterial liquid culture
(in which bacteriologists try to grow M. tuberculosis from
sputum samples and test its drug sensitivity). TB can usually
be cured by taking several powerful drugs daily for at least
six months.
Why Was This Study Done? Mycobacterial culture is a
sensitive but slow way to diagnose TB. To halt the disease’s
spread, it is essential that TB—particularly TB that is resistant
to several treatment drugs (multidrug-resistant, or MDR,
TB)—is diagnosed quickly. Recently, several nucleic acid
amplification technology (NAAT) tests have been developed
that rapidly detect M. tuberculosis DNA in patient samples
and look for DNA changes that make M. tuberculosis drug-
resistant. In December 2010, the World Health Organization
(WHO) endorsed Xpert MTB/RIF—an automated DNA test
that detects M. tuberculosis and rifampicin resistance (an
indicator of MDR TB) within two hours—for the investigation
of patients who might have TB, especially in regions where
MDR TB and HIV infection are common. TB diagnosis in HIV-
positive people can be difficult because they are more likely
to have smear-negative TB than HIV-negative individuals. In
this prospective study, the researchers compare the
performance of Xpert MTB/RIF on a single sputum sample
with that of smear microscopy, liquid culture, and two other
NAAT tests (MTBDRplus and LightCycler Mycobacterium
Detection) in adults who might have TB in Johannesburg
(South Africa), a region where many adults are HIV-positive.
What Did the Researchers Do and Find? The researchers
evaluated adults with potential TB attending a primary
health care clinic for TB according to national guidelines and
determined their HIV status. A sputum sample from 311
participants underwent smear microscopy, liquid culture,
and drug susceptibility testing; 177 samples were also tested
for TB using NAAT tests. They found that 70% of the
participants were HIV-positive and 38.5% had culture-
positive TB. Compared to liquid culture, smear microscopy,
MTBDRplus, LightCycler Mycobacterium Detection, and
Xpert MTB/RIF had sensitivities of 59%, 76%, 76%, and
86%, respectively. That is, assuming that liquid culture
detected everyone with TB, Xpert MTB/RIF detected 86% of
the cases. The specificity of all the tests compared to liquid
culture was greater than 97%. That is, they all had a low
false-positive rate. Among people who were HIV-positive, the
sensitivity of Xpert MTB/RIF was 84%; the sensitivities of the
other NAAT tests were 70%. Moreover, Xpert MTB/RIF
detected TB in 61% of smear-negative, culture-positive
samples, whereas the other NAATs detected TB in only
about a quarter of these samples. Finally, although some TB
cases were identified as drug-resistant by one test but drug-
sensitive by another, the small number of drug-resistant
cases means no firm conclusions can be made about the
accuracy of drug resistance determination by the various
tests.
What Do These Findings Mean? Although these findings
are likely to be affected by the study’s small size, they
suggest that Xpert MTB/RIF may provide a more accurate
rapid diagnosis of TB than smear microscopy and other
currently available NAAT tests in regions where HIV and TB
are endemic (i.e., always present). Indeed, the reported
accuracy of Xpert MTB/RIF for TB diagnosis—85% sensitivity
and 97% specificity—has the potential to save more than
400,000 lives per year. Taken together with the results of
other recent studies (including an accompanying article by
Lawn et al. that investigates the use of Xpert MTB/RIF for
screening for HIV-associated TB and rifampicin resistance),
these findings support the WHO recommendation that Xpert
MTB/RIF, rather than smear microscopy, should be the initial
test in HIV-infected individuals who might have TB.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001061.
N This study is further discussed in a PLoS Medicine
Perspective by Carlton Evans; a related PLoS Medicine
Research Article by Lawn et al. is also available
N WHO provides information (in several languages) on all
aspects of tuberculosis, including general information on
tuberculosis diagnostics and specific information on the
Xpert MTB/RIF test; further information about WHO’s
endorsement of Xpert MTB/RIF is included in a recent
Strategic and Technical Advisory Group for Tuberculosis
report
N WHO also provides information about tuberculosis and HIV
N The US National Institute of Allergy and Infectious Diseases
has detailed information on tuberculosis and HIV/AIDS
N The US Centers for Disease Control and Prevention also has
information about tuberculosis, including information on
the diagnosis of and on tuberculosis and HIV co-infection
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on HIV-related tuberculosis (in English and Spanish)
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CHAPTER 4: DEVELOPING THE PRINCIPLE COMPONENTS 
TO ENSURE BEST PRACTISE FOR MULTI-DISCIPLINARY 
POCT 
Several components of a quality assurance system were addressed and presented in 
Chapter 4.1 to 4.4, which detail the stringent process involved in verification and EQA quality 
material development for HIV and TB. For molecular HIV plasma-based assays, the South 
African Viral Quality Assurance (SAVQA) panel was developed and is now being used to 
assess newly developed POC technologies. The Dried Culture Spot (DCS) program was 
developed for molecular TB assays and also trialled at POC.  
In addition, further components to ensuring the quality of POCT results in the field, in terms 
of ensuring clinic site readiness and appropriate POC operator training, were presented in 
the following conference presentations:    
a). Scott LE, Gous N, Carmona S, Stevens W. 2014. Performance of Xpert® HIV-1 Quant
compared to Roche CAP/CTM v2 and Abbott RealTime HIV-1 on a prequalification
plasma validation panel. In: ASLM, Cape Town, South Africa, 30th November - 4th
December.
b). Gous N, Scott LE, Stevens WS. 2012. Requirements for Point of Care testing: A checklist
for implementation. In: Grand Challenges Diagnostic Meeting, Seattle, Canada,
September.
c). Gous N, Scott L, Cunningham B, Stevens W. 2012. Site and training requirements for
Xpert® MTB/RIF assay implementation in remote settings: Prepare for the unexpected.
In: 3rd SA TB Conference, South Africa, 12 – 15 June.
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4.1 USE OF A PREQUALIFICATION PANEL FOR RAPID SCALE-UP OF 
HIGH-THROUGHPUT HIV VIRAL LOAD TESTING 
Use of a Prequalification Panel for Rapid Scale-Up of High-
Throughput HIV Viral Load Testing
Lesley E. Scott,a Sergio Carmona,a,b Natasha Gous,a Pamela Horsfield,a Melanie MacKay,c and Wendy Stevensa,b
Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africaa;
National Health Laboratory Service, Johannesburg, South Africab; and Contract Lab Services (CLS), Johannesburg, South Africac
Increased access to antiretroviral drugs expands needs for viral load (VL) testing. South Africa’s National Health Laboratory Ser-
vice responded to demands by implementing two testing platforms in 17 laboratories within 8 months. An industry partner’s
collaboration, training programs, and method verification with a VL prequalification panel ensured testing quality and rapid
implementation.
More than 1.4 million patients receive antiretroviral (ARV)treatment in South Africa through the public health services
(1, 8). In response to such demand, 17 HIV viral load (VL) testing
laboratories were identified for the national HIV program be-
tween May 2010 and January 2011. These were distributed
throughout the 9 provinces at both rural and urban laboratory
centers. Several sites were newly implemented (n 5 6), and the
remaining requiredminimal renovation to accommodate the new
VL testing platform footprints. A total of 75 technical staff mem-
bers were trained. Two viral load testing platforms were selected
for implementation using a stringent tender-based procurement
process. The first platform was the COBAS TaqMan HIV-1(CAP/
CTM) version 2.0 docked system (Roche Molecular Systems,
Branchburg, NJ) (n5 20), which combines the extraction of total
nucleic acids on the COBAS AmpliPrep (CAP) with real-time
PCR on the COBAS TaqMan analyzer (CTM). Each site with this
platform also installed a preanalytical sample-handling P630 de-
vice (Roche), ensuring further automation. The second platform
was the Abbott m2000sp (n5 23) for nucleic acid extraction and
the m2000rt for amplification and detection to perform the Ab-
bott RealTime HIV-1 assay (Abbott Molecular Inc., Des Plaines,
Illinois). Both automated systems are based on real-time PCR and
were connected to the National Health Laboratory Service’s
(NHLS) laboratory information system (LIS). Both assays have
been validated (4), including in-country validation (5, 7), and
therefore did not require further validation but, rather, verifica-
tion after platform placement to ensure adequate site perfor-
mance. The verification was required within 1 week of installation
to ensure each instrument was “fit for purpose” for clinical sample
testing and result reporting.
Thematerial used to prepare the verification panels was a com-
bination of known HIV-positive and -negative plasma packs
(;200 ml) obtained from the South African National Blood Ser-
vices (SANBS). SANBS tests all plasma using the Procleix Ultrio
blood donor screening test (Gen-Probe and Novartis Diagnostics,
Emeryville, CA) to confirm positive or negative HIV status. Each
pack was quantitated (using both assays at the NHLS Charlotte
Maxeke Academic Hospital PCR reference laboratory in Johan-
nesburg) and kept frozen (270°C) until results were obtained by
testing on both VL testing platforms in the reference laboratory in
Johannesburg. The bulk plasma packs were then thawed in a 37°C
water bath and diluted (using negative plasma) or pooled and
aliquoted into 6 bulk lots calculated to produce a range of VL.
Once manufactured, these bulk lots were mixed thoroughly at
room temperature on an orbital shaker (Labotec, SA) and then
retested on the Abbott RealTime HIV-1 assay to confirm the cor-
rect dilutions/pooling of VL. The 6 bulk lots, each a maximum
volume of ;120 ml, consisted of one negative and five quantifi-
able bulk lots in the following viral load ranges (500 copies/ml, 2.7
log copies/ml; 1,000 copies/ml, 3.0 log copies/ml; 5,000 copies/ml,
3.7 log copies/ml; 50,000 copies/ml, 4.7 log copies/ml; and
100,000 copies/ml, 5.0 log copies/ml). These were then assigned
into a 42-member verification panel (Table 1) to be processed in
the order stated. Each range was repeated five times and inter-
spersed between 17 negative samples. The choice of 42 tubes was
to ensure coverage of two racks in the CAP/CTM v2 assay.
The verification panel was shipped using couriers with dry ice
packaging to each site. Testing was performed directly from the
dry-ice-transported panel, or panels were stored at 270°C until
testing. Testing at each site was performed over 1 day with the
same lot numbers of reagents and controls per instrument. Once
the results were obtained, they were entered by the site personnel
into a template MS Excel spreadsheet and emailed to the Depart-
ment of Molecular Medicine and Hematology, Research Diagnos-
tic Laboratory, NHLS, in Johannesburg. Statistical parameters
measured were accuracy, precision, carryover, and limit of blank.
The mean (average), standard deviation (SD), and coefficient of
variation (CV) were calculated in each category for both the un-
transformed value (copies/ml) and the log-transformed value (log
copies/ml). Levels of acceptable variability (within-run precision)
were determined as previously reported (2) and according to the
international Viral Quality Assurance (VQA) program (Rush
Presbyterian-St. Luke’s Medical Center, Chicago, IL). These val-
ues were #35% CV on the untransformed copies/ml values and
#0.19 SD on the log transformed copies/ml values. The log dif-
ference (reference 2 new site) or bias was calculated using the
log-transformed values. An acceptable bias was considered #0.3
Received 21 May 2012 Returned for modification 3 July 2012
Accepted 7 September 2012
Published ahead of print 19 September 2012
Address correspondence to Lesley E. Scott, lesley.scott@nhls.ac.za.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.01355-12
December 2012 Volume 50 Number 12 Journal of Clinical Microbiology p. 4083–4086 jcm.asm.org 4083
 o
n
 D
e
c
e
m
b
e
r 5
, 2
0
1
3
 b
y
 W
IT
W
A
T
E
R
S
R
A
N
D
 H
e
a
lth
 S
c
ie
n
c
e
s
 L
IB
R
A
R
Y
h
ttp
://jc
m
.a
s
m
.o
rg
/
D
o
w
n
lo
a
d
e
d
 fro
m
 
144 | P  a g  e
log copies/ml across all categories. In addition, the percentage
similarity was calculated (6) across all log-transformed quantified
values irrespective of categories, and the percentage similarity SD
and percentage similarity CV were calculated. All Abbott Real-
Time HIV-1 results were compared to one Abbott RealTime
HIV-1 panel, and all CAP/CTM v2 results were compared to one
CAP/CTM v2 panel tested on both platforms at the central refer-
ence laboratory in Johannesburg and considered the reference
standard for statistical analysis. Outcomes were reported back to
the sites via email in a standard report document. Carryover and
limit of the blank were reported if any negative sample directly
after a high-VL sample was reported as positive or if any negative
sample irrespective of position was reported as positive. The re-
ports distributed to the sites recorded the maximum SD and CV.
Forty-five instruments were initially enrolled in this verifica-
tion program across the 17 laboratories: 2 instruments did not
pass verification and were removed, and 43 passed verification
and were able to be used for clinical testing. One panel was tested
on each instrument, and where problems were identified, addi-
tional panels were prepared for testing. Four instrument verifica-
tions flagged above the acceptable statistical criteria (2 failed the
limit of the blank, 1 failed the bias, and 1 target was not detected in
a positive sample). Four instruments were moved after initial ver-
ification due to laboratory renovations and were verified again
before clinical sample testing. Twelve instruments did not gener-
ate verification panel results due to run losses for reasons listed in
Table 2. A total of 65 panel units were tested, with 59 units from
the same bulk manufacturing lot (panel 1). A second bulk plasma
batch (panel 2) needed to be manufactured to ship six additional
units to the sites. This second bulk lot was manufactured from
different plasma packs but followed the same manufacturer’s pro-
tocol as the first bulk.
Table 3 lists the summary statistics of the final verification val-
ues for 43 instruments, excluding two instruments that were re-
placed. Panel 1 and panel 2 results are also shown separately, as the
reference comparators were different. In addition to the within-
platform comparison, a section is also included for the across-
platform comparison, in which the Roche (1 instrument) and Ab-
bott (1 instrument) assays are compared to each other using the
reference panel results for panel 1 and panel 2. This comparison
shows the maximum percentage similarity CV obtained between
the two assays and, therefore, used as themaximum limit for with-
in-platform precision acceptability. Any percentage similarity CV
value above this level (maximum, 2.9%) was flagged for further
investigation.
The average maximum CV and bias for both panels on both
platforms were similar, showing that both platforms are suitable
for HIV VL testing on clinical samples from the region. Two in-
TABLE 1 Panel constitution
Tube no. Panel member VL
1 Negative
2 500 copies/ml
3 1,000 copies/ml
4 5,000 copies/ml
5 Negative
6 50,000 copies/ml
7 100,000 copies/ml
8 Negative
9 Negative
10 500 copies/ml
11 1,000 copies/ml
12 5,000 copies/ml
13 Negative
14 50,000 copies/ml
15 100,000 copies/ml
16 Negative
17 Negative
18 500 copies/ml
19 1,000 copies/ml
20 5,000 copies/ml
21 Negative
22 50,000 copies/ml
23 100,000 copies/ml
24 Negative
25 Negative
26 500 copies/ml
27 1,000 copies/ml
28 5,000 copies/ml
29 Negative
30 50,000 copies/ml
31 100,000 copies/ml
32 Negative
33 Negative
34 500 copies/ml
35 1,000 copies/ml
36 5,000 copies/ml
37 Negative
38 50,000 copies/ml
39 100,000 copies/ml
40 Negative
41 Negative
42 Negative
TABLE 2 Problems identified through the program between May 2010
and January 2011 from 45 instruments placed in the field and enrolled
in the prequalification program
Problem reported
No. of
instruments
Results flagged outside the acceptable statistical criteria 4
Failed the limit of the blank 2
Failed the bias 1
Target not detected in a positive sample 1
Instruments moved after initial verification due to
laboratory renovations and were verified again
before clinical sample testing
4
Instruments did not generate verification panel results
due to run losses
12
Power outage 2
Instrument error 1
Transcription error 2
Incorrect carriers 1
Instrument alignment 1
Incorrect sample storage 1
Failed controls 1
Faulty thermocycler 1
Instrument replaced 2
Scott et al.
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TABLE 3 Summary statistics for two manufactured panels showing the performance across and within platforms for their final verification values
Comparison and laboratory no.a
Instrument
no.
Maximum
CV
Maximum
SD
Maximum
bias SD bias
% similarity
CV
Reference panel comparison across platformsb
Reference panel 1 22.5 0.1 0.32 0.1 2.9
Reference panel 2 34.5 0.2 0.25 0.2 2.5
Panel 1 comparison within Roche instruments
1 1 15.4 0.07 20.21 0.11 1.1
2 23.2 0.1 20.26 0.13 1.6
2 3 26.1 0.11 0.09 0.08 1.1
4 30.2 0.14 20.08 0.12 1.5
5 13.2 0.06 20.14 0.07 0.9
6 30.1 0.15 20.32 0.14 2.3
7 18 0.08 20.12 0.13 1.5
8 17.8 0.08 20.16 0.08 1.4
3 9 36.3 0.16 20.19 0.18 2.3
10 17.7 0.08 20.16 0.09 1
4 11 20.1 0.09 20.14 0.1 1.7
12 25.9 0.1 20.26 0.16 2
5 13 25.9 0.1 20.18 0.18 2
14 25.5 0.12 20.11 0.12 1.4
6 15 22.6 0.09 20.17 0.12 1.4
16 22.2 0.1 0.12 0.1 1.6
7 17 23.3 0.1 20.15 0.1 1
8 18 28.4 0.15 20.13 0.13 0.9
19 19.4 0.09 20.11 0.1 1.1
Avg 23.2 0.1 20.1 0.1 1.5
Panel 1 comparison within Abbott instruments
2 20 18.1 0.08 20.22 0.12 1.3
9 21 13.3 0.06 0.15 0.08 1.2
22 24.1 0.1 20.08 0.14 1.5
23 18.1 0.08 20.1 0.07 1.1
24 36.4 0.17 0.09 0.15 1.6
10 25 11.6 0.05 0.16 0.09 1.6
26 16.5 0.07 0.06 0.08 1
11 27 23.8 0.12 0.12 0.12 1.6
28 19.1 0.08 0.1 0.09 1.2
12 29 12.8 0.06 0.17 0.11 1.6
30 19 0.09 0.15 0.13 1.4
13 31 26.6 0.1 20.05 0.12 1.3
14 32 20.5 0.09 0.06 0.11 1.2
15 33 26.8 0.14 0.03 0.11 1.1
34 29.1 0.12 20.06 0.17 1.5
16 35 27.4 0.12 0.1 0.16 1.7
36 16.9 0.08 20.11 0.09 1.1
17 37 15.1 0.06 20.1 0.08 0.9
38 33.2 0.13 0.11 0.15 1.7
Avg 21.5 0.1 0.0 0.1 1.3
Panel 2 comparison within Roche instruments
2 39 18.2 0.1 20.25 0.19 2.4
7 40 17 0.08 20.19 0.13 1.8
41 15.7 0.1 20.23 0.12 2
Avg 17.0 0.1 20.2 0.1 2.1
Panel 2 comparison within Abbott instruments
17 42 23.4 0.11 0.12 0.14 1.7
43 16.1 0.07 0.11 0.14 1.6
Avg 19.8 0.1 0.1 0.1 1.7
a Numbers in the stub are laboratory numbers unless otherwise indicated (i.e., reference panel numbers).
b Roche (n5 1) versus Abbott (n5 1).
Prequalification Panel for Viral Load Testing
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strument (numbers 9 and 24) maximum CVs on the untrans-
formed valueswere.35%butwere considered borderline accept-
ability, as their biases were within acceptable limits. Apart from
the instrument errors identified through this program and listed
in Table 2, a further 11 individual sample tubes (0.4%; 11/2,730)
generated errors (1 internal control failed and 10 were invalid due
to a clot being detected).
Statistical analysis for verification may be daunting, especially
when implementing different platforms, different samples, and
different scoring parameters; however, the design of this panel of
42 samples was well suited to both platforms testing run sizes, and
the selection of panel members well represented the assays’ dy-
namic range and clinically relevant treatment switch range (500 to
1,000 copies/ml). The five replicates in each range also appeared
suitable to identify any issues of precision within these clinically
important ranges, and the 17 negative samples appeared adequate
to investigate carryover and limit of the blank. The percentage
similarity CV was useful as an overall measure of variability to
highlight instrument problems. If the within-assay percentage
similarity CV is greater than the between-assay percentage simi-
larity CV (.2.9%), then further investigation is needed within
each category using the bias, SD, and CV.
This prequalification program design, its central location, and
its rapid deployment (a not-scheduled scheme) with local re-
sources proved suitable for bothVL testing platforms. The process
identified errors related to both the instrument and the laboratory
operator and proved useful in training and managing new sites
(installation, on-site training, and verification within 1 week). It
identified the need to manufacture larger bulk batch sizes but also
that standard laboratory equipment is suitable for such bulk man-
ufacture. Plasma packs were selected as the choice of testing ma-
terial for instrument verification because they were relatively easy
to source (local blood bank material), truly represented clinical
testing material (predominately subtype C [3]), and showed few
sample errors due to clots detected. However, other testing mate-
rial, such as viral cultures in synthetic matrix, spiked negative
plasma, and plasmid preparations, may be investigated. The po-
tential future use of dried blood spots (DBS) for HIV VL testing
will also require instrument verification and thereby also require a
specialized DBS verification panel, which is being investigated. An
ongoing VL assessment program is now being developed to con-
tinue quality VL testing.
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4.2 DRIED CULTURE SPOTS FOR XPERT MTB/RIF EXTERNAL QUALITY 
ASSESSMENT: RESULTS OF A PHASE 1 PILOT STUDY IN SOUTH 
AFRICA 
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Dried Culture Spots for Xpert MTB/RIF External Quality
Assessment: Results of a Phase 1 Pilot Study in
South Africa£
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Implementation of Xpert MTB/RIF requires quality assessment. A pilot program using dried culture
spots (DCSs) of inactivated Mycobacterium tuberculosis is described. Of 274 DCS results received, 2.19%
generated errors; the remainder yielded 100% correct Mycobacterium tuberculosis detection. The probe A
cycle threshold (CT) variability of three DCS batches was <3.47. The study of longer-term DCS stability
is ongoing.
The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) (1,
3–5, 9, 12, 13, 15, 19, 25) for the diagnosis of Mycobacterium
tuberculosis has recently been endorsed by the WHO (28), and
recommendations for data collection to quantify the impact of
this GeneXpert (GX) technology are provided (26). Guidance,
however, with respect to appropriate external quality assess-
ment (EQA) programs is lacking (17). Current international
tuberculosis (TB) EQA programs focus on microscopy, cul-
ture, and susceptibility testing laboratories (24) and highlight
the difficulties in expansion due to labor-intensive preparatory
work and the high cost and regulations associated with ship-
ping drug-resistant isolates (27).
Criteria for a verification (“fit for purpose”) and EQA pro-
gram suited to the characteristics of the Xpert MTB/RIF assay
(3, 8) will require the following elements. (i) The testing ma-
terial must contain whole M. tuberculosis (8). (ii) Transporta-
tion of EQA material needs to be safe. (iii) The testing pro-
cedure needs to be safe and compatible with the Xpert MTB/
RIF current testing protocol. (iv) Health care workers who do
not have laboratory skills must be able to perform the testing
in nonlaboratory settings. (v) Finally, the programs will need to
be cost-effective and sustainable. Such a program using whole
inactivated M. tuberculosis spotted onto filter paper was devel-
oped and piloted in South Africa as part of the National
Health Laboratory Service (NHLS) GX rollout.
M. tuberculosis was obtained from (i) pooled samples from
20 microbial growth incubation tubes (MGIT) of rifampin
(RIF)-susceptible clinical isolates and tested with the MTB-
DRplus (Hain Life Sciences), (ii) 20 pooled MGIT cultures
comprising American Type Culture Collection (ATCC) strain
S-MYCTU-02-P2 (ATCC 25177 [H37Ra]) and well-character-
ized local clinical strain MYCTU 15, and (iii) the ATCC 25618
(H37Rv) laboratory strain grown for single-cell-organism sus-
pensions (11). The MGIT cultures S-MYCTU-02-P2 and
MYCTU 15 and clinical isolates were pooled in their respec-
tive batches (with strains kept separate and not mixed), cen-
trifuged (3,000 3 g for 15 min at 4°C) to pellet cells, and
resuspended in 40 ml phosphate-buffered saline (PBS) fol-
lowed by addition of 80 ml (2:1 ratio of buffer to culture) of the
Xpert sample reagent (SR) buffer. For the H37Rv strain, 200
ml of culture was harvested (by centrifugation at 3,500 3 g) at
room temperature for 10 min, and cells were resuspended in
PBS to 40 ml followed by addition of 80 ml SR buffer (2:1 ratio
of buffer to cells). Both MGIT-grown and H37Rv strain cul-
tures were inactivated in SR buffer for 2 h at room tempera-
ture, with intermittent mixing. The inactivated material was
washed twice with sterile PBS and resuspended in final vol-
umes of 10 ml (S-MYCTU-02-P2 and MYCTU 15) and 40 ml
(H37Rv) PBS. For confirmation of inactivation, washed cul-
tures (0.5 ml) were reinoculated into new MGIT tubes in
Bactec cabinets for 42 days. These inactivated bulk stocks were
enumerated by flow cytometry (FC500 using Flow count mi-
crospheres; Beckman Coulter) and tested with the Xpert
MTB/RIF assay. The cycle threshold (CT) values of the semi-
quantitative categories (high, CT of ,16; medium, CT of 16 to
22; low, CT of 22 to 28; and very low, CT of.28) were recorded
for probe A and were compared to the flow cytometry enu-
meration score. Dilutions that generated a medium (CT of 16
to 22) qualitative Xpert MTB/RIF result were used to prepare
the dried culture spots (DCSs).
DCSs were prepared by spotting 25-ml amounts of inacti-
vated culture material onto Whatman 903 filter cards (Merck)
together with 2 ml of DNA loading dye (Sigma-Aldrich) per
spot for visualization purposes, as illustrated in Fig. 1, and
dried for 1 h at room temperature before being placed in
sealed plastic bags with a desiccant sachet (Sigma-Aldrich).
* Corresponding author. Mailing address: Department of Molecular
Medicine and Haematology, University of the Witwatersrand, 7 York
Road, Parktown, Johannesburg, South Africa. Phone: 27114898567.
Fax: 27114845812. E-mail: lesley.scott@nhls.ac.za.
£ Published ahead of print on 5 October 2011.
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These were couriered (n 5 16), hand delivered (n 5 10), or
surface mailed (repeat DCSs to 4 sites) to various participating
sites, where each spot was cut (using a sterile pair of scissors)
into a 50-ml standard laboratory Nunc centrifuge tube (AEC
Amersham), and 2.8 ml SR buffer (to ensure there was a
sufficient 2-ml concentration to pipette into the Xpert MTB/
RIF cartridge after the DCS incubation) was added to the
tube. The tubes were vortexed (or hand shaken by swirling
TABLE 1. Performance of the three DCS batches on 286 GX modules
Parameter
Result for DCS batch no.:
V002 V004 V005
M. tuberculosis bulk culture
material
MGIT clinical controls (RIF-sensitive
M. tuberculosis)
MGIT ATCC strain (RIF-sensitive
M. tuberculosis)
H37 laboratory strain (RIF-sensitive
M. tuberculosis)
No. of GX modules tested
by DCS
49 (all RIF-sensitive M. tuberculosis) 173 (all RIF-sensitive M.
tuberculosis)a
64 (all RIF-sensitive M. tuberculosis)
No. of errorsb
Error 5007 1
Error 5011 1 3 1
No. of DCSs for statistical
analysis
48 157 63
% of testing in qualitative
category:
Very low 0 5.1 6.25
Low 26.53 47.13 42.19
Medium 69.39 47.77 48.44
High 2.04 0 1.56
CT for probe A
Mean 20.75 22.58 21.89
SD 2.20 2.76 3.47
CV (%) 10.6 12.22 15.86
a A total of 161 modules returned results.
b Error 5011 refers to signal loss detected in an amplification curve, and error 5007 refers to a probe check failure.
FIG. 1. A sample of the DCSs on filter cards and in plastic transport bags with dessicant sachets. Four DCSs on a card containing inactivated
M. tuberculosis culture are visualized by the blue dye.
VOL. 49, 2011 NOTES 4357
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FIG. 2. Frequency distributions overlaid with normal curves of the CT values for probe A from the three DCS batches. (A) Batch V002;
(B) batch V004; (C) batch V005. The standard deviation and mean CT values are represented in insets in each of the panels.
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vigorously if no vortexer was available) and left at room tem-
perature for 15 min with intermittent mixing. One DCS was
then tested on each Xpert MTB/RIF module. The CT mean,
standard deviation, and coefficient of variation (CV) were cal-
culated for probe A.
Three DCS batches were manufactured for 31 GXs: GX
Infinity-48 (n 5 1), GX16 (n 5 9), and GX4 (n 5 21). A total
of 286 DCSs were distributed to the 26 participating sites, and
results were received for 274 DCSs, thereby identifying sites
with nonconformities. Six testing errors (error no. 5011 [n5 5]
and 5007 [n 5 1]) were reported, and the remaining 268 DCSs
generated results with 100% M. tuberculosis positivity and RIF
sensitivity (Table 1). Probe A was the first probe to reach the
amplification CT, with similar standard deviations across three
DCS batches with a CT of <3.47. Frequency distributions in
Fig. 2 illustrate the greatest variability in batch V005 (CV of
15.86%) from the single-cell-generated culture.
National Xpert MTB/RIF implementation programs are
challenged by determining the scope and composition of EQA
panels and the infectious nature of M. tuberculosis material.
This study provides a preliminary demonstration through the
use of inactivated M. tuberculosis coupled with easier transpor-
tation of DCS material that an EQA program can be safely
provided. The DCS material proved successful for verification
of GX instruments and highlighted expected error code fre-
quencies (2.1%) and site nonconformities.
Although this is a uniquely designed EQA program that
appears so far suitable for Xpert MTB/RIF verification using
different strains from different culture methods, the individual
components are not unfamiliar to the field: filter paper has
been used for the transportation and molecular testing of M.
tuberculosis DNA (7, 14), and flow cytometry has been used for
the analysis of M. tuberculosis (2, 10, 16, 18, 20–23). Flow
cytometry has the advantage of rapidly and accurately identi-
fying inactivated single whole bacterial cells, which circum-
vents conventional, time-consuming CFU enumeration meth-
odologies. Enumeration of flow cytometric events can also be
performed below the minimum McFarlane concentrations
(1 3 107 CFU/ml) and could more accurately be used in strain
mixing to test “dropout” or “delayed” CTs (3). Flow cytometry
is also available in settings that currently perform CD4 count-
ing of HIV patients for treatment initiation and monitoring
and therefore represent a platform and infrastructure already
in place (6).
The variability in CT values may result from the spotting
technique, different DCS reconstitution techniques (including
vortexing/hand shaking), and variability in the amount of SR
buffer added to each DCS. Other sources of variability may be
explained by M. tuberculosis clumping from the MGIT-grown
cultures being better trapped by the Xpert MTB/RIF filter
membrane, whereas an M. tuberculosis single cell (;0.4 mm
wide by 1.0 mm long) may pass through the 0.8-mm membrane
pore. The advantage of single-cell-cultured material is that no
sonication or declumping methods are required before flow
cytometry enumeration and spotting.
Future design of an Xpert MTB/RIF EQA program could
be similarly based on line probe assay programs using one
pansusceptible strain, one RIF-monoresistant strain with a
common rpoB mutation, one multidrug-resistant (MDR)
strain, one nontuberculous mycobacterium (NTM) strain, and
a negative control (17), each placed on a DCS card and dis-
tributed 3 times per year.
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4.3 PERFORMANCE MONITORING OF MYCOBACTERIUM TUBERCULOSIS 
DRIED CULTURE SPOTS FOR USE WITH THE GENEXPERT SYSTEM 
WITHIN A NATIONAL PROGRAM IN SOUTH AFRICA 
Performance Monitoring of Mycobacterium tuberculosis Dried Culture
Spots for Use with the GeneXpert System within a National Program
in South Africa
N. Gous,a B. Cunningham,a B. Kana,b W. Stevens,a,c L. E. Scotta
Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africaa;
DST/NRF Centre of Excellence for Biomedical TB Research, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and the National Health
Laboratory Service, Johannesburg, South Africab; National Priority Program of the National Health Laboratory Service, Johannesburg, South Africac
The use of dried culture spots (DCSs) has been reported in the verification of GeneXpert instruments as being “fit for purpose”
for the South African National implementation program. We investigated and compared the performance of the DCSs for verifi-
cation across different bulk batches, testing the settings and cadre of staff, and the Xpert MTB/RIF assay version. Four bulk
batches (V005 to V008) were used to prepare (i) 619 DCS panels for laboratory testing on G3 or G4 cartridges by a technologist,
(ii) 13 DCS panels (batch V005) used for clinic verification on G3 cartridges by a nurse or lay counselor, and (iii) 20 DCS panels
(batch V005) used for the verification of 10 GeneXpert 16 module instruments in mobile vehicles on the G3 cartridge performed
by a scientist. The stabilities of the DCSs over 6 months at 4°C, room temperature, and 37°C were investigated. The mean cycle
threshold (CT) and standard deviation (SD) for probe A were calculated. The proportions of variability in the CT values across
bulk batches, assay versions, and settings and cadre of staff were determined using regression analysis. Overall, the DCSs dem-
onstrated SDs of 3.3 (n5 660) for the G3 cartridges and 3.8 (n5 1,888) for the G4 cartridges, with an overall error rate of 1.5%
and false rifampin resistance rate of 0.1%. The proportions of variability (R2) in the CT values explained by batch were 14%, by
setting and cadre of staff, 5.6%, and by assay version, 4.2%. The most stable temperature in a period of up to 6 months was 37°C
(SD, 2.7). The DCS is a robust product suitable for storage, transport, and use at room temperature for the verification of the
GeneXpert instrument, and the testing can be performed by non-laboratory-trained personnel in nonlaboratory settings.
Following the endorsement of the XpertMTB/RIF assay (Ceph-eid, Sunnyvale, CA) by theWorldHealthOrganization (1), the
South African National Department of Health (NDoH) and the
National Health Laboratory Service (NHLS) undertook national
implementation of the GeneXpert MTB/RIF assay in March 2011.
The implementation involved rapid successive placement of
GeneXpert instruments in a phased approach into smear micros-
copy centers across high-burden tuberculosis (TB) districts, en-
compassing all 9 provinces in South Africa. By 31 March 2013,
approximately 2,315,380XpertMTB/RIF cartridges had been sold
globally, over half of which had been procured for use in South
Africa alone (2). In parallel to this implementation, a GeneXpert
instrument verification program consisting of inactivated Myco-
bacterium tuberculosis organisms spotted onto filter cards, termed
dried culture spots (DCSs), was developed and successfully used
to verify and ensure that newly placed instruments during phase I
of the implementation (n5 26 sites) were “fit for purpose” before
clinical specimen testing (3). A website (www.tbgxmonitor.com)
was developed to automatically perform statistical analyses and to
generate verification reports in real time.
With the ongoing South African national GeneXpert imple-
mentation program (4), continuous monitoring and field testing
of the DCS program need to be investigated to ensure that the
material is not only suitable for the verification of instruments in
laboratory settings by skilled personnel but that it is also appro-
priate for instrument verification in remote nonlaboratory set-
tings, such as clinics, by non-laboratory-trained personnel.
We report here the GeneXpert assay verification results for
DCSs in various settings, namely: (i) laboratory instrument veri-
fication from the NHLS national implementation program, (ii)
clinic instrument verification by non-laboratory-trained person-
nel, and (iii) instrument verification of GeneXpert assays situated
in mobile vehicles for an intensified case finding event for World
TB Day 2012 at KDC gold mine in Carltonville, South Africa (see
http://www.nhls.ac.za/?page5world_tb_day_2012&id577). The
performance of the DCSs under the most common transport and
storage conditions was also evaluated to demonstrate the stability
of the material.
MATERIALS AND METHODS
Preparation of DCSs and testing in different settings. The manufacture
of the DCSs has been reported previously (3); briefly, it involves growing
the culture strain M. tuberculosis ATCC 25618 (H37Rv) in a single-cell
suspension (5) in bulk, followed by inactivation. Although not reported,
prior to DCS panel preparation, all bulk manufactured stock was quanti-
fied using flow cytometry, which included quality control parameters for
single-cell counting, such as measurement of the percentage of doublets.
The material was then spotted with a blue dye (Sigma-Aldrich) onto per-
forated Munktell specimen collection cards (Lasec, South Africa) as pre-
viously described, dried, packed, and sent to the sites (3). Four bulk
batches (V005 to V008) of this inactivated single-cell stock were used to
prepare DCS panels for the program.
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At the testing sites, a single-use DCS was tested for each GeneXpert
module by pushing the perforated spot into a sterile 50-ml Nunc tube
using an additional pipette. A volume of 2.8 ml of sample reagent buffer
(SR; Cepheid, Sunnyvale, CA) was added to the spot to resuspend the
bacteria. This was incubated for 15 min, unless otherwise stated. During
the incubation period, the DCS was mixed by either hand shaking (field
test setting) or vortex (laboratory setting). Following incubation, all the
SR mixture (.2 ml) was added to the cartridge and tested as per the
manufacturer’s instructions (6). In January 2012, a new cartridge version,
G4, was released for use in the national program. The most prominent
modifications to the G3 cartridge included sequence changes to probe B,
a new quencher, and minor PCR cycle time reductions.
At the completion of testing, all comma-separated value (CSV) files
were uploaded onto theWeb-based platform (www.tbgxmonitor.com) by
staff performing the verification, and all data were downloaded from the
website into MS Excel format. These included the semiquantitative ranges
and the cycle threshold (C
T
) values, which is the point at which fluores-
cence from the hybridized probes increases with product amplification
and is used as an indication of the bacterial load (7). A C
T
of,16 indicates
a high bacterial load, 16 to 22 indicates a medium load, 22 to 28 indicates
a low load, and.28 indicates a very low load.
DCS batch usage. (i) NHLS laboratories. Four bulk batches, V005 to
V008, of the M. tuberculosis-positive rifampin (RIF)-sensitive stock cul-
tures were used to prepare DCSs for the verification of GeneXpert mod-
ules in NHLS laboratory sites performing the Xpert MTB/RIF assay. A
total of 619 DCS panels were sent out to verify 2,476 GeneXpert modules,
some of which had already been switched to the newer G4 cartridge. All
verification was performed by the technologists who routinely performed
GeneXpert testing.
(ii) Primary health care clinics. BatchV005was used to prepareDCSs
for 13 nongovernmental organization (NGO)-fundedprimary health care
clinics using the GeneXpert assay for research purposes. All these clinics
are primarily HIV counseling and testing (HCT) sites that provide anti-
retroviral and TB treatment to patients. Thirteen DCS panels were sent
out as follows: 7 sites in region F, Johannesburg, 4 sites in Motlasana
District, North West Province, one site at Witkoppen Clinic, and one at
Themba Lethu Clinic, both in Johannesburg. Verification at the clinical
sites was performed on G3 cartridges by the nurse or lay counselor doing
the GeneXpert testing for the study.
(iii) Mobile vehicles. Twenty DCS panels were prepared from batch
V005 for verification of 10 GeneXpert 16 module instruments situated in
mobile vehicles at the KDC gold mine in Carltonville, South Africa, for an
NDoH health and wellness campaign held on National TB Day 2012. Due
to electrical power failures on the day of testing, DCSs were incubated in
SR buffer for up to 1 h. All verification was performed on G3 cartridges by
a scientist. Time constraints on the day caused by the power failures led to
only 79 modules being randomly chosen for verification (in an even dis-
tribution across the four frames of the instrument).
DCS performance testing: stability over time and temperature.
Twenty-seven panels (3 DCSs/card) were prepared from batch V005 for
DCS performance testing. DCS panels were packaged in zip-locked plastic
packets with a desiccant and stored in either a 4°C refrigerator (range, 4°
to 8°C), at room temperature (RT; approximately 25°C), or at 37°C (In-
coTherm digital incubator; Labotec, South Africa), with stability evalua-
tions performed at 9 different time points. One entire card (containing 3
DCSs) per temperature was then tested in the Xpert MTB/RIF assay at
each time point: 1, 2, 3, 4, 8, 12, 16, 20, and 24 weeks (6 months).
Statistical analysis. The mean cycle threshold (C
T
) values, standard
deviations (SD), and coefficients of variation (%CV) for probe A (the first
probe to bind) (3) were calculated for all DCS Xpert verification and
stability results. All errors/invalids/no results findings were described but
excluded from the quantitative analysis. The proportions of variability in
C
T
values across (i) bulk batches (same assay version and operator or
setting), (ii) operators and settings (same batch and assay version), and
(iii) assay version (same batch and operator or setting) were determined
using regression analysis and reported as the R2 values (%) using Stata 12
software.
RESULTS
Performance of DCSs across bulk batches. The bulk batches
V005, V006, V007, and V008, which were tested in similar labo-
ratory settings on the same assay version (G4) by laboratory tech-
nologists, excluding errors, gave an overall mean CT value of 19.4
(n 5 1,888) and overall variability of 3.8 SD (Table 1). Batches
V007 and V008 had greater overall mean CT values (fewer bacteria
on average). The overall error rate across all bulk batches (V005 to
V008)was 1.5% (29/1,928), with an invalid rate of 0.1% (2/1,928).
TABLE 1 Performance of DCSs by bulk stock, assay version, and cadre of staff or testing settinga
Performance variable
and result
Performance by bulk batch and cartridge type
V005 V006 V007 V008
G3 G4 G3 G4 G3 G4 G4
Setting (operator) Clinic (nurse) Mobile
(scientist)
Laboratory
(technologist)
Laboratory
(technologist)
Laboratory
(technologist)
Laboratory
(technologist)
Laboratory
(technologist)
Incubation time for
DCSs
15 min 1 h 15 min 15 min 15 min 15 min 15 min 15 min 15 min
Method of DCS
resuspension
Hand shaking Hand shaking Vortex Vortex Vortex Vortex Vortex Vortex Vortex
Results (no.) 48 79 520 444 24 548 4 504 432
Errors (no. [%]) 1 (2.1) 3 (3.8) 8 (1.5) 6 (1.4) None 9 (1.6) None 7 (1.4) 7 (1.6)
“No result” (no. [%]) 1 (0.4) 2 (0.4)
Invalid results (no. [%]) 2 (0.5)
Rifampin sensitivity
results (no. [%])
RIF sensitive 47 (100) 76 (100) 509 (99.6) 437 (99.8) 24 (100) 537 (99.6) 4 (100) 491 (99.2) 423 (100)
RIF indeterminate 1 (0.2) 3 (0.6)
RIF resistant 2 (0.4) 1 (0.2)
M. tuberculosis not
detected
1 (0.2) 1 (0.2)
CT for probe A (mean
[SD])
24.1 (3.3) 16.2 (1.9) 21.6 (3.3) 17.7 (3.5) 22.8 (3.4) 17.3 (3.0) 17.8 (2.1) 21.5 (3.0) 21.4 (3.5)
%CV of the CT for
probe A
13.8 11.8 15.3 17.7 14.8 17.5 11.6 13.8 16.2
a The overall SD and error rate for G3 (n5 660) were 3.3 and 1.8%, respectively, and for G4 (n5 1,888) were 3.8 and 1.5%.
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Only one false-resistant result was reported for batch V006 (de-
layed hybridization on probe B), but the module passed verifica-
tion on a repeat DCS. If batch V005 was used as the reference in
regression analysis, the proportion of variability in CT values ex-
plained by batch was approximately 14% (R2).
Performance of DCS by operator/setting. A total of 647 DCSs
(48 at the clinics, 79 at mobile vehicles, and 520 at the laboratory)
from the same bulk batch (V005) were performed on the same
cartridge assay versionG3but by a different cadre of staff (nurse or
lay counselor, scientist, or laboratory technologist) in different
test settings (Table 1). Both clinic and laboratory testing had sim-
ilar variability (measured by the SD), while DCSs tested in the
mobile vehicles had a lower SD of 1.9. The latter testing site was
the only one where the incubation time in SR buffer increased
beyond 15 min to approximately 1 h. In addition, the CT values
from the clinic (where no vortex was used) was greater than that
from the laboratory. The error rate was highest for DCSs tested in
the mobile vehicles, with only one of these being operator depen-
dent (volume related). The proportion of variability in CT values
explained by setting (and, therefore, the cadre of staff) was 5.6%
overall (R2).
Performance of DCSs across different cartridge assay ver-
sions. In order to compare any differences in the assay versions,
DCSs tested on theG3 andG4 cartridges from the same bulk batch
V005 and in the same laboratory testing setting were compared.
Both assay versions showed a similar SD for probe A and similar
error rates (Table 1). G3 cartridges generated a higher false rifam-
pin resistance result of 0.4% (1 dropout on probes D and E and 1
delayed hybridization on probe B), but one false M. tuberculosis-
negative result was reported for the G4 cartridge, probably due to
low bacterial load on the DCS. The proportion of variability in the
CT values (mean CT values, 21.2 for G3 cartridges and 19.4 for G4
cartridges) explained by assay version was 4.2%.
Irrespective of the bulk batch or test setting, DCSs gave an
overall SD of 3.3 (n5 660) on G3 cartridges and 3.8 (n5 1,888)
on theG4 cartridges. DCSs tested on the older G3 cartridge had an
overall higher mean CT of 21.2 (medium semiquantitative cate-
gory) versus 19.4 forG4 cartridges (alsomedium semiquantitative
category) but lower overall %CV across the data set (17.5% versus
19.5%). The percent error rate on any G3 cartridge was 1.8%
(12/675), whereas G4 cartridges had slightly fewer errors at a rate
of 1.5% (29/1,928).
Long-term performance of DCS material: stability testing. A
total of 81 DCSs were evaluated to determine the performance of
the DCSs under various storage and temperature conditions (Ta-
ble 2). Across all time points, three errors (signal loss failures) and
3 “no results” (2 due to on-site temporary power failures and 1
syringe motion error) were reported. Of the remaining results
(n 5 75) reported in Table 2, 2 RIF-indeterminate values were
reported from two samples yielding very low semiquantitative re-
sults. The SD for probe A remained low for all temperatures
tested, with the lowest SD (2.7) occurring forDCSs stored at 37°C.
Overall, most of the DCS results were in the low semiquantitative
category (mean CT range, 22.6 to 24.7).
DISCUSSION
DCS verification results from the National GeneXpert rollout
showed comparable variation (660 G3 cartridges [SD, 3.3] and
1,888 G4 cartridges [SD, 3.8]) to previously reported findings on
DCSs (268 G3 cartridges [SD, #3.8]) (3). The stability of intact
mycobacterial cells on filter paper for up to 6 months at all tem-
peratures (4°, RT, and 37°C) was well within the expected time
limits for shipping to testing in a national program. Of the tem-
peratures tested,DCSsweremost stable at 37°C,whichmay be due
to an increased number of bacteria being more easily able to re-
suspend from the paper. One potential limit would be that if Gen-
eXpert users are found to prefer using a liquid external quality
assessment (EQA) format instead of using DCSs, stability testing
will need to be done on the bulk liquid batches.
The variability in the DCS product was minimal for the differ-
ences in assay version (4.2%) and operators or settings (5.6%) but
higher between bulk batches (14%). This is to be expected due to
the manufacturing process, which ensures single-cell format and
spotting procedures. This did not, however, affect the overall
mean semiquantitative results reported; all bulk batches, assay
versions, and operator results were determined to be in the me-
dium category.
The overall error rate across all batches, regardless of assay
version, was 1.5%. This is currently below the average failure rate
for the national program (;3%) (8), indicating that it is the min-
imum error rate to be expected in a national program.
The false rifampin resistance result generated from the DCS
material was 0.1% (3/2,548), highlighting the overall good perfor-
mance of the Xpert MTB/RIF assay. It is worth noting that two of
these were due to the reduced probe B hybridization that is typical
of the G3 cartridge. A total of four M. tuberculosis-positive/RIF-
indeterminate values (stocks V006 and V007) and two M. tuber-
culosis negatives (stocks V005 and V007) were reported. These
findings were most likely due to variable amounts of bacteria be-
ing spotted onto each DCS due to problems with retaining the
cells in a homogenous suspension during the postmanufacture
spotting process. Earlier bulk batches showed increased clumping
during the inactivation process, whichwas subsequently corrected
for all new batches.
The use of DCSs has also proven to be accurate (with accept-
TABLE 2 Overall performance data for DCSs after 6 months at various
temperatures in batch V005
Performance data
Results at temp ofa:
4°C RT 37°C
No. (%) of errors,
invalids, or no
results
1 (3.7) error 2 (7.4) errors, 2
(7.4) no
results
1 (3.7)
error
False RIF resistance
calls
1 RIF
indeterminate
1 RIF
indeterminate
None
No. of analyzable
results
25 22 26
Semiquantitative
results (%)
Very low 3.9 12.5 7.7
Low 61.5 62.5 76.9
Medium 34.6 25 15.4
High 0 0 0
CT value for probe A
(mean [SD])
22.6 (3.2) 24.5 (4.1) 24.7 (2.7)
%CV of the CT for
probe A
13.9 16.6 10.9
a
n5 27 for each temperature.
Gous et al.
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able variability) and feasible for the verification of GeneXpert in-
struments in clinics, at the point of care (POC), by non-laborato-
ry-trained personnel, although it highlights the need for the
verification program to supply extra consumables (50-ml Nunc
tubes and a pipette to push out the perforated DCSs) at an addi-
tional cost. Furthermore, a comparison between operators or set-
tings with the newer G4 assay version cartridge would be benefi-
cial.
The robustness of the DCS program was further demonstrated
by its use at an outdoor NDoH campaign on World TB Day 2012,
held at a mining community in Carltonville, South Africa. DCSs
were used to verify 10GeneXpert instruments situated in 5mobile
vehicles, but due to a power failure, the DCSs already prepared for
use could not be tested following the 15-min incubation time. The
lowermean CT value observedwas due to the increased number of
bacteria resuspended off the filter paper after the longer incuba-
tion time. This effect was similarly shown in the lower CT value
that was observed for the laboratories where a vortex was used to
resuspend the bacteria off the filter paper compared to the clinic,
where hand shaking was used (CT values of 24.1 versus 21.6, re-
spectively).
The data presented in this study show the suitability of DCSs
for GeneXpert instrument verification in all settings across a na-
tional program of broad geographic coverage and by all cadres of
testing staff.
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4.4 A PILOT EVALUATION OF EXTERNAL QUALITY ASSESSMENT OF 
GENOTYPE MTBDRPLUS VERSIONS 1 AND 2 USING DRIED CULTURE 
SPOT MATERIAL 
A Pilot Evaluation of External Quality Assessment of GenoType
MTBDRplus Versions 1 and 2 Using Dried Culture Spot Material
N. Gous,a L. E. Isherwood,b A. David,b W. Stevens,a,b L. E. Scotta
Department of Molecular Medicine and Haematology, School of Pathology, University of the Witwatersrand, Johannesburg, South Africaa; National Health Laboratory
Service, Johannesburg, South Africab
Dried culture spots (DCS) of inactivatedMycobacteria strains designed as part of an external quality assessment (EQA) program
for the GeneXpert system has applications to other molecular tuberculosis (TB) diagnostic platforms. DCS tested on the Geno-
TypeMTBDRplus andMycobacterium CM assays performed well withMTBDRplus version 2 but require increased bacterial
concentration for use with version 1.
Quality assurance (QA) refers to an umbrella of quality checkswithin a medical laboratory encompassing the entire testing
process from specimen collection to result reporting (i.e., preana-
lytical, analytical, and postanalytical steps) to ensure high-quality
testing (1). External quality assessment (EQA), sometimes re-
ferred to as proficiency testing, is just one component of a QA
program and is defined as a system for objectively checking the
performance of a laboratory using an external agency or facility
(2). This is often challenging and costly for tuberculosis (TB) lab-
oratories but is particularly exacerbated in low-resource settings
(3), which may not always be equipped with an adequate level of
biosafety to receive live Mycobacterium tuberculosis (MTB) cul-
tures, and stringent requirements for transportation of such ma-
terials exist (4). Several TB EQA molecular schemes exist (http:
//www.cap.org; 5, 6), but some provide the EQA material in a
format containing preextracted DNA, making them inappropri-
ate for themonitoring of the entire testing process from extraction
to detection.
To address the complexities of ongoing molecular diagnos-
tic EQA systems in TB laboratories, a verification (fit-for-pur-
pose) (7) and EQA program (pre-/postanalytics) (8) consisting
of dried culture spot (DCS) material was developed for the
molecular GeneXpert instrument performing the Xpert MTB/
RIF assay (Cepheid, Sunnyvale, CA) (9). The major advantage
of this approach is that the DCS contain whole, inactivated, and
quantitated mycobacterial strains that can be safely trans-
ported as one would transport documents by mail, without the
requirement of cold-chain transport. The spots are easy to use
and robust, with a minimum shelf life of 9 months confirmed
to date (10).
The DCS EQA program has been successfully implemented in
207 National Health Laboratory Service (NHLS) GeneXpert test-
ing laboratories in South Africa and 82 non-NHLS sites in 21
countries. The Global Laboratory Initiative (GLI) (advisors to the
World Health Organization) has also endorsed the DCS for veri-
fication of the GeneXpert instrument. As the DCS material is not
platform specific, we determined the potential application of the
GeneXpert DCS program for the molecular line probe assay
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TABLE 1 Initial results on use of the DCS material on the GenoType MTBDRplus versions 1 and 2 tested in a research laboratory
No. of DCS tested by
GenoType MTBDRplus
versiona DCS strain Observed result on GenoType MTBDRplus assay (no. observed/total no. [%])
Version 1
8 M. kansasii 16/16 (100) negative
8 M. intracellulare 16/16 (100) negative
16 M. tuberculosis RIFr, INHs 15/16 (94) positive, RIFr INHs; 1/16 (6) negative
16 M. tuberculosis RIFs, INHs 8/16 (50) positive, RIFs INHs; 2/16 (12.5) positive, RIF and INH inconclusive; 6/16 (37.5) negative
Version 2
8 M. kansasii 24/24 (100) negative
8 M. intracellulare 24/24 (100) negative
8 M. fortuitum 24/24 (100) negative
40 M. tuberculosis RIFr, INHs 40/40 (100) positive, RIFr INHs
16 M. tuberculosis RIFs, INHs 16/16 (100) positive, RIFs INHs
a Number of DCS tested per strain dependent on available stock.
April 2015 Volume 53 Number 4 jcm.asm.org 1365Journal of Clinical Microbiology
 o
n
 August 4, 2015 by UNIVERSITY O
F W
ITW
ATERSRAND
http://jcm.asm.org/
D
ow
nloaded from
 
160 | P  a g  e
(LPA), GenotypeMTBDRplus versions 1 and 2 (Hain Lifescience,
GmbH, Nehren, Germany).
DCS panels (each comprising 4 spots) were initially tested in a
research laboratory in Johannesburg and then piloted in four rou-
tine service TB laboratories in SouthAfrica, namely, theMycobac-
teriology Referral Laboratory, Johannesburg; Ampath, Pretoria;
Lancet, Johannesburg; and Centre for Clinical Tuberculosis Re-
search (CCTR) Laboratory, Task Applied Science, Cape Town.
The Xpert MTB/RIF DCS panels (7), comprising M. tubercu-
losis rifampin (RIF)-resistant (Xpert probe D mutant)/isoniazid
(INH)-susceptible, M. tuberculosis RIF-susceptible/INH-suscep-
tible, and nontuberculous mycobacteria (NTM) (namelyM. kan-
sasii,M. intracellulare, andM. fortuitum), were tested on the MT-
BDRplus versions 1 and 2 . This involved resuspending the DCS in
a 50-ml Nunc tube containing 2 ml of phosphate-buffered saline
(PBS) for 15 min, with intermittent vortexing. This was followed
by manual extraction (for MTBDRplus version 1) or GenoLyse
extraction (for MTBDRplus version 2) of the entire lysate, as per
the manufacturer’s instructions. The extracted material was then
amplified and hybridized as per the standard manufacturer’s pro-
tocol for versions 1 and 2. The species identifications of the nega-
tive results for theMTBDRplus version 2 (TUB band absent) were
determined using the GenoType Mycobacterium CM assay (Hain
Lifescience, Germany).
Table 1 lists the observed findings for the initial research labo-
ratory testing and Table 2 for the pilot site testing.
The species of all DCS that tested negative on version 2 of the
LPA in the research laboratory (Table 1) were further identified
with the GenoType Mycobacterium CM assay. Of the eight M.
kansasii, M. intracellulare, and M. fortuitum spots tested, the spe-
cies of 6 from each were successfully identified (18/24 [75%]).
TheM. intracellulareDCS tested on LPA version 2 at two of the
pilot sites (Table 2; n  3 per site) were also tested on the Myco-
bacterium CM assay, and the species of 5/6 (83%) were correctly
identified. One DCS (17%) was incorrectly reported asM. avium.
Although partially successful in the initial laboratory testing
phase, the two pilot sites performing version 1 failed to produce
interpretable results. This was due to the low bacillary load on the
DCS designed for detection at a minimum of 150 CFU/ml, which
is the lower limit of detection of the XpertMTB/RIF test (9). Since
the LPA version 1 is validated only for use with smear-positive
specimens, which has a limit of detection of 10,000 bacteria/ml3
(11), it is feasible to accept that version 1 will not detectM. tuber-
culosis on the DCS below this lower limit.
The reverse is true for the use of DCS with the MTBDRplus
version 2 assay, as all (80/80) DCS results from the research labo-
ratory and 96% (23/24) of the pilot site results were correctly
reported. Rifampin resistance was identified by an rpoB wild-type
7 (WT7) missing band and a mutant 2A (MUT2A) band present
by the LPA, which corresponds to the Xpert MTB/RIF probe D
mutant. One of the pilot sites detected an RIF-resistant DCS as
having a WT7 band and MUT2A band present. This may have
been due to incorrect interpretation or contamination, but the
finding was not considered clinically relevant. Of the three sites
(one research laboratory and 2 routine service laboratories) that
performed Mycobacterium CM assay testing on the negative re-
sults by MTBDRplus version 2, only one incorrect species identi-
fication was reported, possibly due to a mislabeled laboratory
specimen.
Overall, the DCS program appears to be suitable not only for the
Xpert MTB/RIF assay but also for the MTBDRplus assay version 2,
due to their similar sensitivities, and it providesmeasurements for the
entire testing process (DNA extraction through result reporting), as
opposed to just the amplification and hybridization steps on DNA-
prepared EQA materials. The added advantage of the DCS technol-
ogy is the ability to transport inactivated tuberculosis-positive speci-
mens at room temperature, thereby reducing the overall program
costs. Even though the GenoType MTBDRplus version 1 assay has
been discontinued in several countries (Hain Lifescience, South Af-
rica [Pty], Ltd., personal communication), if laboratories wish to use
the DCS with this version, an increased bacterial concentration will
need to be spotted onto the paper card.
Currently, the result reporting of the GeneXpert MTB/RIF
EQA DCS program is automated and managed remotely through
TBGxMonitor for real-time turnaround of the results, but it could
be expanded to provide amore automated result reporting for the
MTBDRplus assays. Other M. tuberculosis strains could also be
included in the DCS panels that are suitable for second-line drug
resistance testing, such as those with the MTBDRsl assay (Hain
Lifescience, GmbH, Nehren, Germany).
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CHAPTER 5: DETERMINING THE FEASIBILITY OF 
MULTIPLE POCT FOR HIV AND TB SERVICE INTEGRATION 
IN THE FIELD 
Once assay validations were complete and the various components of a quality 
management system were developed, the feasibility of a nurse performing multi-disciplinary 
POCT in a clinical setting was evaluated. This also included acceptance criteria by patients 
as well as the practical considerations for performing multiple POCT.  
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5.1 IMPLEMENTATION OF MULTIPLE POINT OF CARE TESTING IN TWO 
HIV ANTIRETROVIRAL TREATMENT CLINICS IN SOUTH AFRICA  
(SUBMITTED TO JAIDS) 
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Abstract: 
5
Background: A plethora of point-of-care (POC) tests exist in the HIV and TB diagnostic 
7
pipeline which require rigorous evaluation to ensure performance in the field. The accuracy 
8
and feasibility of nurse-operated multidisciplinary-POC testing for HIV antiretroviral therapy 
9
(ART) initiation/monitoring was evaluated. 
:
L
2
3
4
5 6
5 5
5 7
5 8
5 9
5 :
5 L
5
2
5 3
5 4
7 6
7 5
7 7
Methods: Random HIV-positive adult patients presenting at two treatment clinics in South 
Africa for ART initiation/monitoring, were consented and enrolled. POCT was performed by a 
dedicated nurse on a venepuncture specimen; Pima (CD4), HemoCue (haemoglobin), 
Reflotron (alanine aminotransferase, creatinine), Accutrend (lactate) and compared to 
laboratory testing using the Bland-Altman and percentage similarity methods of agreement. 
External quality assessment (EQA), training, workflow and errors were assessed to 
determine feasibility of POC testing.  
Results: n=324 enrolled at site1; n=469 enrolled at site2. Clinical data on n=305 
participants: 65% (n=198) female with a mean age of 39.8[range 21-61] years; mean age of 
males 43.2[range 26-61] years; 70% of patients required 3 or more POC tests/visit. EQA 
material was suitable for POCT. CD4, haemoglobin and alanine aminotransferase testing 
showed good agreement with predicate methodology; creatinine and lactate had increased 
variability. Pima CD4 misclassified up to 15.6% of patients at 350cells/µl and reported 
4.3-6% error rate. A dedicated nurse could perform POCT on 7 patients/day; inclusion of 
Pima CD4 increased time for testing from 6 to 110minutes. Transcription error rate was 1%.  
Conclusions: Multi-disciplinary POCT is accurate and feasible for ART initiation/monitoring if 
performed by a dedicated nurse but will increase duties. Use of Pima CD4 will increase 
patients initiated on ART. Connectivity will be central to ensure quality management of 
results but overall impact will need to still be addressed. 7 8
Keywords 
7 9
Multiple-disciplinary; point-of-care testing; HIV; antiretroviral; implementation
7 :
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Introduction 
5
Laboratory systems and services are critical in global health and point-of-care testing 
7
(POCT) may have a place within this framework to address unmet diagnostic needs, 
8
especially in resource-limited environments 1-3.  Appropriate clinical management of ill 
9
patients presenting at primary health care clinics (PHC) remains a global health challenge 
:
and lack of accessibility to an appropriate laboratory diagnosis is a major reason why health 
L
services are failing. A recent report in the New England Journal of Medicine describing 20 
2
years of health care in South Africa, stated that improving access to health care requires 
3
restructuring and strengthening of existing district-based PHC facilities, with nurses and 
4
community healthcare workers (HCWs) playing an increasingly important role in remote 
5 6
areas 4.  
5 5
5 7
POCT is currently the fastest growing market in medical diagnostics with many innovative 
5 8
technology developments 1, 5. The purpose of POCT is to provide a test that has immediate 
5 9
impact on patient outcome 6 and that can be used in outpatient clinics, emergency rooms, 
5 :
theatres, mobile clinics, PHC clinics, or even small laboratories 7. The potential benefits for 
5 L
POCT identified in low to middle income countries are to avoid patient hospitalisation (or 
5
2
reduce length of stay), help manage chronic conditions 3, 7, 8, improve accessibility of 
5 3
services, reduce turnaround times, potentially improve patient retention and improve staff 
5 4
convenience and satisfaction 9-13. 
7 6
A number of disadvantages also exist, such as the poor regulatory control 14, lack of 
7 5
connectivity, inadequate quality control and assurance 15, 16, a potential increase in cost and 
7 7
over-use (duplication) of existing laboratory and POC services, as well the need for 
7 8
appropriately trained POC operators 17. Several guideline documents detailing the 
7 9
requirements for POCT exist 18-20 and all emphasise the need for quality in POCT. The 
7 :
complexities of managing quality of the entire process (pre-analytical, analytical and post-
7 L
analytical) however, are well described for glucose testing 21, but less so elsewhere.   
7
2
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:
POCT for infectious diseases in the developing world are largely in the form of strip-based 
5
lateral flow assays for the diagnosis of syphilis, malaria and HIV 14. The massive expansion 
7
of anti-retroviral (ARV) therapy (ART) in lower and middle-income countries has relied 
8
entirely on the use of one or more rapid tests for diagnosing HIV, which are frequently 
9
performed by lay counsellors or lower-level HCWs. In many countries, this has facilitated 
:
expansion of services where laboratories were inadequately equipped to handle the volume 
L
of testing or where infrastructure hampered the safe and timeous transportation of biological 
2
samples 22, 23.  In South Africa, the track record for HIV rapid testing at POC has been 
3
challenged with studies showing poor compliance to standard operating procedures and 
4
poor quality management 24.  
5 6
In addition to rapid strip-based testing for diagnosis of HIV, ART initiation has relied on CD4 
5 5
count testing for treatment initiation. The value of the CD4 assay is under scrutiny with 
5 7
treatment thresholds increasing to 500cells/µl and more emphasis being placed on viral load 
5 8
testing for monitoring treatment success 25, 26. ART treatment guidelines in South Africa 27 
5 9
also include additional diagnostic assays prior to ART initiation: Alanine aminotransferase 
5 :
(ALT), creatinine (Cr) (for Tenofovir usage), haemoglobin (Hb) (particularly if Zidovudine is 
5 L
used) and hepatitis B antigen. This highlights the need for a multi-disciplinary array of testing 
5
2
requirements for ART initiation and subsequent monitoring.  
5 3
Prior work has alluded to the fact that the expanded repertoire of assays could possibly be 
5 4
performed by nurses or other HCWs at POC 28. A limitation to this process however, in many 
7 6
countries including South Africa, has been the need for phlebotomy skills for which the 
7 5
scope of work is defined for a certain cadre of nursing staff and is mandated by the Health 
7 7
Professions Council of South Africa (HPCSA) 29. The use of finger stick testing can eliminate 
7 8
the need for skilled phlebotomists, but for HIV treatment could mean patients may require up 
7 9
to four finger sticks for POCT at each visit 30, over and above the initial two finger sticks 
7 :
required for HIV rapid testing.  
7 L
7
2
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L
While numerous reviews are available on the use of POCT and the need in resource limited 
5
settings 2, 31, 32 in the HIV testing arena, few have dealt with logistics around sample 
7
collection, connectivity, result reporting or whether improving logistics would be more cost-
8
effective.  In addition, most of the new POC technologies have limited field evaluation and 
9
few studies have evaluated clinical outcome, impact on overall health care, cost 
:
effectiveness and cost benefit of POC, especially in the developing world and specifically for 
L
multi-disciplinary POCT. To address some of these issues, we implemented nurse operated 
2
multiple POCT in two busy ART clinics in South Africa, to assess the feasibility and accuracy 
3
of the process.  
4
5 6
Methods 
5 5
This project formed part of a Grand Challenges Canada study (grant # 0007-02-01-01-01). 
5 7
Human Ethics was obtained and approved through the University of the Witwatersrand, 
5 8
(M10333) and the University of Pretoria, South Africa (M090688).   
5 9
5 :
Clinic sites 
5 L
All laboratory validations, training and research and development were performed at the 
5
2
National Health Laboratory Service (NHLS) Department of Molecular Medicine and 
5 3
Haematology in Johannesburg, South Africa.  The clinic phase validation to determine nurse 
5 4
operated POCT versus laboratory testing was performed in two well managed urban ART 
7 6
PHC sites: a) non-governmental organisation (NGO) supported Themba Lethu Clinic, part of 
7 5
the Clinical HIV Research Unit (CHRU) located within the infrastructure of the Helen Joseph 
7 7
Hospital, Right to Care in Johannesburg, which manages 21 000 HIV infected patients on 
7 8
ARV treatment  33; b) Comprehensive Care Management and Treatment (CCMT) Clinic, 
7 9
Tshwane District Hospital in Pretoria. Both clinics enrol more than 350 patients per month, 5 
7 :
days a week and both are within walking distance from high throughput routine laboratories 
7 L
managed by the NHLS.  A POCT laboratory was established in each clinic in a dedicated 
7
2
room adjacent to the consultation rooms. The POCT instruments were installed by suppliers 
7 3
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2
as per good clinical laboratory practice guidelines (GCLP) 34. Reagent kits were procured 
5
and stored appropriately. Three dedicated research nurses (professional nurses experienced 
7
in phlebotomy and HIV/Tuberculosis (TB) treatment) were employed and trained on all POC 
8
instruments by the instrument suppliers and local laboratory staff. In all sites selected, 
9
provincial approval and support was obtained and dedicated staff and instrumentation were 
:
placed to support all the project activities. 
L
2
Participant eligibility for POCT 
3
Individuals (>18 years of age, with known HIV-positive status) were approached for 
4
enrolment in the study when they presented for routine phlebotomy related to their HIV ARV 
5 6
initiation and monitoring at the clinics. The nurses conducted informed consent, enrolled 
5 5
participants and performed the required phlebotomy. The selection of POCT was based on 
5 7
the SA HIV treatment guidelines at the time of the study 35, and included the following tests: 
5 8
CD4 for ART initiation, followed by Cr, ALT and Hb. Lactate was included but rarely 
5 9
requested (stavudine usage high at time of study). Each participant consented to providing 
5 :
an additional EDTAk3 (for CD4, Hb, Cr and lactate) and/or a Heparin tube (for ALT), which 
5 L
was used for on-site POCT. The POC platforms were the PIMA (Alere, Inc., Waltham, MA, 
5
2
USA) for CD4; HemoCue DM201 (HemoCue AB, Ängelholm, Sweden) for Hb; Reflotron Plus 
5 3
(Roche Diagnostics, GmbH, Germany) for ALT and Cr; and COBAS Accutrend Plus (Roche 
5 4
Diagnostics, GmbH, Germany) for Lactate. The selection of these POCT platforms was 
7 6
based on the POC diagnostic pipeline document at the time36, available literature 28, 37-41 and 
7 5
in-house validations.  
7 7
Post-phlebotomy, the nurses took the additional blood tube to the POCT room in the clinic, 
7 8
opened the vacutainer tube and performed POCT. A fixed volume pipette supplied with the 
7 9
Reflotron (Roche Diagnostics) was used to dispense the required blood volume onto the 
7 :
rapid strips (ALT, Cr and lactate) or to dispense blood into the Hb microcuvette or PIMA 
7 L
cartridge. Results were manually recorded in a log book. At CHRU, the nurse also used a 
7
2
Vacudrop (Greiner Bio-One, Dublin, Ireland) device which allows the withdrawal of a single 
7 3
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3
drop of blood from a closed blood tube, similar to a finger stick. This method was 
5
investigated to determine the performance of the POC tests without the use of a pipette. 
7
POC results were not used for clinical management. The routine bloods were sent as per 
8
standard-of-care to the NHLS laboratories for routine laboratory testing. These reference 
9
result values were made available to the study through the NHLS laboratory information 
:
system and used for patient management.  
L
2
POC instrument verification and quality management 
3
After placing the POCT platforms in the clinic sites and prior to their use, each platform 
4
(Pima CD4, HemoCue and Reflotron) was verified using 25 specimens (ensuring they were 
5 6
M N O P N Q R S T R S Q U V W X U S X R P Q N Y Z [ \ R V ] T O R V ^ V _ P U `
42. The verification specimens were randomly
5 5
collected from routine, residual patient specimens in the adjoining NHLS reference 
5 7
laboratories. As lactate measurements need to be performed immediately upon blood 
5 8
collection, the first 25 patients recruited on the study requiring a lactate test, were used as 
5 9
verification material for the Accutrend Plus instrument. 
5 :
For quality monitoring throughout the study, quality control (QC) material was tested on each 
5 L
of the instruments according 
P Q ^ X _ T N X a P T R V R b U O _ U P R T a P O Q _ U
 by the POC nurses. A log sheet
5
2
was used to record QC test results. In addition, one round of external quality assessment
5 3
(EQA) was performed at the CHRU clinic on the PIMA CD4, HemoCue and Accutrend
5 4
instruments using EQA material obtained from the NHLS EQA regional and national 
7 6
programs.  Results were sent to the NHLS EQA Division for independent analysis and 
7 5
reporting (Z-scores of <2 were considered acceptable). No NHLS EQA material was 
7 7
available for the Reflotron instrument as this is a dry chemistry based system compared to 
7 8
the laboratory platforms which use wet chemistry.  
7 9
7 :
Comparator laboratory testing platforms 
7 L
NHLS derived results were considered the reference standards against which the POC 
7
2
results were compared, these included: CD4 single platform PanLeucogating method using 
7 3
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4
flow cytometry (Beckman Coulter, Miami, FL); Advia 120 and 2120 Heamatology system for 
5
Hb (Siemens, Diagnostic Solutions, Tarrytown, NY); Advia 1800 Chemistry analyser 
7
(Siemens Healthcare Diagnostics, Inc, Germany) and Synchron DXC 800 (Beckman Coulter, 
8
Miami, FL) for ALT and Creatinine; Advia 1800 for Lactate.  
9
:
Statistical analysis  
L
The performance of multidisciplinary POCT performed by nurses directly in clinics was 
2
compared to laboratory generated reference results using the Bland-Altman 43 and 
3
percentage similarity 44 methods of agreement. Accuracy was measured using the bias 
4
(laboratory reference - POCT) and this was reported in the context of the data sets 
5 6
summarised by their median values. Confidence intervals (CI) at 95% were included. Overall 
5 5
agreement between the laboratory reference and POC results was measured using the 
5 7
percentage similarity coefficient of variation (CV), which includes accuracy and precision. 
5 8
Total misclassification (false positive and false negative compared to predicate) was 
5 9
reported for CD4 counts at the 350cells/µl level and included sensitivity and specificity 
5 :
(including 95% CI) for completeness. Instrument errors were recorded. Functions were 
5 L
performed using STATA 12. Scatter plots were used to represent outliers in the clinically 
5
2
relevant ranges for each analyte. Normal ranges for each analyte were determined by the 
5 3
NHLS reference technology as follows: Hb 12c 18g/dl; ALT 10-40U/l; Cr 64-104umol/l, 
5 4
lactate <2.2mmol/L. Royal College of Pathologists of Australasia (RCPA) allowable 
7 6
differences 45 were also applied to determine outliers: Hb ±0.5 <10g/dl and ±5% >10g/dl, 
7 5
ALT ±5 d e f g h i
X _ j k l m n
 >40U/l, Cr±8 <100umol/l and ±8% o
l
f f
T ^ Q
i h i , lactate ±0.5mmol/L 
7 7
<4mmol/L and ±12% >4mmol/L.  
7 8
Qualitative data (measured prior to and during the study) of the multiple POC 
7 9
implementation process addressed workflow and feasibility issues, rather than simply 
7 :
comparative laboratory data. These variables included: training and additional consumable 
7 L
needs, length of time and number of added duties required to perform multiple POCT and 
7
2
number of transcription errors during manual result recording.  
7 3
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5 6
5
Results 
7
Data summary 
8
A total of 324 patients were approached to participate over a 6 month period at CHRU 
9
(December 2010 to June 2011) and 469 patients at CCMT over 1 month (January 2012 to 
:
February 2012). No patient declined participation. Clinical data was available for 305 CHRU 
L
study participants as follows: 65% (n=198) of the patients were female; mean age of females 
2
was 39.8 [21-61] years and males was 43.2 [26-61] years; mean number of days on ART at 
3
the time of POC testing was 833 days for men and 764 days for women. Patients on first line 
4
ART: n=175; the remainder were either not on therapy (being initiated on ART) or had 
5 6
missing demographics at time of blood draw. 
5 5
The number of diagnostic tests requested by HCWs for patients at a particular visit attending 
5 7
the CCMT site is represented in the pie chart in Figure 1 and shows that 70% (325/464) of 
5 8
patients required 3 or more POCT to be performed per visit.  
5 9
5 :
Method comparison of POCT versus laboratory testing  
5 L
All POCT platforms placed in both clinics passed verification using 25 laboratory specimens 
5
2
(and clinical specimens for lactate). No QC failures were observed on any of the instruments 
5 3
and 100% compliance was obtained by the POC nurses in performing instrument QC as 
5 4
reflected in Table 1. EQA material tested on the PIMA, HemoCue and Accutrend showed 
7 6
results to be within acceptable limits despite material not being specific for all POC 
7 5
instruments. One sample for each instrument tested flagged outside the reference range 
7 7
according to the Z-score of >2, but the values were not in the clinically relevant range.  
7 8
7 9
Table 2 and Figure 2 detail the method comparison statistics and scatter plots of nurse 
7 :
operated POCT compared to laboratory reference results. Pima CD4 testing performed at 
7 L
CHRU had a bias of 26cells/µl which showed better accuracy than testing performed at 
7
2
CCMT (54cells/µl), in spite of their similar CD4 results (similar CD4 median and range). CD4 
7 3
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5 5
testing performed at CCMT also yielded more misclassification at the 350cells/ml threshold 
5
than testing performed at CHRU however at both sites, misclassification of CD4 using Pima 
7
would have resulted in more patients identified for ART initiation. The Pima CD4 error rates 
8
at both sites were similar. 
9
The performance of ALT and lactate POCT was variable and significantly different between 
:
the sites (CI did not overlap), but the majority of specimens were within the clinically relevant 
L
range, and would not have resulted in a change in clinical management.  
2
The bias for Hb and creatinine testing was accurate and similar at both sites. POC testing of 
3
CD4, Hb and ALT using the VacuDrop at CHRU generated acceptable bias values similar to 
4
the main study at this site.  
5 6
5 5
Qualitative analysis multi-disciplinary POCT  
5 7
POCT ease of use: Practical training for the nurses on all the POCT instruments took 
5 8
approximately half a day per instrument and included sample testing, performing QC, 
5 9
instrument maintenance and troubleshooting. Additionally, the POC nurse had to be trained 
5 :
on general laboratory safety, handling of a pipette, waste disposal and laboratory spill clean-
5 L
up. Apart from hard copy standard operating procedures provided to each POC testing 
5
2
laboratory, it was found that quick reference charts containing visual aids were preferred. 
5 3
Upon interview of the nurses after the study, no difficulties in performing the individual POCT 
5 4
were reported. Both the Reflotron pipettes and Vacudrop were easy to use. However, with 
7 6
the Vacudrop there was no guarantee or quality measure to ensure single use only.  
7 5
7 7
The need for additional consumables to perform multiple POCT: Several POCT 
p q
consumables were required which were not typical to the clinic environment. These were: 
p r
pipettes (10-100µl) (requiring calibration) and sterile pipette tips (universal: 10-100µl) for 
p s
blood sample dispensing, parafilm/plastic for Hb microcuvette filling and specimen racks for 
p t
transport of blood tubes to the POCT laboratory. To ensure safety, several additional 
p u
components were required: laboratory coat, non-powdered gloves, suitable disinfectant, 
p v
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ethanol and bleach for instrument cleaning, measuring cylinder for preparing cleaning 

reagents, wash bottles for storing reagents and paper towel. Miscellaneous items required 
p
were: multi-plugs, network cables, fridge for EQA/QC material storage, paper for result 
q
printing. 
r
s
The number of added duties required to perform multiple POCT: Table 3 lists the 
t
general responsibilities (duties) required by nurses in HIV ART clinics (not specific to the two 
u
clinic sites in our study) and then the additional list of duties that the nurse would perform if 
v
they were responsible for POCT, as seen in our study.  

 Ł
The length of time to perform the multiple POCT: This was measured at the CHRU site 
 
(n=160) and showed the earliest time a POCT was performed was 9:30am (median 11:00; 
 p
which did include patient consent and enrolling). The latest time a POCT was performed was 
 q
16:26pm (median 12:25). The median time from starting the first POCT to starting the last 
 r
POCT varied, depending on the number and type of tests requested; when CD4 was 
 s
included, 4 tests took 1hr47minutes; when CD4 was not included, 3 tests took 6minutes. The 
 t
median number of patients that could be consented, enrolled, bled and tested by one study 
 u
nurse in one day was 7 (minimum 2, maximum 12).  It should be noted that this was under 
 v
circumstances where dedicated nursing staff were placed at sites to only perform this study. 
 
p Ł
POCT errors: At the CHRU site, the PIMA CD4 instrument reported 9 errors (6%). Channel 
p 
filling error was reported once and device application errors were reported 8 times. CCMT 
p p
reported an error rate for the PIMA CD4 up to 4.3% (13/302) of which only one specimen 
p q
could not be resulted on repeat testing.  No errors or invalids were reported for the 
p r
HemoCue, Reflotron and Accutrend. A total of five (5/469) transcription errors (incorrect 
p s
value) were discovered during the statistical analysis at the CCMT site and three (3/324) at 
p t
the CHRU site, totalling 1%. 
p u
p v
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Discussion 

A plethora of POC technologies are in the HIV and TB diagnostic pipeline which will require 
p
rigorous evaluation to assess performance in the field. This is the first study in South Africa 
q
to investigate nurse operated multi-disciplinary POCT for ART initiation and monitoring in a 
r
clinical site. In our setting, nurses were easily trained on multiple POCT platforms placed in a 
s
dedicated POC testing room, with minimal disruption to clinic workflow. The combination of 
t
training materials developed was effective in ensuring competency.  
u
Although POCT has been shown to reduce errors in only a few steps of the entire testing 
v
process compared to laboratory testing, quality and risk management is still required 46. To 

this end, our dedicated nurses showed 100% compliance on the test specific QC procedures 
 Ł
from each of the POC manufacturers. In addition, NHLS EQA material was also trialled on 
 
the Pima, HemoCue and Accutrend and demonstrated suitability on POC instruments tested 
 p
performed by non-laboratory trained staff. EQA in future will be an important component of 
 q
ensuring quality management of the entire POCT process but may require development or 
 r
modification before scale up of current services for POCT sites. In South Africa, the South 
 s
African National Accreditation System (SANAS) has ISO guidelines for medical testing 
 t
laboratories (ISO 15189) and more recently, specifically for the implementation of POCT 
 u
(ISO 22870).  
 v
 
Overall, 70% of our study patients required 3 or more tests per visit in both clinic settings. 
p Ł
This raises several issues if multiple POCT is to be implemented. Firstly, if a venepuncture 
p 
specimen is used, which has been shown in some circumstances to be more accurate 39, 
p p
this could be used for repeat testing and/or referral of residual blood to the laboratory in the 
p q
case of test failures. Venepuncture will however, require skill in phlebotomy and qualification 
p r
as HPCSA/SANAS/National Department of Health/NHLS regulated personnel (at least in 
p s
South Africa where the study was conducted), as well as extra training on opening blood 
p t
                -                                       ¡    ¢ £ A further challenge 
p u
will be to minimise duplication in services. ¤                ¥                        -
p v
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 ¦ task shifting and decentralisation 47, but would require 

multiple finger sticks per patient per clinic visit a process which has been shown to be 
p
accurate 39.   
q
 
r
The accuracy of nurse operated multiple POCT was demonstrated. Hemocue Hb testing in 
s
particular, showed excellent agreement with predicate methodology and the same was true 
t
for CD4 and ALT. Cr and lactate at POC showed increased variability. This may be due to 
u
variability between operators (two different nurses performed POCT at CCMT site) and 
v
some seasonal variability (some testing done in winter at CHRU site, possibly leading to 

colder hands, poorer blood flow) 30. In spite of quality systems in place at the POCT sites, 
 Ł
error rates (4.3-6%) were evident from the PIMA CD4 instrument only, but were in line with 
 
other studies 38, 48. This together with characteristics of the CD4 technology platform (Pima 
 p
CD4 over-misclassification) will need to be taken into consideration before implementation. 
 q
 r
The length of time taken to perform and result multiple POCT would require workflow 
 s
considerations within the clinic. In this study, at least 22 extra duties were required by a 
 t
NIMART (nurse initiated management of antiretroviral treatment) trained nurse 49. This will 
 u
further increase with the addition of screening tests such as cryptococcal antigen and 
 v
hepatitis B antigen 25. An increase in workload leads to increased transcription errors and 
 
even in this study, where dedicated nurses performed POCT without any NIMART duties, 
p Ł
transcription errors occurred. The need for centralized data monitoring and the ability to 
p 
interface with information systems is required 10, 50 to ensure that data can be audited and 
p p
managed.  
p q
p r
For wide-scale implementation of POCT in South Africa, the first step will need to be 
p s
identification of appropriate clinics where there are gaps in service delivery. This is already 
p t
being done through Geographical Information System (GIS) mapping tools, not only to 
p u
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identify gaps but also decide on the most cost-effective implementation strategies. The role 

of connectivity, cost-effectiveness and overall impact of POCT remain to be addressed 
p
through a randomised controlled trial.  
q
r
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Tables 

p
Table 1: Internal quality control (QC) results for CD4, Hb, ALT, Creatinine and lactate 
q
analytes performed by nurses at two POCT sites and external quality assessment (EQA) 
r
performed at one POCT site. 
s
t
u
Table 2: Method comparison summary statistics of nurse operated POCT for CD4, Hb, ALT, 
v
Creatinine and lactate versus laboratory generated reference results. The sections highlight 

independent studies performed at two different clinic sites (CHRU and CCMT) using 
 Ł
venepuncture derived specimens. A section is included for the use of the Vacudrop at one 
 
site.  
 p
 q
Table 3: List of general clinic duties for nurses in HIV ART clinics and the added duties 
 r
required for performing multiple POCT. 
 s
 t
 u
Figure Captions 
 v
Figure 1: A pie chart representing the percentage of tests requested by HCW on their 
 
patients (n=469) attending the CCMT clinic. The pie chart reflects the number of POCT tests 
p Ł
required per visit from 464 patients (n=5 not recorded).  
p 
p p
Figure 2: Scatter plots of method comparison of POC testing arms for the two sites 
p q
compared to routine laboratory results. The vertical axis in each plot is either percentage 
p r
similarity (A) or difference (B-E) between POC and routine and the horizontal axis is the 
p s
absolute value of predicate tests: A) Percentage similarity for CD4. Red dashed line 
p t
indicates the 350 cells/ul threshold. B-E) Bland Altman difference scatter plots for POC 
p u
versus predicate methodology for Hb (B), ALT (C) and Cr (D) and lactate (E). Grey areas 
p v
indicate normal ranges for analytes based on reference method.  
p 
q Ł
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Tables 
Table 1: Internal quality control (QC) results for CD4, Hb, ALT, Creatinine and lactate 
analytes performed by nurses at two POCT sites and external quality assessment (EQA) 
performed at one POCT site. 
Analytes 
CHRU CCMT 
QC EQA QC 
PIMA CD4 Daily low (n=26), 
high control 
(n=26),  0 failures, 
100% compliancy 
Survey 1 Trial 1 sample A:  
Error (internal cartridge error) 
Survey 1 Trial 1 sample B: 
110c/ul (Z-score -0.68) 
Survey 2 Trial 2 sample A: 
573c/ul (Z-score -2.05)* 
Daily low (n=33), high 
control (n=33), 0 failures, 
100% compliance 
HemoCue 
Hb 
Weekly High 
(n=5), normal 
(n=6), low (n=6)., 
0 failures, 100% 
compliancy 
0710W: 9.3g/dl (Z-score 1.94) 
0710X: 8.0g/dl (Z-score 2.46) 
0810W: 9.5g/dl (Z-score 0.12) 
0810X: 11.2g/dl (Z-score 
1.65) 
Weekly High (n=7), 
normal (n=7), low (n=6). 0 
failures, 100% 
compliance 
Reflotron 
Cr 
One monthly 
universal control 
(n=4) 0 failures, 
100% compliancy 
No POCT EQA material 
available from NHLS 
One monthly universal 
control (n=7) on each 
instrument, 0 failures, 
100% compliance 
Reflotron 
ALT 
One monthly 
universal control 
(n=4), 0 failures, 
100% compliancy 
No POCT EQA material 
available from NHLS 
One monthly universal 
control (n=7) on each 
instrument¥, 0 failures, 
100% compliance 
Accutrend 
Lactate 
Monthly low (n=3), 
high (n=3) 
controls, 0 
failures, 100% 
compliancy 
Sample 1: 3.8mmol/l (Z-score 
1.7)  
Sample 2: 0.8mmol/l (Z-score 
0.64)  
Sample 3: 4.5mmol/l (Z-score 
2.5) 
Monthly low (n=32),  high 
(n=32) controls per 
instrument¥, 0 failures, 
100% compliance 
Values underlined are>z-score 2, however *not in the clinically relevant range; ¥ two instruments were used during the study time frame 
??????
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Table 3: List of general clinic duties for nurses in HIV ART clinics and the added duties required 
for performing multiple POCT. 
Current clinic duties POC DUTIES (pre-analytical, analytical, post-analytical) 
Patient registration Additional finger stick/venepuncture 
History taking Specimen labeling 
Physical examination Multiple instrument QC testing (~ four instruments) 
Counseling Multiple instrument maintenance (~four instruments) 
Rapid HIV testing (HCT) Perform POCT (ALT, Creat, Hb: <2minutes; PIMA = 20 
minutes; Xpert MTB/RIF =2 hours*) 
Pregnancy testing Result recording/printing/reporting 
Phlebotomy External quality assessment (EQA) 
Treatment Infection control 
Return visit booking Spill cleaning 
Waste disposal 
Additional skills required: Phlebotomy and pipetting skills 
Additional duties: Operator certification and on-going 
monitoring, managing test failures, instrument downtime, stock 
and waste control, specimen storage. 
*GeneXpert test added since this could also be included for POCT in ART clinics.
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Figure 2: Scatter plots of method comparison of POC testing arms for the two sites compared to routine 
laboratory results. The vertical axis in each plot is either percentage similarity (A) or difference (B-E) 
between POC and routine and the horizontal axis is the absolute value of predicate tests: A) Percentage 
similarity for CD4. Red dashed line indicates the 350 cells/ul threshold. B-E) Bland Altman difference 
scatter plots for POC versus predicate methodology for Hb (B), ALT (C) and Cr (D) and lactate (E). Grey 
areas indicate normal ranges for analytes based on reference method.  
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5.2 FEASIBILITY OF PERFORMING MULTIPLE POINT OF CARE TESTING 
FOR HIV ANTI-RETROVIRAL TREATMENT INITIATION AND 
MONITORING FROM MULTIPLE OR SINGLE FINGERSTICKS 
Feasibility of Performing Multiple Point of Care Testing
for HIV Anti-Retroviral Treatment Initiation and Monitoring
from Multiple or Single Fingersticks
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Abstract
Background: Point of Care testing (POCT) provides on-site, rapid, accessible results. With current South African
anti-retroviral treatment guidelines, up to 4 fingersticks /patient/clinic visit could be required if utilizing POC. We
determined the feasibility and accuracy of a nurse performing multiple POCT on multiple fingersticks followed by
simplification of the process by performance of multiple POC on a single fingerstick.
Method and Findings: Random HIV positive adult patients presenting at a HIV treatment clinic in South Africa, for
ART initiation/ monitoring, were approached to participate in the study between April-June 2012. Phase I: n=150
patients approached for multiple POCT on multiple fingersticks. Phase II: n=150 patients approached for multiple
POCT on a single fingerstick. The following POC tests were performed by a dedicated nurse: PIMA (CD4), HemoCue
(hemoglobin), Reflotron (alanine aminotransferase, creatinine). A venepuncture specimen was taken for predicate
laboratory methodology. Normal laboratory ranges and Royal College of Pathologists Australasia (RCPA) allowable
differences were used as guidelines for comparison. In 67% of participants, ≥3 tests were requested per visit. All
POCT were accurate but ranged in variability. Phase I: Hemoglobin was accurate (3.2%CV) while CD4, alanine
aminotransferase and creatinine showed increased variability (16.3%CV; 9.3%CV; 12.9%CV respectively). PIMA
generated a misclassification of 12.4%. Phase II: Hemoglobin, alanine aminotransferase and creatinine showed good
accuracy (3.2%CV, 8.7%CV, 6.4%CV respectively) with increased variability on CD4 (12.4%CV) but low clinical
misclassification (4.1%). No trends were observed for the sequence in which POC was performed on a single
fingerstick. Overall, PIMA CD4 generated the highest error rate (16-19%).
Conclusions: Multiple POCT for ART initiation and/or monitoring can be performed practically by a dedicated nurse
on multiple fingersticks. The process is as accurate as predicate methodology and can be simplified using a single
fingerstick.
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Introduction
The most important determinants of success in anti-retroviral
treatment (ART) programs in South Africa rely on rapid HIV
diagnosis, linkage to care, timely treatment initiation, and long-
term retention of patients in care [1]. By 2012, South Africa had
scaled up its ART services to access approximately 7.1 million
people [2] and has 2.5 million people currently receiving
treatment [3]. This rapid scale up has led to large investment in
developing laboratory capacity in the public sector through the
expansion of the National Health Laboratory Services (NHLS)
centralised laboratory infrastructure (currently 62 CD4 and 17
HIV viral load centralised laboratories). According to the
Department of Health’s National Strategic Plan for 2012/2013–
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2016/2017, emphasis will be placed on the need for universal
annual screening of HIV and TB, thus further increasing testing
requirements [4]. Many HIV infected patients who need access
to laboratory services for management, live in remote areas
with limited access to even basic healthcare services [5]. To
meet these demands, decentralisation of laboratory testing
through the implementation of Point-of-Care (POC) may
provide a solution particularly, for those clinics that are low
volume sites and are serviced by laboratories more than a few
hours drive from the clinic. The vast numbers of patients in
South Africa requiring ART initiation and monitoring however,
increases the volumes of tests required, thus challenges of the
feasibility of wide-scale implementation of multiple POC
assays.
POC or near-patient testing, employs small, simple-to-use,
portable technologies for low volume settings [6] and are
designed to allow rapid pathological sample analysis at the
point of care [7], on easily available specimens such as
fingerstick blood (capillary) or sputum. Fingerstick blood
collection for POC testing has advantages over venous blood
draw in that it is less invasive, faster to perform and provides
results immediately [8]. In remote settings, phlebotomy skills
are also a limiting factor to improving access to laboratory
tests. In this context, the use of fingersticks and heel pricks has
gained momentum in two scenarios: 1) HIV rapid diagnostic
testing for adults and older children performed by lay
counsellors, 2) collection of blood by heel sticks for dried blood
spots, to be processed in central laboratories, for HIV exposed
infants for HIV PCR assays [9,10].
In South Africa, the National Department of Health (NDoH) is
calling for the strengthening of primary healthcare through
systems re-engineering [11]. POC testing as an extension of
laboratory systems and services may have a place in this
process [12]. Advances in the POC testing arena may help to
alleviate many of the problems faced by low resource, high HIV
and TB burden settings, by providing on-site, rapid accessibility
to laboratory tests and timely treatment initiation. The use of
POC testing devices has previously proven feasible and
accurate on fingerstick blood [13] and CD4 at POC has been
shown to reduce pre-treatment patient loss to follow up and
improve overall ART initiations [13-16].
According to the South African treatment guidelines at the
time of the study [17] the initial laboratory tests needed for
initiation of ART included a CD4, followed by creatinine (Cr),
alanine aminotransferase (ALT) and hemoglobin (Hb). Indeed,
the use of multiple POC testing platforms for this group of
patients may prove beneficial, especially in terms of improving
turnaround times to clinical decision-making and decreasing
loss to follow up. In the scenario of a patient initiating ART as
per current in-country treatment guidelines, this could require
up to 4 fingersticks per visit if utilising POC testing, over and
above the initial two fingersticks needed for HIV counselling
and testing. An obvious way of overcoming the multiple
fingerstick hurdle, would be to perform POC testing on a
venepuncture specimen. This would have cost implications for
added materials and require the cadre of POC staff to be
trained phlebotomists. One research study has shown
acceptable performance of multiple POC (up to three POC
tests) for ART initiation [13], but little is known about the
feasibility and accuracy of performing multiple POC testing on
multiple fingersticks on a single patient and no data is available
on whether this process can be simplified by performing
multiple POC testing from a single fingerstick specimen. This
study therefore investigated the following issues: (i) Can
multiple POC testing be performed from multiple fingersticks in
terms of operational practicality and still yield accurate results?;
(ii) Can multiple POC testing be simplified by performing all
POC testing from a single fingerstick specimen?; and (iii) Does
the sequence of POC tests performed contribute to result
variability?
Methods
Ethics statement
The study was approved by the Faculties of Health Sciences
ethics committees at both the University of the Witwatersrand,
(protocol number M120143) and the University of Pretoria/
Tshwane (CD4 and Hb POC protocol number 151/2010;
chemistry POC protocol number 240/2010).
Patient enrolment
Patients visiting the Comprehensive Care Management and
Treatment (CCMT) clinic, Tshwane District Hospital in Pretoria,
South Africa, were consented (written consent) and enrolled
into the study between the periods of April to June 2012, by
two trained study nurses. Criteria for inclusion in the study
included: individuals >18 years of age, with known HIV positive
status and presenting for either ART initiation or monitoring at
designated time points.
Study procedures
The doctor requested the test repertoire as per National ART
treatment guidelines at the time of the study [17]. The study
staff collected all fingerstick specimens and performed POC
testing in a designated POC testing room in the clinic. POC
results were not acted on for clinical management. The POC
instruments available for the study were the PIMA (Alere Inc.,
Waltham, MA, USA) for CD4, the HemoCue 201+ (HemoCue
AB, Ängelholm, Sweden) for Hb and the Reflotron®Plus
(Roche Diagnostics, GmbH, Germany) for ALT and Cr (age
and sex can be used to calculate Cr clearance). These were
selected based on current testing guidelines for HIV initiation
and monitoring as well as instrument availability at the time of
the study. An additional EDTA tube (for CD4 and Hb) and/or
clotted blood (for ALT and Cr) was collected by venepuncture
for predicate laboratory testing as per routine standard-of-care
(SOC) and used for clinical decision-making. All blood
specimens were transported to the laboratory and tested within
6 hours post-venepuncture. The NHLS laboratories performing
the predicate testing all comply to Good Laboratory Practice
standards and are SANAS accredited (South African National
Accreditation system) [18].
Quality control (QC) on all the POC instruments was
performed as per manufacturer’s instructions using supplier
recommended material and briefly described: PIMA - daily QC
Multiple Fingersticks for Multiple POCT
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with a low and high control cartridge (Alere Inc.); HemoCue –
weekly QC with 3 Hemotrol controls namely, low, normal and
high (Eurotrol); Reflotron – weekly QC with a universal control,
Precinorm U, for Cr and ALT (Roche Diagnostics). A log sheet
was used to record QC values.
Multiple POC testing from multiple fingerstick
specimens
According to the study objectives, two phases were carried
out.
Phase 1, performance of multiple POC testing on multiple
fingersticks: POC nurses recruited 150 patients into the
multiple fingerstick phase of the study. This phase followed
each POC test manufacturer’s standard operating procedures
for blood collection by fingerstick. Each POC test was
performed on a separate fingerstick using supplier
recommended lancets (Table 1) [19-21].
Multiple POC testing from a single fingerstick specimen
Following on the first phase, phase 2 measured the
performance of multiple POC tests on a single fingerstick. 150
patients were enrolled into this phase, which followed a
simplified version of the manufacturer’s standard operating
procedures for each POC test; if multiple POC tests were
requested, all tests were performed on a single fingerstick
(depending on the amount of blood available) using a single
lancet. The lancet chosen for this arm was the PIMA Sarstedt
safety lancet (Sarstedt Group), as it uses a blade to produce a
finger slice as opposed to a traditional fingerstick and thus
produces a larger amount of blood [22]. If insufficient blood was
available to perform all the tests requested on the single
fingerstick, a second fingerstick was performed.
The sequence of POC tests from a single fingerstick
The sequence of blood collection and testing was changed
during the second phase of the study to allow for the different
instruments to be tested first on the single fingerstick (n = 50
for each sequence). Sequence 1: Reflotron followed by
HemoCue and PIMA; Sequence 2: HemoCue, Reflotron, PIMA;
Sequence 3: PIMA, Reflotron then HemoCue.
Any POC instrument/cartridge errors/failures in either phase
were only repeated with an additional fingerstick if the patient
was willing.
Table 1. Supplier recommended lancets for multiple POC
arm based on supplier information/recommendations
[19-22].
POC instruments   Supplier recommended lancets Lancet Specifications
PIMA Sarstedt safety lancet 1.6mm depth
HemoCue HemoCue safety lancet 2.25mm depth
Reflotron Roche AccuChek Softclix Pro lancet 1.7mm depth
doi: 10.1371/journal.pone.0085265.t001
Predicate laboratory testing procedures
The predicate methodology used by the Core Laboratory
included: PLG CD4 using the FC 500 (Beckman Coulter,
Miami, FL); Hb using Advia 120 and 2120 analysers (Siemens
Diagnostic Solutions, Tarrytown, NY); ALT and Cr on the
Synchron DXC 800 (Beckman Coulter, Miami, FL). The normal
ranges for each analyte using predicate methodologies were
used as a reference for determining potential clinical changes
in decision-making if POC results had been used. These
reference ranges were: Hb 12g/dL - 18g/dL; ALT 10-40U/l; Cr
64-104umol/l; a cut off of 350 cells/ul for CD4 was applied for
clinical misclassification. The Royal College of Pathologists of
Australasia (RCPA) allowable differences [23] were also used
as guidelines for assessing performance of each of the phases,
these were: Hb ±0.5<10g/dL and ±5%>10g/dL, ALT ±5≤40 U/l
and ±12%>40U/l, Cr±8<100umol/l and ±8%≥100umol/l.
Comparison was also made in terms of the sequence in
which analytes were tested on POC instruments from a single
fingerstick (phase 2).
Statistical analysis
The numbers of tests (fingersticks required) per patient and
test (or instrument) errors per phase were quantified. T-tests
were used to determine any difference in age and CD4 count
and a Chi-squared test was used to determine any difference in
gender between the two groups with 95% confidence. Assay
performance (precision and accuracy) and method comparison
(agreement) between POC and predicate methodology was
measured using mean, median, range, percentage similarity
(using percentage similarity standard deviation [SD] and
coefficient of variation [7] [24]) and Bland-Altman (using bias)
[25]. Functions were performed using STATA 12. Scatter plots
were used to represent outliers and included the normal
reference ranges. Similar scatter plots were used to visualize
sequence of testing during the single fingerstick phase.
Misclassification for CD4 was determined using the 350 cell/ul
threshold and sensitivity and specificity were calculated.
Results
Patient demographics
The mean age of all participants consented and enrolled
between the 30th April and 15th June 2012 was 35.5 years
(n=299) of which 75.6% were female (n=226). There was no
significant difference in the two groups (multiple or single
fingerstick) for patient age (p=0.64), gender (p=0.24) or CD4
count (p=0.65). Of the total patients enrolled into the study,
67% required three or more tests per single visit based on
standard ART guidelines at time of study (South African 2010
guidelines). A schematic of the study design is shown in Figure
1.
Multiple POC testing from multiple fingerstick
specimens
One hundred and fifty patients were approached for this first
part of the study. Two patients, both requiring four POC tests
withdrew from the study; one after receiving two fingersticks
Multiple Fingersticks for Multiple POCT
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and the other after receiving three fingersticks (Figure 1). Six
percent (9/150) of patients required a 5th or 6th fingerstick to
complete the POC test repertoire, mostly for CD4 and Cr due
to poor blood flow from the fingerstick. The total number of
tests requested during phase 1 was 475 with Cr the most
frequently requested analyte. The PIMA instrument reported
the highest error rate at 16.33% (n=16) (7 exposure control, 3
cell movement control, 1 reagent control, 4 image control, 1
gating control error), of which 6 were repeated on another
fingerstick. The Reflotron had 2 operator errors and 4 POC
tests could not be completed due to insufficient blood flow.
Three venepuncture samples were rejected from laboratory
testing during this phase.
Method comparison of the POC test results on multiple
fingerstick specimens versus predicate laboratory methodology
is shown in Table 2 and Figure 2A-D. PIMA CD4 demonstrated
good accuracy (mean percentage similarity of μ=100.7%) but
increased variability (percentage similarity SD 16.5%),
compared to the laboratory predicate assay. Bias was
acceptable (32 cells/ul) for the data set (~median of 380 cells/
ul). The scatter plot in Figure 2A demonstrated a downward
trend in PIMA CD4 results indicating that the PIMA reads
higher in the low CD4 count (<350 cells/ul) range and lower in
the high CD4 count (>500 cells/ul) range, compared to the
predicate laboratory method. A few outliers are visible, but all
are below the <350 cells/ul category. The overall
misclassification of PIMA CD4 at the 350 cells/ul threshold was
12.4% giving a sensitivity of 86.4% (Table 3).
HemoCue Hb showed good accuracy (mean percentage
similarity of 100.9%), precision and overall agreement
(percentage similarity SD and %CV of 3.2). Figure 2B shows
random scatter of outliers (16.5%, 19/115) based strictly on the
RCPA guidelines. As the bias is low (-0.19) compared to
predicate methodology, it would not alter clinical decision-
making.
ALT testing on the Reflotron was 100% accurate for phase I
when compared to predicate method and showed good
precision (9.3%) and overall agreement (percentage similarity
CV 9.3%). Random scatter of values across the data set with
very few outliers are visible (1.7%, 2/115) using RCPA
allowable differences (Figure 2C). As both these outliers were
above the normal predicate reference range of 40U/l, they may
have affected clinical decision-making. The mean negative bias
of -0.58U/L was low.
The mean percentage similarity for Cr measurements
generated lower values than predicate methodology (97.4%)
and showed variability (percentage similarity of SD12.6%)
attributable to outliers (19.1%, 25/131). The scatter plot (Figure
2D) also shows a trend due to the minimum cut off of
44.2umol/l on the Reflotron instrument, as well as a trend
towards reading lower than predicate methodology as Cr levels
increase. However, an overall acceptable bias (within RCPA
limits) was observed.
Figure 1.  Schematic of study design.  
doi: 10.1371/journal.pone.0085265.g001
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Multiple POC testing from a single fingerstick specimen
One hundred and forty nine patients where consented for
this part of the study, with one individual declining to
participate. The total number of tests requested was 407 with
Cr again the most frequently tested analyte. All the POC tests
requested could be completed on 91.9% (137/149) of patients
from a single fingerstick specimen and 8.1% (12/149) required
a second fingerstick (Figure 1). PIMA generated the highest
error rate of 19.18% (n=14) (9 cell movement control, 1
insufficient volume, 3 exposure control, 1 gating control error),
of which only one could be repeated on a second fingerstick
specimen. One CD4 POC test could not be completed due to
insufficient blood flow. No errors were observed from any other
POC instruments.
Method comparison of analyte results from phase II are
reported in Table 2 and Figure 3A-D. From a single fingerstick,
PIMA CD4 demonstrated good accuracy (mean percentage
similarity μ=99.4%) and a bias of 30 cells/ul (median of 398
cells/ul) but increased variability of 12.4% percentage similarity
SD. One outlier is visible above 350 cells/ul, but would not
have changed clinical patient management as both PIMA and
predicate technologies identified this patient as not suitable for
ART initiation. The overall misclassification of PIMA CD4 at the
350 cells/ul threshold was 4.1%, giving a sensitivity of 97%
(Table 3).
Hb results also showed good accuracy (mean percentage
similarity of 101.5%), precision and overall agreement
(percentage similarity SD and %CV of 3.2) and low bias
compared to predicate, however applying strict RCPA limits,
20.2% (19/94) of results would be considered outliers (Figure
3B).
ALT measurements from a single fingerstick showed good
accuracy and precision (99.1% and 8.6% respectively) and
similar overall agreement (percentage similarity CV 8.7%). A
few random outliers (using RCPA limits) are highlighted in
Figure 3C (5.2%, 5/97), all above 40U/l, which potentially could
have affected clinical decision-making. Single fingerstick
testing showed a positive but low bias that was different to the
negative but low bias in multiple fingerstick testing.
Cr testing generated lower values than predicate
methodology (μ=96.4%) with low variability (percentage
similarity SD6.2%) and bias of 4.95umol/l (within RCPA limits).
A trend however, is present in Figure 3D with Reflotron
generating lower values as Cr levels increase, resulting in
potentially 19 outliers (14.7%).
Sequence analysis of multiple POC testing on a single
fingerstick
Evaluation of the POC test results across the sequence of
testing from a single fingerstick specimen showed random
distribution of outliers and no trends were evident across assay
performance (Figure 4A-D).
Quality control
The quality control material on all the POC instruments
performed within acceptable limits, with only one outlier
occurring on the PIMA low control. After repeat testing, this
control performed within acceptable manufacturer’s standards.
Discussion
Many potential benefits are reported after introduction of
POC testing into non-laboratory environments in low resource
countries, such as reduced skill requirements, faster
turnaround times, better patient management and resource
utilization [6] and improved staff satisfaction [26]. In South
Table 2. Method comparison of POC results for all analytes versus predicate laboratory methodology.
Variables CD4 (cells/ul) Hb (g/dl) ALT (U/l) Cr (umol/l)
Phase 1: Multiple fingersticks vs predicate
N 98 115 115 131
Mean (range) 384 (36-917) 12.9 (3.8-18.3) 35.3 (5-775) 59.6 (44.2-528)
Median 380 13.1 22 52.1
Bias* (95% CI) 32 (12; 53) -0.19 (-0.34 ;-0.05) -0.58 (-2.11;0.95) 5.32 (3.14;7.5)
Bias SD 101.33 0.8 8.3 12.6
Mean % similarity 100.7 100.9 100 97.4
% Similarity SD 16.5 3.2 9.3 12.6
% Similarity CV 16.3 3.2 9.3 12.9
Phase 2: Single fingerstick vs predicate
N 73 94 97 129
Mean (range) 402 (42-824) 12.5 (6.1-17.1) 27.8 (5-165) 53.8 (44.2-97)
Median 398 12.5 21 49.4
Bias* (95% CI) 30 (-3; 63) -0.3 (-0.49 ;-0.19) 0.64 (-0.69;1.97) 4.95 (3.68;6.22)
Bias SD 143.7 0.7 6.6 7.3
Mean % similarity 99.4 101.5 99.1 96.4
% Similarity SD 12.4 3.2 8.6 6.2
% Similarity CV 12.4 3.2 8.7 6.4
doi: 10.1371/journal.pone.0085265.t002
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Africa, which has the largest ART roll out program in the world,
the implementation of multiple POC testing for monitoring could
be highly beneficial for detecting acute and chronic adverse
events associated with ART [27]. It has been proposed that
POC should be an extension of the laboratory network using
the tiered approach, as proposed by the Maputo declaration
Figure 2.  Scatter plots of method comparison for POC testing from multiple fingersticks compared to routine laboratory
methodology (Phase I).  The vertical axis in each plot is either percentage similarity (A) or difference (B-D) between POC and
predicate and the horizontal axis is the absolute value of predicate tests: A) Percentage similarity for CD4. Red dashed line
indicates misclassification point of 350 cells/ul and circle highlights outliers. B-D) Bland Altman difference scatter plots for POC
versus predicate methodology for Hb (B), ALT (C) and Cr (D). Grey areas indicate normal ranges for analytes based on predicate
method and circles highlight outliers mostly based on RCPA guidelines.
doi: 10.1371/journal.pone.0085265.g002
Table 3. ART eligibility misclassification, sensitivity and specificity of PIMA based on a CD4 threshold of 350 cells/ul for
phase I (multiple fingerstickS) and II (single fingerstick).
True Positive False Positive True Negative False Negative
Total misclassi-
fication
Sensitivity at 350 cells/ul
(95% CI)
Specificity at 350 cells/ul
(95% CI)
Multiple (n=96) 38 (39.6%) 6 (6.2%) 46 (48%) 6 (6.2%) 12.4% 86.4% (72; 94) 88.5% (76; 95)
Single (n=73) 30 (41.1%) 2 (2.7%) 40 (54.8%) 1 (1.4%) 4.1% 97.5% (81.4; 99.8) 95% (82.5; 99.1)
doi: 10.1371/journal.pone.0085265.t003
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[28]. However, this small study highlights that more than half of
patients attending the clinic for routine ART monitoring/
initiation, required 3 to 4 tests per visit. This equates to multiple
fingersticks per patient, per visit if POC is introduced. The
operational capacity and feasibility of this practice on a national
scale needs further analysis. Study findings demonstrated that
multiple POC tests performed as per manufacturer’s
instructions (i.e. single fingerstick using supplier recommended
lancet) can practically be performed by a dedicated nurse. Only
6% of subjects needed a 5th or 6th fingerstick to complete the
POC test repertoire in this cohort. However in more remote
settings where individuals undertake manual labour such as in
farming or mining communities, obtaining a fingerstick
specimen from calloused fingers may be more difficult. This is
being investigated in a further study. Overall, the performance
of the POC analytes, compared to predicate laboratory
methodology, was accurate for Hb and ALT. Increased
variability was more evident with PIMA CD4 and Reflotron Cr.
In an attempt to simplify the POC testing process from
necessitating multiple fingersticks and reduce discomfort to
patients, we performed multiple POC tests on a single
fingerstick specimen. This process was found to be practical
and simple and only a small percentage of patients (8%,
12/149) required a second fingerstick to complete the
requested POC testing repertoire. Advantages of this simplified
testing would be reduction in the number of fingersticks per
patient and thus a significant reduction in nurse exposure to
blood and other contaminants, reduced discomfort to the
patient, as well as a reduction in consumables used. The
overall performance of the various POC tests from a single
fingerstick was acceptable for all analytes tested compared to
predicate methodology. Based on the RCPA guidelines, some
Figure 3.  Scatter plots of method comparison of POC testing from a single fingerstick compared to routine laboratory
methodology (phase II).  A) Percentage similarity for CD4. Red dashed line indicates misclassification point of 350 cells/ul and
circle highlights outliers. B-D) Bland Altman difference scatter plots for POC versus predicate methodology for Hb (B), ALT (C) and
Cr (D). Grey areas indicate normal ranges for analytes based on predicate method and circles highlight outliers mostly based on
RCPA guidelines.
doi: 10.1371/journal.pone.0085265.g003
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values may be considered outliers on the plots for Hb, ALT and
Cr, however no trends or differences were visible between the
sequence in testing protocol from a single fingerstick.
In scrutinizing the performance of each platform in more
detail, starting with the CD4 test, examples of within technology
variability such as FACSCount and PLG studies report
acceptable variability (%CV) on repeat venous sample testing
of 5%-9.3% [29] [30]. PIMA within variability (and across 5
different instruments) on venous samples (range in CD4 of 44
-504 cells/ul) shows higher but acceptable variability ranging
from 4.2% to 15.5% respectively [31].
The PIMA CD4 evaluation in our study (across technology)
on fingerstick specimens generated values at this upper
venous limit (16.3%CV for phase 1 and 12.4%CV for phase 2),
reflecting the PIMA acceptability for ART initiation, but less
assurance from this study data if this technology were to be
used for monitoring (unless venepuncture specimens are
tested). This latter application however, is of less concern with
the new South African and WHO ART 2013 guidelines using
CD4 for initiation and a reduction in CD4 monitoring after the
first year, with greater emphasis on VL monitoring. The
alternative would be to use venepuncture for PIMA CD4
monitoring. Increases in variability of capillary PIMA CD4
testing have previously been documented, where % similarity
CV’s ranged from 11% in a Johannesburg Clinic, to as high as
28.8% in an antenatal hospital clinic [32]. Irrespective of this
variability, the overall bias in PIMA CD4 versus predicate
testing in both the phases is acceptable (~30 cells/ul) for the
range in CD4 count (median >350 cells/ul), however the
variability (SD) of this bias was broad (~100 cells) probably
Figure 4.  Scatter plots showing sequence of POC testing from a single fingerstick (phase II) compared to routine
laboratory methodology.  A) Percentage similarity for CD4. B-D) Bland Altman difference scatter plots for sequence of POC
testing versus predicate methodology for Hb (B), ALT (C) and Cr (D). Blue indicates sequence 1: Reflotron followed by HemoCue
and PIMA; Red indicates Sequence 2: HemoCue, Reflotron, PIMA; and green indicates Sequence 3: PIMA, Reflotron then
HemoCue.
doi: 10.1371/journal.pone.0085265.g004
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indicative of a small sample size. The total misclassification of
12.4% for multiple fingersticks and 4.1% for testing on a single
fingerstick has similarly been documented in other studies and
shows more patients would be initiated on ART than missed if
testing were done on a single fingerstick specimen [33-35].
Concern is noted over the high PIMA CD4 error rate (16% and
19%), which was higher than any other POC instrument used
in our study, and was slightly higher during the single
fingerstick phase. Similar error rates for PIMA CD4 have been
observed in other reports [32,34].
The HemoCue instrument’s good performance for Hb
measurements on fingerstick, whether multiple or single (bias
of -0.2±0.8g/dL multiple and -0.4±0.9g/dL for single) is in
contrast to literature which demonstrates significant variability
in capillary blood measurements [36] and a tendency for POC
to increase at higher Hb values [37,38]. Bland Altman
difference plots showed random distribution of outliers but
more outliers (16% versus 20%) are visible when POC was
performed from a single fingerstick specimen.
Reflotron performed well for ALT measurements, regardless
of whether single or multiple fingersticks were performed.
These findings are in contrast to Grounden et al [27] who found
significant biases for Reflotron ALT. The better performance in
our study for both phases could be attributed to the experience
and thorough training of the nurse operators that may have
resulted in better sample collection. With creatinine
measurements however, which are known to be challenging
due to haematocrit variations and interference by bilirubin [39],
the Reflotron was found to read lower than predicate method
as creatinine levels increased, regardless of whether POC was
performed from multiple or a single fingerstick. Similar findings
have been observed in other studies where Reflotron was
found to underestimate creatinine measurements at
concentrations between 90 and 150umol/L [39]. One factor that
may result in overestimation of creatinine in the routine
laboratory specimens is sample haemolysis [40] which is
mainly due to poor sample collection. However, we do not
believe this to have influenced our results, as these samples
are generally checked and rejected by the routine laboratory.
In summary, this study demonstrates the feasibility of
performing multiple POC testing on multiple fingersticks to
accurately monitor ARV treatment. We also demonstrated that
a single fingerstick produces sufficient blood to accurately
perform up to four POC tests (approximately 95ul of blood), to
simplify the testing process. This may be the preferred method
to ensure quality testing if multiple POC tests are to be
introduced for ART initiation in South Africa.
POC testing can reliably and accurately be performed on
fingerstick blood thereby minimizing potential bio-hazardous
risk introduced by uncapping EDTA tubes and pipetting of
venepuncture blood, does not require a trained phlebotomist,
generates minimal biological waste, is minimally invasive and
relatively easy to perform [41] but multiple POC will need
dedicated staff. Patient acceptance of multiple fingersticks for
POC testing is also a consideration for uptake of POC and is
being evaluated in a further study. We envisage that a new
cadre of staff would need to be trained for POC operation, one
that has both technical skills and clinical knowledge. Monitoring
of quality POC testing will have to be a component of
implementation, as previously outlined for these issues around
HIV rapid testing [42].
Limited guidelines on multiple POC testing for ART initiation
and monitoring are available, so field testing studies such as
this are important to understanding how POC performs in the
field. Many other obstacles to implementation will need
clarification before POC can be implemented. Depending on
where POC is placed, different facilities will likely have differing
needs and resources; throughput of POC instruments will have
to be taken into consideration; management of stock control
and quality control; the cadre of POC staff needed;
management of testing volumes and results; impact on patient
care.
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5.3 AN INVESTIGATION OF FINGERSTICK BLOOD COLLECTION FOR 
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Background. Viral load (VL) quantification is an important tool in determining newly developed drug resistance or problems with adherence 
to antiretroviral therapy (ART) in HIV-positive patients. VL monitoring is becoming the standard of care in many resource-limited settings. 
Testing in resource-limited settings may require sampling by fingerstick because of general shortages of skilled phlebotomists and the 
expense of venepuncture supplies and problems with their distribution.
Objective. To assess the feasibility and ease of collecting 150 µL capillary blood needed for the use of a novel collection device following a 
classic fingerstick puncture.
Methods. Patients were recruited by the study nurse upon arrival for routine ART monitoring at the Themba Lethu Clinic in 
Johannesburg, South Africa. Each step of the fingerstick and blood collection protocol was observed, and their completion or omission 
was recorded.
Results. One hundred and three patients consented to the study, of whom three were excluded owing to the presence of callouses. From a 
total of 100 patients who consented and were enrolled, 98% of collection attempts were successful and 86% of participants required only 
one fingerstick to successfully collect 150 µL capillary blood. Study nurse adherence to the fingerstick protocol revealed omissions in several 
steps that may lower the success rate of capillary blood collection and reduce the performance of a subsequent VL assay.
Conclusion. The findings of this study support the feasibility of collecting 150 µL of capillary blood via fingerstick for point-of-care HIV-1 
VL testing in a resource-limited setting.
S Afr Med J 2015;105(3):228-231. DOI:10.7196/SAMJ.7799
The World Health Organization (WHO) has esti-
mated that about 34 million individuals are infected 
by the current HIV/AIDS pan demic.[1] Although 
much progress has been made in controlling this 
disease, in sub-Saharan Africa approximately 23 
million people remain infected,[1] with South Africa (SA) alone 
contributing about 11 087 cases/100 000 population.[1]
The monitoring of the HIV viral load (VL) in patients receiving 
antiretroviral therapy (ART) is critical to ensure treatment success, 
identify problems with treatment adherence, and identify HIV drug 
resistance to inform the decision to switch to second-line or future 
third-line therapies.[2] Currently there is much discussion regarding 
the role of VL monitoring in the care of HIV/AIDS patients. The 
WHO recommends VL monitoring as the preferred approach because 
of its ability to identify treatment failure earlier than immunological 
and clinical modalities.[2] Treatment failure is defined by the WHO as 
a plasma VL >1 000 copies/mL after two consecutive measurements 
during a 3-month interval accompanied by adherence support.[2] 
However, despite the updated WHO recommendations, poor access 
to VL testing often persists in resource-limited settings owing to 
simple logistical issues such as the collection and transportation of 
specimens.
Recently, alternatives such as dried blood spots (DBSs) and point-
of-care (POC) devices are being investigated as potential ways to 
increase access to VL testing in low- and middle-income countries 
(LMICs). While standard laboratory platforms typically retain high 
accuracy when utilising the recommended threshold of 1 000 copies/
mL, both DBS and POC devices may need to utilise a higher limit 
(3 000 - 5 000 copies/mL has been suggested) until better sensitivity 
is established at the lower limit of detection.[2] A study by Viljoen 
et al.[3] in Durban using DBS HIV-1 RNA testing appeared accurate 
and feasible down to approximately 3 000 copies/mL. In a study 
conducted in southern India by Neogi et al.,[4] DBS HIV-1 RNA 
testing revealed 100% sensitivity and specificity at 5 000 copies/mL, 
but only 50% sensitivity with 100% specificity at 1 000 copies/mL. 
Most recently, when Kleshik et al.[5] quantified HIV-1 RNA in single 
50 µL DBSs and limited incubation time prior to sample preparation 
to 30 minutes, a limit of detection of 866 copies/mL was reported.
An important concern regarding the use of DBSs for HIV-1 RNA 
quantification is the amplification of cell-associated HIV nucleic 
acid in whole blood, leading to a falsely high VL measurement 
when compared with the amplification of viral nucleic acid in 
plasma specimens. Several recent studies using DBSs have shown 
reasonable correlation for VLs >3 000 copies/mL, but significant over-
quantification has been observed in specimens with <3 000 copies/
mL.[6-9] Unless this over-quantification is addressed, the usefulness 
of DBSs for VL monitoring may be limited in samples containing 
<3 000 copies/mL.
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DBSs may serve to improve access to VL 
monitoring by linking any existing central 
laboratory infrastructure to regions with 
poor access to VL testing, where transport 
delays and centrifugation to plasma are 
not feasible. However, blood collection and 
the shipment of DBSs, with subsequent VL 
quantification and reporting of results, is not 
easily achieved during the same day in order 
to impact on patient care on the same visit. 
Rapid POC testing may address this logistical 
shortcoming by quantifying VL on site during 
the same visit. Subsequent ART intervention 
may then take place during the same day, as 
patients with poor adherence to treatment or 
those with newly developed drug resistance 
are screened earlier in the process.
Shortages of skilled phlebotomists and 
the expense of venepuncture supplies have 
contributed to the development of a POC VL 
quantification device for use in resource-limited 
settings that may utilise sampling by fingerstick 
instead of venepuncture. Fingerstick specimens 
are currently used for a wide range of tests 
for haematology, chemistry and serology.[10-13] 
Recently the University of the Witwatersrand, 
Johannesburg, SA, investigated the feasibility 
and accuracy of performing multiple point-
of-care tests (POCTs) on fingersticks. This 
study found that capillary blood for up to 
four POCTs (95 µL) could be obtained from 
a single fingerstick in 92% of the subjects.[14] 
A collaboration between the Quidel Corpor-
ation and the Northwestern Global Health 
Foundation (NWGHF), USA, is deve loping a 
POC RT-PCR testing platform and VL assay 
that will require a volume of 150 µL capillary 
blood to reach a sensitivity with a lower limit 
of detection of 1 000 copies/mL.[12] The 150 µL 
whole blood will be converted to plasma 
using sample preparation materials provided 
by the NWGHF.[12] A significant barrier to 
implementing this platform in the future will 
be overcome if 150 µL capillary blood can be 
reliably collected following a fingerstick. In 
order to facilitate the collection of capillary 
blood for this study, a novel EDTA-treated 
capillary blood collection device with a capacity 
of 150 µL was developed.
The aim of this study was to assess: (i) 
the proportion of collection attempts that 
obtain 150 µL capillary blood using a newly 
developed fingerstick-based collection 
device; (ii) the number of puncture sites 
required to obtain 150 µL blood; and (iii) 
study nurse adherence to the fingerstick and 
blood collection protocol.
Methods
Setting and participants
The study was conducted at the Themba 
Lethu Clinic at Helen Joseph Hospital, 
Johannesburg, where a medical student from 
the Feinberg School of Medicine in Chicago, 
USA, observed a study nurse perform 
fingerstick punctures and collect capillary 
blood specimens from 100 patients having 
routine blood tests for ART monitoring. Each 
patient routinely received one venepuncture 
for blood collection during their visit. 
Fingerstick punctures were not performed at 
this clinic for the routine blood tests involved 
in ART monitoring. For the purposes of 
this study, a phlebotomist first performed a 
venepuncture on each patient for their routine 
blood tests and then one or more fingersticks 
were performed by the study nurse. The study 
nurse was highly experienced, with over 
1 000 venepunctures and 1 000 fingersticks 
performed during her career.
Eligible patients were HIV-positive indi-
viduals currently receiving ART who had 
previously been tested for CD4 and/or HIV 
VL. Primary exclusion criteria included 
the presence of heavy callouses, severe 
dehydration, clinically identifiable illness and/
or opportunistic infection, and persistently 
cold fingers after a warming attempt. Suitable 
participants were recruited from the blood 
collection room after a phlebotomist had 
administered venepuncture and collected 
the requested routine standard-of-care blood 
specimens. Each patient was asked to sign an 
informed consent waiver before enrolling in 
the study and receiving a fingerstick. Ethics 
approval for this study was granted by the 
Institutional Review Board at Northwestern 
University (ID: STU00076689) and the 
Human Research Ethics Committee at the 
University of the Witwatersrand (Protocol 
M120143).
Data collection and measurements
Fingerstick punctures were delivered using 
a device with a blade depth and width of 
2.0 mm and 1.5 mm, respectively. The 
BD Microtainer Contact-Activated Lancet 
(BD Diagnostics, USA) was initially used 
to deliver fingerstick punctures until 
a stock shortage necessitated the use of 
the BD Genie Lancet (BD Diagnostics), 
with identical blade depth and width 
specifications. The study nurse was not 
given explicit instructions on how to 
perform the fingersticks; instead, she was 
simply asked to perform them according 
to her usual methods until blood collection 
was complete. A fingerstick and blood 
collection protocol checklist was created for 
the purpose of this study to assess baseline 
study nurse adherence to the protocol 
without training or specific instructions 
provided. The study nurse was blinded 
with respect to the fingerstick and blood 
collection protocol checklist used to assess 
adherence (Appendix 1) for the fingerstick 
and blood collection protocol in its entirety.
A novel blood collection device capable 
of holding 150 µL was used to discriminate 
between successful and unsuccessful col-
lection attempts. The device contained sev-
eral layers of EDTA-treated membrane strips 
designed to wick exactly 150 µL capillary 
blood. A complete collection was described 
to the nurse as the moment when both the 
front and rear of the membrane strips in 
the collection device appeared solid red in 
colour. Each step of the protocol checklist 
was observed, and completion or omission of 
any step was recorded on a template for every 
patient. A stopwatch was started immediately 
after the fingerstick to time the duration of 
the fingerstick procedure followed by blood 
collection. When more than one fingerstick 
was necessary, the study nurse obtained ver-
bal consent before proceeding with each 
additional fingerstick. The result of each 
collection attempt was recorded. The study 
nurse performed translations as needed. Any 
unique insights offered by her were docu-
mented.
Results
A total of 132 patients were approached 
for participation in this study. Twenty-nine 
patients refused to give consent: 18 offered 
no reason for their refusal to do so, 7 stated 
that they were in a hurry, 2 did not want 
additional tests performed, and 2 stated that 
they were scared of receiving a fingerstick. Of 
the remaining 103 patients, 3 were excluded 
from the study because of the presence of 
callouses and/or extremely thick skin, self-
described as relating to their respective 
occupations. One hundred remaining 
patients participated in the study.
Ninety-eight out of 100 collection attempts 
were successful, and 86% required only 
one fingerstick to successfully collect 150 
µL of capillary blood (Table 1). The two 
failed collection attempts were in adult men 
without callouses, exceptionally thick skin 
Table 1. Number of fingersticks required 
to obtain 150 µL blood
Fingersticks 
received, n
Patients 
(N=100), n
1 87*
2 10
3 2
4 1†
*One collection attempt failed to obtain 150 µl blood.
†The combined collection from four fingersticks failed to 
produce 150 µL blood.
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or persistently cold fingers after a warming attempt. After four 
consecutive fingersticks were conducted on the first patient, he 
refused additional attempts. In the second patient, slow blood flow 
was observed after the first fingerstick. He declined to give consent 
to perform any additional fingersticks. Neither patient exhibited a 
negative response to receiving their fingerstick(s), as neither was 
observed to wince in pain, pull away or cry out. Neither patient 
exhibited physical signs of dehydration, but further questioning 
revealed a history of possible low fluid intake.
The mean time to perform one fingerstick followed by a successful 
collection was 76 seconds (range 27 - 225). Study nurse adherence to 
the fingerstick and blood collection protocol is summarised in Table 2.
Discussion
The successful monitoring of VL in patients receiving ART is critical 
in identifying treatment failure resulting from adherence issues 
or the development of HIV drug resistance. The world’s largest 
population of HIV-positive individuals resides in sub-Saharan Africa, 
yet this region has variable and often limited access to VL testing. 
Development of a simple, cost-effective and readily accessible VL 
assay with high sensitivity is therefore needed. Currently, DBSs 
and novel POC platforms are being investigated as opportunities 
to expand access to VL monitoring in LMICs. Failure to access VL 
testing is frequently due to simple issues such as sample collection 
and transport. This study aimed to assess the feasibility of collecting 
150 µL of capillary blood following a fingerstick puncture for use in a 
POC rapid RT-PCR testing platform and VL assay.
Although 86% of collection attempts successfully achieved a 
complete collection from a single fingerstick, the study nurse 
adherence to the protocol (Table 2) revealed omissions in several 
key steps that may adversely affect the success of capillary blood 
collection and/or the sensitivity of a subsequent VL assay. However, 
it should be noted that fingerstick device training may occur in an 
informal manner that fails to emphasise strict adherence to every 
step of the detailed manufacturer’s protocol for fingerstick blood 
collection. Notably, with 0% adherence, the study nurse was never 
observed wearing a pair of gloves during this study. While wearing 
gloves ultimately has no effect on the success of blood collection, 
repeated omission of this step may inform the subsequent design 
of a blood collection device that minimises the risk of healthcare 
worker contact with the collected blood specimen.
The two most commonly omitted steps that may adversely affect 
the success of blood collection were: (i) patient’s fingers warmed 
in advance by any method; and (ii) positioning of the patient’s 
hand below elbow level, with 7% and 56% adherence, respectively 
(Table 2). Occasionally a patient with cold fingers was asked to rub 
their hands together quickly to generate heat. A warm cloth, which 
would have been ideal, was not readily available for the purpose 
of warming fingers. Placement of the patient’s hand below the 
level of their elbow also presented a significant challenge in many 
cases. Patients were seated in a chair rather than on an elevated 
examination table because they were subjected to phlebotomy 
immediately before fingerstick testing, and the routine practice in 
this setting was for phlebotomy to be done with the patient in a 
chair. Placing the patient’s hand below the level of their elbow while 
seated in a chair meant that the study nurse would have to bend over 
and painstakingly reach down in order to perform the fingerstick 
and observe progress in filling the collection device. Lastly, the first 
drop of blood was wiped away from the puncture site in only 5% of 
all fingersticks performed in this study (Table 2). It is hypothesised 
that the first drop of blood may contain interstitial fluid that could 
adversely affect the results of a subsequent VL assay, but this has yet 
to be confirmed.
Omissions in potentially important steps of the protocol suggest 
that when a POC VL platform and novel VL assay are first introduced 
to clinics, supplemental quick reference materials and/or brief 
maintenance training may improve the quantitative performance of 
a POC VL assay. When training healthcare personnel or preparing a 
protocol checklist for them in the future, special attention should be 
given to those frequently omitted steps that may adversely affect the 
outcome of a subsequent assay. The need for ongoing quality monitoring 
and training has been reported for performing rapid HIV testing and 
is a critical component of successful diagnostics.[15] Additionally, 
all necessary fingerstick materials should be conveniently located 
to facilitate optimal adherence to the manufacturer’s fingerstick 
protocol.
The unique perspective of the study nurse highlighted several 
important benefits of performing a fingerstick over venepuncture. 
First, nurses or community healthcare workers with minimal 
training can perform fingersticks, potentially resulting in increased 
access to VL monitoring for patients. Nursing assistants in SA, for 
instance, receive 1 year of formal training and are not qualified to 
perform venepuncture on patients. A POC VL quantification assay 
relying on fingersticks rather than venepuncture could be widely 
utilised by this workforce. Second, fingersticks result in fewer blood 
spills and so decrease biohazard risk to healthcare workers, and 
require far less blood than venepuncture. In some cases a dehydrated 
and/or sick patient will provide an insufficient quantity of blood 
by venepuncture, requiring the test(s) to be completed again at a 
later time. Fingerstick blood collection may be more successful 
than venepuncture in certain patients. Finally, fingersticks require 
less counter space, fewer waste bins and less disposal of packaging 
materials.
The transition to fingerstick blood collection for VL testing 
may initially complicate the workflow in clinics that require 
other routine tests for ART monitoring. Venepuncture blood 
collection is often used for a variety of laboratory tests, including 
but not limited to CD4, a full blood count, liver function 
tests, and haemoglobin, creatinine, cholesterol and triglyceride 
measurements. A transition to fingerstick blood collection for VL 
testing would initially require phlebotomists to perform one or 
more fingersticks in addition to venepuncture for most patients. 
The overall utility of fingerstick blood collection would therefore 
increase if multiple POC tests could be performed simultaneously 
for ART monitoring.
Table 2. Nurse adherence to protocol
Protocol steps Adherence, % (N)
Pair of gloves worn by nurse 0 (0)
Patient sitting 100 (100)
Patient’s fingers warmed in advance 7 (7)
Puncture site disinfected with alcohol pad 86 (101)
First drop of blood wiped away 5 (109)
Hand positioned palm down 100 (100)
Hand positioned below elbow 56 (65)
Collection device held above skin; scraping 
avoided
96 (104)
Gentle pressure applied; strong milking 
avoided
95 (103)
Pressure applied after collection 100 (100)
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Conclusions
Capillary blood collection was highly successful in this study, with the 
vast majority of patient encounters yielding 150 µL blood after only 
one or two fingersticks. The widespread implementation of a POC 
VL assay in a resource-limited setting would not be hindered by the 
ability to collect the targeted volume of 150 µL capillary blood when 
using the appropriate lancet, but would require training and ongoing 
quality monitoring.
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Fingerstick and blood collection protocol 
1. Assemble materials
• Disposable gloves
• 70% isopropyl alcohol pads
• Lancets
• Blood collection device
• Sterile gauze pad
• Warming device (moist towel or sodium acetate hand warmer)
2. Wash hands and put on pair of disposable gloves
3. Position patient and select the fingerstick puncture site
• Patient should be sitting or lying down
• Patient should have their hand in a downward position, allowing 
gravity to increase blood supply to the hand
• Middle or ring finger is preferable; fifth finger should not be 
punctured, because tissue depth is insufficient to prevent bone injury
4. Warm the site
• Use a warm, moist towel or other appropriate warming device 
(not exceeding 40oC/105oF) for 3 minutes; alternatively, have the 
patient vigorously rub their hands together to generate heat
5. Disinfect the site
• Cleanse the site using a 70% isopropyl alcohol pad
• Allow the site to air dry in order to provide effective disinfection 
and to prevent possible haemolysis or erroneous results from 
residual alcohol
6. Perform the puncture
• Have the patient hold their hand below elbow level
• Turn the patient’s hand palm down
• Hold the lancet with two fingers
• Position the lancet firmly against the puncture site
• Press lancet against puncture site until release mechanism is 
activated
7. Discard used lancet into a sharps container
8. Collect the blood specimen
• Wipe away the first drop of blood, as this drop may contain 
an excess of tissue fluids that may cause erroneous results
• Position the collection device directly beneath the puncture 
site and avoid scraping across skin
• Gently apply intermittent pressure along finger capillaries and 
open the puncture slightly to maximise blood flow
• Avoid strong repetitive pressure or ‘milking’, as this may cause 
haemolysis or tissue fluid contamination of the specimen
• Blood collection is complete when both sides of the collection 
device appear solid red in colour
9. Cover the puncture site and dispose of all materials
• Wipe the site dry and apply direct pressure with a sterile 
gauze pad until bleeding has stopped
• Place all used materials in appropriate biohazard containers
Appendix 1
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Abstract 28 
Background: Plasma viral load (VL) testing is recommended at 6months and yearly intervals 29 
thereafter for HIV antiretroviral treatment (ART) monitoring. VL testing on plasma is currently 30 
laboratory-based using high throughput platforms, which limits access and relies heavily on 31 
specimen integrity. A recent laboratory evaluation of the Liat™ platform (IQuum, Inc) for HIV 32 
VL testing showed the Liat HIV Quant plasma assay can be used interchangeably with existing 33 
VL technologies in South Africa. We evaluated the clinic performance (nurse operated at point 34 
of care (POC)) of this platform for VL testing from whole blood using the Liat HIV Quant blood 35 
(IQuum, Inc) assay. 36 
Method: HIV-positive patients attending the Themba Lethu clinic in Johannesburg, South 37 
Africa for routine ART monitoring were recruited. Finger stick blood was collected in an EDTA 38 
microtainer tube and tested on the Liat HIV Quant blood assay within 5minutes. POC VL results 39 
were compared to the Roche COBAS CAP/CTM v2.0 (Roche) on plasma EDTA specimens, 40 
collected at the same visit. 41 
Results: Of 101 patients (mean age 41.4yrs and 62.4% females), 82% (81/99) generated 42 
quantifiable plasma VL values (median 251c/ml [2.4log copies/ml]) and 24% of these patients 43 
(19/81) had a VL>1000 cp/ml.  The Liat HIV Quant blood assay was easy to perform by a nurse 44 
at POC, but generated 97% (96/99) quantifiable results (median VL 5370c/ml [3.73log cp/ml]) 45 
of which 92% patients (88/96) VL were >1000cp/ml. The Liat HIV Quant blood assay 46 
misclassified 70% patients (69/99) at 1000cp/ml (100% sensitivity [confidence interval 47 
(CI):82.4%, 100%]); 13.8% specificity [CI:54%, 94%)]). If the VL ART monitoring threshold 48 
were raised to 5000copies/ml, the specificity improved to 53.8% (CI: 42.2%, 65%), and 53% 49 
patients (52/99) generated VL >5000cp/ml, resulting in 41% patients (41/99) misclassified. 50 
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Conclusion: The total nucleic acid extraction methodology of the Liat HIV Quant blood assay, 51 
increases the number of patients identified as ART failure at both 1000c/ml and 5000c/ml 52 
thresholds compared to plasma testing. Whole blood VL testing using the Liat HIV platform in 53 
niched clinic settings (such as maternity wards) would, however, be advantageous in the 54 
diagnosis of HIV. 55 
56 
57 
Introduction 58 
By the end of 2013, 12.9 million HIV infected people had accessed life-saving antiretroviral 59 
therapy (ARVs) globally (1). The Joint United Nations Programme on HIV/AIDS (UNAIDS), 60 
recently released the ambitious new treatment targets for 2020, called ‘90-90-90’, which aim to 61 
place 90% of all HIV-positive people on ARV (1). For limited resource, high HIV burden 62 
settings, meeting these goals will require substantial speed in resource scale up and 63 
programmatic adaptation (2). 64 
65 
With the recent changes to the ARV treatment guidelines, a viral load (VL) is now the preferred 66 
method for treatment monitoring and is recommended at month 6 following treatment initiation 67 
and then at 12 monthly intervals thereafter for identifying treatment failure and non-adherence 68 
(3). The current threshold for identifying virological treatment failure is a plasma VL result of 69 
more than 1000 copies/milliliter (cp/ml) or 3 log cp/ml. Anything above this threshold will result 70 
in the patient receiving adherence intervention (check for adherence compliance, tolerability and 71 
drug- drug interaction or psychological issues) (4) and a follow up plasma VL test 2 months later, 72 
which if confirmed at >1000 cp/ml, results in treatment switch to second line therapy (3). 73 
74 
212 | P  a g  e
At present, VL testing on plasma is laboratory-based and relies on high throughput 75 
instrumentation, infrastructure and trained technologists/technicians (5-7). Besides these 76 
constraints, logistical challenges are also present, such as the need for phlebotomists to draw 77 
blood and efficient specimen transport with cold chain storage (8), thus limiting access in many 78 
low- and middle-income countries (LMICs). A recent survey by the World Health Organisation 79 
(WHO) found that on average, one VL instrument was servicing 8,706 persons on ART in 80 
LMICs, demonstrating the need to not only improve access to VL testing but also scale up and/or 81 
extend existing capacity (9). 82 
83 
The need to diagnose high burden diseases in low resource settings where laboratory facilities 84 
may not be accessible is driving the need for alternative solutions to plasma VL testing. Dried 85 
Blood Spots (DBS), already used for early infant diagnosis (EID) (10-13), are being investigated 86 
to improve access to VL testing for treatment monitoring (14-18) as they reduce the complexities 87 
associated with plasma transport (19). DBS make use finger or heel stick blood specimens, 88 
thereby foregoing the need for trained phlebotomists. DBS are easy to transport at ambient 89 
temperature (20), but have reduced sensitivity due to small specimen input testing volumes (50-90 
100µl for DBS versus 200-600µl for plasma) (15, 16) or may over-quantify below a plasma VL 91 
of 1000cp/ml due to assay extraction and amplification  of integrated VL DNA and cell 92 
associated viral RNA (3). If a 5000 cp/ml threshold is applied, however, DBS have been shown 93 
to be reliable indicators of true virological treatment failure (20). 94 
95 
VL point-of-care testing (POCT) offers a further alternative to extend access to testing services 96 
(21, 22). Until recently, commercially available POC VL tests did not exist for HIV but major 97 
technological developments in the field have now seen many new assays and platforms in the 98 
pipeline (22, 23). One such POC VL technology under development is the Liat™ HIV Quant 99 
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Assay (developed by IQuum, Inc, Marlborough, MA, USA) which was acquired by Roche 100 
Molecular Systems, Inc. (Branchburg, NJ, USA) in 2014, to ensure scale up and market, and is 101 
being renamed the COBAS Liat analyser (24). 102 
Based on automated sample preparation, total nucleic acid extraction, amplification and real-time 103 
detection, the assay provides a quantitative, interpreted VL result in 35 minutes on whole blood 104 
(25).  An initial laboratory evaluation in South Africa on the HIV Quant plasma and whole blood 105 
assays gave 100% sensitivity versus plasma VL with decreased specificity on whole blood 106 
(41.2%) (26). 107 
108 
To date, the Liat™ analyser has not been evaluated within a clinical setting by the intended 109 
operator. The objective of this study was to investigate the option of extending laboratory plasma 110 
based VL testing with finger stick whole blood POCT testing, through: 1) evaluating the 111 
feasibility of nurse operated POC VL testing, within a busy ARV treatment clinic; 2) assessing 112 
the performance of the Liat™ Quant blood assay on whole blood specimens derived from finger 113 
stick, in comparison to plasma VL at the 1000 cp/ml and 5000 cp/ml thresholds. 114 
115 
Methods 116 
Ethics statement 117 
The study was approved by the Human Research Ethics Committee of the University of the 118 
Witwatersrand, Johannesburg, South Africa (protocol number M120143). 119 
Study site and patient enrolment 120 
HIV-positive patients attending the Themba Lethu ARV treatment clinic (Right to Care, Helen 121 
Joseph Hospital), Johannesburg, South Africa, for routine ART monitoring, were recruited by a 122 
study nurse when they presented at the phlebotomy room requiring a VL test. 123 
Study procedures 124 
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After patients received their venepuncture for standard-of-care (SOC), an additional finger stick 125 
specimen was obtained by the study nurse using the BD Microtainer® Contact-Activated lancet 126 
(21 G x 1.8 mm) (Becton Dickinson Diagnostics, Franklin Lakes, NJ, USA). The manufacturer 127 
recommended collecting finger stick blood directly into the supplied pasteur pipette and 128 
transferring into the Liat™ cartridge immediately, but due to the clinic workflow and need for 129 
patient enrolment and consent, this was not possible. Finger stick blood was therefore collected 130 
in an EDTAK3 microtainer tube (Becton Dickinson) and taken directly to a designated POC 131 
laboratory (adjacent to the phlebotomy room) within the clinic for POC VL testing on the Liat™ 132 
HIV Quant blood assay within 5 minutes of blood collection. The POC laboratory was 133 
established in order to avoid disruption of clinic workflow and because of space constraints 134 
within the phlebotomy room. Two Liat™ analysers were available for the study. 135 
Briefly, testing on the HIV Blood Quant assay involved transferring 75µl of whole blood from 136 
the EDTAK3 microtainer, using the supplied pasteur pipette (IQuum, Inc.), directly into the 137 
Liat™ cartridge opening, closing the cartridge cap, scanning the assay cartridge barcode and 138 
loading it into the Liat™ instrument. Quantitative whole blood results were available in 35 139 
minutes. No POC VL results were acted on, and patient management was per SOC. 140 
141 
Predicate laboratory testing 142 
All routine SOC VL testing was performed on plasma specimens at a SANAS (South African 143 
National Accreditation Service) accredited laboratory, the National Health Laboratory Service 144 
(NHLS) PCR laboratory, Johannesburg, on the Roche COBAS AmpliPrep/COBAS Taqman 145 
(CAP/CTM v2) (Roche Molecular Systems, Inc., Branchburg, NJ, USA). These results were 146 
used as the reference method for comparison of the Liat™ HIV Quant whole blood results. 147 
148 
149 
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Statistical Analysis 150 
Bland Altman (27) and percentage similarity (28) using MS Excel, STATA 12 and Medical 151 
Calculator (29) were used to determine assay accuracy (agreement) between the Liat™ HIV 152 
Quant blood assay and the CAP/CTM v2.0 on plasma. The sensitivity, specificity and 153 
misclassification of blood specimens on the Liat™ was also calculated compared to the 154 
CAP/CTM v2 using the 1000cp/ml and 5000cp/ml WHO cut-off values for virological failure (3). 155 
Qualitative characteristics of the assay were reported as: ease of use, error rates, space 156 
requirements and waste disposal. 157 
158 
Results 159 
Patient demographics  160 
A total of 101 patients were approached for inclusion into the study between the 2nd August and 161 
28th October 2013. The mean age of all participants consented and enrolled was 41.4 years 162 
(n=101) and 63 participants were female (62.4%). The median time participants had received 163 
ART at the time of enrolment was 3 years (mean 3.36 years). One patient was excluded from 164 
analysis due to insufficient blood flow from the finger stick and the Liat HIV Quant blood 165 
reported one invalid result (not repeated on a second finger stick as patient had left the clinic). 166 
167 
Description of study data 168 
Overall the Liat HIV Quant blood assay generated higher VL values compared to plasma based 169 
testing, with  65.7% (65/99) generating an absolute difference of >1.0 log cp/ml. 170 
Plasma specimens tested on the Roche CAP/CTMv2 plasma-based assay yielded 13% (13/99) as 171 
lower than detectable limit (LDL), 5% (5/99) as target detected but not quantified (<20 cp/ml) 172 
and 81.8% (81/99) generated a quantifiable result. Of those specimens generating a quantifiable 173 
result, 19 had VL>1000 cp/ml (3 log cp/ml) and would therefore have required adherence 174 
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counselling and a follow up VL in 8 weeks. The median plasma VL on the Roche CAP/CTMv2 175 
was 2.40 log cp/ml (or 249 cp/ml). 176 
Whole blood specimens tested on the Liat HIV Quant blood assay yielded 3% (3/99) specimens 177 
(as target not detected (TND) and 97% (96/99) had a quantifiable result, of which 91.6% (88/96) 178 
had VL>1000cp/ml. The median VL on the Liat HIV Quant blood assay was 3.73 log cp/ml (or 179 
5592 cp/ml). 180 
The distinction between the plasma and whole blood assays, visualised in figure 1, shows that 181 
13% of specimens reported by Roche CAP/CTMv2 as LDL were detectable by the Liat HIV 182 
Quant blood assay and all were reported as VL>1000 cp/ml. The Liat HIV Quant blood assay 183 
reported 3% of specimens as TND but these were all detected by plasma based testing on Roche 184 
as VL<1000 cp/ml (38, 102 and 320 cp/ml respectively; median 3.6log cp/ml).  This confirms the185 
Liat HIV Quant blood assay did not miss any patients with plasma VL>1000c/ml. 186 
187 
As described in Figure 2, at the current 1000 cp/ml treatment failure threshold, plasma VL 188 
results categorised 19 patients as treatment failures, whilst blood-based (total nucleic acid 189 
extraction methodology) testing categorised 88 patients as treatment failures. This generated a 190 
Liat HIV Quant blood assay sensitivity of 100% but a poor specificity of 13%, resulting in 191 
69.7% (69/99) total misclassification, all of which were upward misclassified compared to 192 
plasma VL. If the treatment failure threshold was adjusted to 5000 cp/ml [as for DBS (20)], 193 
based on Liat Quant blood testing, 52 patients (52.5%) would have required a follow up plasma 194 
VL. At this threshold, the Liat HIV Quant blood assay sensitivity reduced to 79% but specificity 195 
improved (53.8%). The total misclassification at the 5000 cp/ml threshold was 41%; 37 patients 196 
were upward misclassified and 4 patients were downward misclassified (plasma VL values were: 197 
1008c/ml, 1882c/ml, 2139c/ml and 2628c/ml). 198 
199 
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Analytical Performance of the Liat™ HIV Quant blood assay 200 
Overall, the Liat HIV Quant blood testing showed a high (21.6%CV) percentage similarity 201 
coefficient of variation and a mean log bias of -1.0 log cp/ml (SD 0.91c/ml).  Figure 2 further 202 
illustrates the analytical performance of the Liat HIV Quant blood compared to the Roche 203 
CAP/CTMv2 on plasma, categorized according to the 1000 cp/ml and 5000 cp/ml treatment 204 
failure thresholds. The overall mean bias for the Liat™ HIV Quant blood assay was acceptable at 205 
values >1000 cp/ml, however the absolute numbers of specimens in this data set is low for 206 
typical evaluation studies.   207 
208 
Qualitative results 209 
Installation of two Liat analysers was completed by the study nurse and training using 210 
instructions provided by the manufacturer was completed within an hour by a scientist. The 211 
analysers have a small footprint of approximately 11.4 cm (wide) by 19 cm (high) by 24.1 cm 212 
(deep) and weighed approximately 3.8kg, requiring little bench space. All test cartridges were 213 
stored in a 4°C fridge available within the POC laboratory for general use. The study nurse was 214 
able to test 4-6 specimens per analyser per day, but this also included patient consenting and 215 
enrolment into the study. Two indeterminate VL results were reported on the Liat HIV Quant 216 
blood assay, but only one could be repeated on a second finger stick specimen as the patient was 217 
still available. No errors were reported, and all Liat HIV Quant blood assay cartridges were 218 
easily disposed in the standard clinic biohazard waste removal bins. 219 
220 
221 
222 
223 
224 
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Discussion 225 
A laboratory evaluation of the Liat HIV Quant plasma assay demonstrated that the technology is 226 
interchangeable with existing high throughput VL platforms in terms of performance but due to 227 
the total nucleic acid extraction protocol which detects cell associated DNA and RNA, the whole 228 
blood assay over quantified VL in <4 log cp/ml range (26). This current study aimed to quantify 229 
the performance of the Liat™ HIV Quant blood assay in a clinic setting, receiving majority ART 230 
experienced patients, and determine the feasibility of a nurse performing POC VL testing. 231 
Similar to laboratory findings, in this urban clinical study setting, the Liat HIV Quant blood 232 
assay operated by a nurse on finger stick derived whole blood specimens, showed an overall 233 
increased detection of VL below the 5000cp/ml threshold compared to plasma VL on the Roche 234 
CAP/CTMv2. This was exacerbated by the fact that 19% patients visiting this clinic would be 235 
required to have follow up VL testing using existing plasma based technologies, but 88% on 236 
whole blood VL testing. Overall agreement of the Liat HIV Quant blood assay compared to 237 
plasma testing on this patient group (ART experienced) was above the acceptable level of 2.9% 238 
similarity CV (30)(21.56% CV) with increased variability (SD of the bias of 0.91log c/ml). 239 
When categorised according to the two treatment failure thresholds, Liat HIV Quant blood 240 
showed acceptable bias with plasma >1000 cp/ml and >5000 cp/ml. 241 
242 
Three patient specimens were undetectable by the Liat HIV Quant blood assay but all were 243 
below the 3 log c/ml threshold on plasma based testing and would therefore not have had any 244 
effect on the clinical management of these patients. The Liat HIV Quant blood assay did, 245 
however, detect 13 patients as containing quantifiable HIV which were all lower than detectable 246 
limit by plasma-based testing. 247 
248 
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The specimens collected in this study typically represent those from ART monitoring patients 249 
visiting an urban clinic in South African. Within this setting, the Liat HIV Quant blood assay 250 
clinically misclassified 69.7% of VL results as treatment failures (non-adherence) at the 1000 251 
cp/ml threshold (88 patients identified as treatment failures by Liat HIV Quant blood assay 252 
versus 19 patients truly identified by plasma VL) but had 100% sensitivity compared with 253 
plasma VL. Thus, use of the Liat HIV Quant blood assay using the current guidelines (4) would 254 
translate into a substantial increase in the number of patients requiring adherence counselling and 255 
return clinic visits for follow up plasma VL testing, which would increase costs to patients, 256 
impact patient clinic flow, and increase laboratory plasma testing costs and testing volumes. The 257 
Liat HIV Quant blood assay, however, did not miss any patients that based on plasma testing 258 
would truly require treatment switching.  If the virological treatment failure threshold were to be 259 
elevated to 5000 cp/ml for whole blood monitoring, 52.5% of the Liat HIV Quant blood VL 260 
results would have been misclassified, 4% of these patients who were true virological failures 261 
would have been missed, although their plasma VL values did not exceed 3000c/ml. 262 
263 
In our setting, the study nurse performing the POC VL testing had no prior laboratory experience 264 
and was easily trained on the operation of the Liat platform (including finger stick collection, 265 
waste disposal, spill clean-up and safety) within an hour. Besides the instruction provided by the 266 
supplier, an easy to understand standard operating procedure was also developed and found to be 267 
valuable. The Liat analyser can be accommodated into the clinic workflow by either being 268 
placed directly into the phlebotomy room or placement elsewhere and finger stick blood 269 
collected into a microtainer EDTA tube, as was the case with our study. The study nurse was 270 
able to test 4-6 patients per instrument per day (including patient enrolment and consent) but the 271 
Liat has the potential to perform 15 samples per 8 hour day (22), and includes battery 272 
functionality and full connectivity. As most patients attend the clinic in the morning the majority 273 
220 | P  a  g  e
of POCT would need to be performed by midday (manuscript under review), which would 274 
require reengineering the clinic workflow to accommodate VL testing and ensure optimal patient 275 
throughput. The only current aspect of Liat HIV POC testing (either plasma or blood) which 276 
could potentially be seen as a drawback is the need for cold-chain storage of the test cartridges, 277 
requiring access to a fridge, which will require strict control in a clinic environment. 278 
279 
In South Africa, the National Health Laboratory Service (NHLS) provides testing services to 280 
more than 80% of the population and currently has 17 high throughput, centralised VL 281 
laboratories that manage ~3million VL tests per year. POC testing would never replace this 282 
current workflow, but certainly can extend this service and thereby help to meet the ‘90-90-90’ 283 
targets. Provision of a VL result in 35 minutes (as for Liat HIV Quant blood protocol) directly in 284 
the clinic will allow clinicians to decide on the need for appropriate adherence counselling and 285 
follow-up visit for VL testing or immediate discharge of the patients from the clinic until their 286 
annual routine next visit. However, this study has alerted the fact that VL tests for monitoring 287 
that are based on total nucleic acid extraction, performed on whole blood specimens, will 288 
increase the misclassification rate of patients identified as ART failures.  Alternatively, 289 
introducing plasma-based Liat HIV Quant plasma POC VL testing which is interchangeable with 290 
existing VL platforms in terms of performance (26) may be more effective, even though it will 291 
require the need for specimen centrifugation. Extending current plasma based VL services, 292 
would therefore need to take these pros and cons into consideration. 293 
The ability of the Liat HIV Quant blood assay to measure proviral DNA as well as cell 294 
associated RNA would, however,  make it advantageous in diagnosing HIV in key populations 295 
such as babies at birth from HIV-positive mothers (26) and may warrant a place as a niched POC 296 
VL test. Currently, VL testing for early HIV infant diagnosis is fraught with challenges (20); 297 
laboratory testing for infants is not always available and even though qualitative testing is 298 
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becoming more accessible through the use of DBS, turnaround times may take weeks (31). This 299 
together with full costing remains to be addressed. 300 
301 
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List of figures 403 
Figure 1: Scatter plot of log transformed VL values (y axis) for the Liat™ HIV Quant whole 404 
blood and the Roche CAP/CTMv2 assays, sorted according to increasing VL on plasma VL (x 405 
axis). a) Red dotted line indicates the current 1000 cp/ml (3 log cp/ml) treatment failure 406 
threshold used for plasma VL and b) the orange dotted line indicates the 5000cp/ml (3.7log 407 
cp/ml) threshold recommended for dried blood spot testing (20). 408 
409 
Figure 2: Bland-Altman difference plot of Liat™ HIV Quant blood assay versus Roche 410 
CAP/CTMv2 showing the mean difference and SD in the <1000c/ml, 1000-5000c/ml and 411 
>5000cp/ml ranges. 412 
413 
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Sensitivity: 100% [95% CI: 82.4% - 100%] 
Specificity: 13.8 [95% CI: 7.1% - 23.3%] 
Sensitivity: 79.0% [95% CI: 54.4% - 94.0%] 
Specificity: 53.8 [95% CI: 42.2% - 65.0%] 
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Figure 1: Scatter plot of log transformed VL values (y axis) for the Liat™ HIV Quant whole 
blood and the Roche CAP/CTMv2 assays, sorted according to increasing VL on plasma VL (x 
axis). a) Red dotted line indicates the current 1000 cp/ml (3 log cp/ml) treatment failure 
threshold used for plasma VL and b) the orange dotted line indicates the 5000cp/ml (3.7log 
cp/ml) threshold recommended for dried blood spot testing (20). 
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Figure 2: Bland-Altman difference plot of Liat™ HIV Quant blood assay versus Roche 
CAP/CTMv2 showing the mean difference and SD in the <1000c/ml, 1000-5000c/ml and 
>5000cp/ml ranges. 
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CHAPTER 6: POLICY DEVELOPMENT 
All the components described above have contributed to the development of the current 
status of POCT in South Africa (2013), entitled ‘Point of Care Testing: Position paper Forum 
Report to support National strategic Plan for POCT for the management of HIV and TB in 
South Africa’. This paper initiated the national policy discussion with a scientific basis. 
(Complete document available on request from the candidate). 
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CHAPTER 7: CONCLUDING CHAPTER 
7.1 DISCUSSION 
Great strides have been made in the fight against the HIV/AIDS epidemic. As a 
consequence of the success of the ART program, there was a resultant 44% decline in HIV 
infection rates between 2001 and 2012 and two of the hardest hit areas, Southern Africa and 
Central Africa, have seen declines of 48% and 54% respectively (1). Despite these 
achievements, there were still 2.1 million new HIV infections reported globally in 2013; 1.5 
million of these were reported in sub-Saharan Africa (1), where it is estimated that three 
quarters of HIV infected adults have not achieved viral suppression due to gaps and 
shortfalls in service delivery (2). Expansion of ART programs will be imperative to achieving 
the ‘90-90-90’ treatment goals, which in turn will require expanded laboratory capacity.  
South Africa is unique in terms of both the high prevalence of HIV and TB co-infection rates 
and the availability of centralized laboratory infrastructure and capabilities to address high 
testing demands. Although capacity in these centralized facilities can handle high throughput 
volumes through the use of sophisticated laboratory equipment, expertise and resources, 
there is still an uneven distribution of these tertiary reference laboratories throughout the 
country, with most servicing industrialized urban areas (3). Approximately 19 million South 
Africans live in rural areas according to the World Bank database (4), where barriers to 
healthcare access include high travel costs and travel distances to clinics (5), long queues in 
clinics (6) and disproportionate healthcare costs (5). Many of these rural areas are serviced 
by PHC clinics that lack infrastructure, skilled workers and resources and are only capable of 
performing technically non-demanding tests (such as rapid HIV tests and pregnancy tests). 
In theory these tests, while easy to perform, are notorious for their poor quality (7) and the 
improvement of testing quality is now a national focus. 
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To address these challenges, new testing strategies such as POCT, which look beyond 
expansion of centralized testing capacity to improve access to healthcare services and 
achieve the global ‘90-90-90’ goals, are being investigated (8). In South Africa, these 
challenges may need to be addressed through a hybrid model, much like for CD4 testing (9). 
In preparation for this, the current work, as part of a GCC funded project, evaluated new 
diagnostic technologies for HIV and TB, developed essential quality components for POCT 
and determined the feasibility of multiple POCT in the field through the presentation of 11 
conference abstracts, 9 publications published in peer reviewed journals, two submitted and 
under review and 1 contribution to a policy document. This work culminated in support of a 
randomized clinical study assessing the feasibility of using multi-disciplinary POCT versus 
standard of care to support ART treatment for HIV infected individuals in PHC clinics (to be 
reported on in 2015). 
7.1.1 ENGAGING GOVERNMENT AND ASSESSING CLINICAL NEED 
Before embarking on widespread POC implementation in South Africa, the NDoH required a 
concrete recommendation for the country on what POC tests would best address the clinical 
needs of the country and how best to implement them. A POCT forum was organized by the 
NHLS and hosted by the NDoH and involved key stakeholders (NDoH, NHLS, non-
governmental organizations (NGO’s), clinical advisory groups and partner organizations) in 
an effort to establish the context for POC implementation in South Africa.  
The key challenges likely to emerge during large-scale POCT implementation efforts were 
presented by the literature review in Chapter 2. The review addressed the clinical needs 
based on in-country treatment guidelines at the time and placed a strong emphasis on CD4 
and VL testing. The evolving role of VL testing for treatment monitoring and the potential of 
moving to ‘test and treat’ strategies however, has led to scale up of VL testing services 
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becoming even more important in achieving the ‘90-90-90’ treatment goals (10). The 
necessity of other core tests (haematology, biochemistry and opportunistic infections, 
especially TB) was also acknowledged for the management of HIV-positive individuals, and 
hence formulated the need to develop a ‘multiple POCT’ policy for HIV and TB integration of 
services.  
7.1.2 THE EVALUATION OF NEW TECHNOLOGIES FOR THE DIAGNOSIS 
AND/OR MONITORING OF HIV AND TB 
Challenges that may hinder national POC implementation efforts will be the selection and 
evaluation of suitable POC tests from the plethora of upcoming HIV and TB technologies in 
the development pipeline. To this end, two plasma-based VL POC technologies were 
evaluated. The Liat™ HIV-1 Plasma Quant VL assay (IQuum Inc, now Roche Molecular) 
(presented in Chapter 3.1) was evaluated against two in-country VL predicate platforms. The 
Liat™ plasma assay showed good performance with 100% sensitivity at the 1000 copies/ml 
treatment failure threshold and no virological failures were missed. The second plasma 
based POC VL assay evaluated was the Xpert® HIV-1 VL on the GeneXpert® platform 
(Cepheid, Sunnyvale, CA). Preliminary evaluation data on the Xpert® HIV VL has been 
presented at various forums (11, 12) and shows acceptable performance in comparison to 
the Roche COBAS® CAP/CTM version 2 and does not miss any true virological failures. 
Both the Liat™ and Xpert® assays thus appear promising candidates and could be 
interchangeable with existing in-country predicate technology in terms of performance, but 
have limitations. As both are plasma-based, the requirement for a centrifuge make neither 
suitable for a ‘true’ POC environment and thus may be better placed within a district or 
community level facility.  
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Two further POC VL assays, both blood-based, were therefore also investigated; the Liat™ 
HIV-1 Blood Quant VL assay (presented in Chapter 3.1) and the Alere™ q HIV-1/2 assay 
(Alere™) (13). Although these assays were easy to perform, both overestimated VL (much 
like DBS,) due to their total nucleic acid (TNA) extraction protocols. One can therefore 
expect a 10.6% and 45% upward misclassification with the Liat™ and Alere™ q assays, 
respectively (13). The implications of such overestimation would lead to more patients 
identified as treatment failures, thus increasing the need for follow-up plasma VL testing and 
increased programmatic costs. This suggests that a change in the clinical on-site treatment 
algorithm would probably be required if used for ART monitoring but would likely be difficult 
to implement. The application of these POC VL assays could therefore be in a niched 
environment; providing a blood-based POC VL test within a maternity ward to diagnose HIV 
in new-borns at risk of further transmission from HIV-positive mothers, and plasma based 
POCT for mothers to reduce risk of HIV transmission. 
When investigating options for increasing access to VL testing, it should be acknowledged 
that POCT may not be the only option. Alternative strategies to improve the logistical 
challenges around transportation of blood specimens from clinics to laboratories are also 
warranted as centralized testing is always more controlled and affordable in the laboratory 
environment. The use of DBS for ART treatment monitoring has been investigated on a 
longitudinal cohort of patients and proven as valuable as plasma VL for detecting patients 
failing treatment at the 1000 copies/ml threshold (14). Blood collection, transport and storage 
technologies, such as Primestore media (Longhorn Vaccines and Diagnostics, San Antonio, 
TX, USA) may also present a viable option (15). 
In terms of TB diagnosis, limitations to conventional testing methods have made it 
notoriously difficult to diagnose, especially among HIV-positive individuals (16). In 2010, the 
world geared up for a game-changer in TB diagnosis, the molecular-based GeneXpert® 
MTB/RIF assay. The first publications on GeneXpert® described its analytical performance 
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(17, 18) and the demonstration study by Boehme (19) illustrated the performance of the 
GeneXpert® in 10 countries. There was however, little guidance on the implementation of 
the Xpert® MTB/RIF assay into national TB programs, particularly in high HIV and TB 
endemic regions such as South Africa. To address this, the Xpert® MTB/RIF assay was 
evaluated in Johannesburg in order to inform policy development for TB diagnosis in South 
Africa (Chapter 3.2).  The laboratory performance of the Xpert® MTB/RIF against several 
current TB diagnostic assays on a single sputum specimen, demonstrated the superiority of 
the Xpert® MTB/RIF. More importantly, the Xpert® MTB/RIF did not show reduced 
sensitivity in HIV-positive specimens. These findings gave confidence to the South African 
NDoH to proceed as the first country with a single, national, phased implementation plan to 
replace smear microscopy with the Xpert® MTB/RIF as the first line TB diagnostic (20, 21). 
Even though the GeneXpert® was placed into smear microscopy centres due to the 
prohibitive cost of placement at POC (22), many groups have provided compelling data on 
use of the Xpert® MTB/RIF in clinical settings, showing same day treatment initiation and 
shorter time to treatment (23-25).  
Use of the Xpert® MTB/RIF has also expanded to paediatrics/childhood TB, a process which 
has historically been hampered by the type of specimen which can be collected, multiple 
samplings over several days (26), poor quality and low volume of specimens (27), and 
facilities which are ill-equipped to perform induced sputum collection. Initial evaluation 
studies using the Xpert® MTB/RIF in paediatrics, performed testing on laboratory 
decontaminated and concentrated specimens (27-31). Through a study performed by the 
candidate, the technicalities of using the Xpert® MTB/RIF for pediatric TB diagnosis within a 
clinical setting, at the POC, on raw sputum specimens was investigated (32) and showed 
that the majority (67%) of “routinely obtained” sputum specimens from children (≤14; n=484) 
were below the required volume for Xpert® testing and required ‘topping up’ with saline. 
Even though the Xpert® MTB/RIF outperformed smear microscopy, it would be difficult to 
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implement as a replacement for smear and culture in paediatrics due to the high rejection 
rate of low volume specimens and lower sensitivity compared to culture (32). Numerous 
studies have since been presented on implementation of GeneXpert® for pulmonary (33-37) 
and extra-pulmonary (38-40) TB diagnosis in children.  
In an attempt to address the lack of GeneXpert® testing at POC in the South African model, 
the candidate investigated an “equipment-free” TB diagnostic assay that appeared close to 
market, the EasyNat® MTB detection Kit (Ustar Biotechnologies, Hangzhou, Ltd). An initial 
laboratory evaluation of the technology yielded excellent sensitivity and specificity but the 
testing process was found to be very laborious and in the current format and not suitable for 
POCT (41). The difficulty too, within a program that is GeneXpert® dominated, is the inability 
of some POC tests to simultaneously investigate RIF (and INH) drug susceptibility, which the 
Xpert® MTB/RIF does for RIF.  
7.1.3 DEVELOPING THE PRINCIPLE COMPONENTS TO ENSURE BEST 
PRACTISE FOR MULTI-DISCIPLINARY POCT: QUALITY, SITE 
READINESS, TRAINING 
There is a general lack of guidelines detailing the quality, infrastructure and training 
requirements for POC implementation (42), specifically for South Africa. To address this 
need, the candidate investigated these requirements in order to inform best practise for 
quality POCT to complement exisiting laboratory testing.  
Ensuring the quality of POCT results in the field is a major challenge, especially when 
current HIV rapid testing in clinics is fraught with problems (43). As a starting point, the 
candidate presents the development of two distinct but compatible quality monitoring 
programs in Chapter 4, one for molecular HIV VL platforms (Chapter 4.1) and the other for 
molecular TB platforms (Chapter 4.2).  The SAVQA (South African Viral Quality Assurance) 
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panel was originally developed in response to the need for ensuring newly placed high 
throughput VL testing platforms in centralized laboratory facilities were ‘fit for purpose’. The 
usefulness of this standardized HIV-1 panel was quickly realized as a tool for assessing the 
performance of newly developed VL POC technologies (44-47) against existing in-country 
technologies. To date, the panel has been successfully used to verify the Liat™ HIV-1 Quant 
(IQuum, Inc), Alere™ q HIV-1/2 (Alere) and the Xpert® HIV-1 VL (Cepheid) assays prior to 
laboratory evaluation (48, 49). Through collaboration with numerous VL technology 
development groups, this panel will continue to be manufactured and supplied to aid 
developers in assessing their product for the South African market, and will also be further 
developed for use by healthcare workers at POC. 
The rapid national implementation of the GeneXpert® technology into smear microscopy 
sites informed the need for a quality monitoring system (21), particularly since its use by 
numerous NGO’s (Wits Reproductive Health and Research Institute, Right to Care, Aurum 
Institute) at the POC and expansion of the program by the NHLS into correctional services 
and mobile vans (50). The Dried Culture Spot (DCS) verification program was developed in 
2011 to ensure that newly placed GeneXpert® instruments were ‘fit-for-purpose’ and has 
successfully been used to verify >4,600 GeneXpert® modules at laboratory and clinical 
sites. Through a public/private partnership between the University of the Witwatersrand and 
Cepheid, verification panels are now shipped together with new GeneXpert® instruments to 
test every module installed in the field, both nationally and internationally. The DCS program 
used for verification of the GeneXpert® was endorsed by the WHO and the Global Laboratory 
Initiative in 2014. Further to this, the DCSs were launched as an EQA program in 2013, to 
ensure ongoing quality and accuracy of Xpert® MTB/RIF patient results (51). The EQA 
program is offered as three panels per year and currently supports 207 NHLS, 2 private and 2 
AIDS Clinical Trial Group (ACTG) laboratories in South Africa. Additionally, the program is 
also supporting 289 sites in 20 different countries worldwide.  
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The success and versatility of the DCS program in the field is apparent by its use in remote 
settings and mobile laboratories by non-laboratory trained staff (Chapter 4.3), and in its 
application to other TB diagnostic technologies, most notably the Genotype MTBDRplus 
LPA (Chapter 4.4). In light of this work, a collaboration has been established with the 
National Institute of Health funded ACTG in the United States, in order to set up a pilot 
trial of the DCS material for ACTG sites performing line probe testing. Interest in the 
product has also been expressed by other TB platform/assay developers, such as 
Abbott Molecular (Des Plaines, IL, USA) for their upcoming high throughput MTB assay. 
This work has proven the versatility and ease of use of the matrix from centralised 
laboratories to decentralised POC sites. 
The Research and Development team involved in the development of the DCS program, has 
been acknowledged for their work through three awards: the NHLS Top Award for Innovation 
in 2013 (at the National Innovation Annual Awards Ceremony), the Gauteng Accelerator 
Program (GAP) Biosciences Award in 2014 (52) and a special Social Impact award for Africa 
held in Morocco in 2015 (53).  
To ensure the appropriate infrastructure and training needs for POCT are met, the candidate 
developed a POC implementation checklist specifically designed to assess the South African 
PHC clinic readiness prior to multidisciplinary POC placement for HIV and TB service 
integration. This checklist assesses variables such as clinic space and storage availability, 
infrastructure, security, ventilation, power supply and connectivity (54, 55) (Appendix C) (not 
ISO requirements) and has been adopted and modified for use by the NHLS NPP for 
assessment of POC laboratory sites prior to GeneXpert® MTB/RIF installation. In terms of 
training of POC operators, the golden rule is to always assume no prior experience (56). The 
candidate developed a simple training package with the non-laboratory user in mind, which 
included easy-to-follow standard operating procedures, quick reference and workflow charts 
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(Appendix D1 and D2), maintenance and stock templates, a practical training module and a 
‘clinic starter’ kit (including basic consumbles required to perform POCT) (57). The standard 
operating procedures and reference charts developed are currently being used by the NPP 
trainers for GeneXpert® training. 
Although not part of the candidates work, central to ensuring the quality of POCT results will 
be the need for connectivity (58). POCT will need to fit within the current national LIS which 
connects diagnostic instruments in the public sector directly and then stores all results 
generated in a central data warehouse to allow central management and monitoring. 
Connectivity will also allow for a centralised system to coordinate and ensure stock supply.
7.1.4 DETERMINING THE FEASIBILITY OF MULTIPLE POCT FOR HIV AND 
TB SERVICE INTEGRATION IN THE FIELD 
In Chapter 5.1, the feasibility and accuracy of nurse performed multi-disciplinary POCT 
within a clinical setting is demonstrated. A key component to ensuring the success of this 
study was the selection of appropriate clinics using the site assessment checklist and 
thorough training of non-laboratory staff using the developed POC training material. This 
was the first study in South Africa to demonstrate how a dedicated nurse was able to 
perform multidisciplinary POCT as accurately as laboratory testing on multiple analytes. This 
study highlighted the fact that introduction of POCT into a clinic led to a notable increase in 
daily duties for the POC staff. With clinic nurses already experiencing work-related stress 
and burnout (59, 60), a new cadre of technical staff specifically for POCT will be needed and 
this level of staff will depend on the site and complexity of the POC tests required. In this 
study, all POCT was performed on a single venous specimen. POC tests are however, 
designed for use on minimally invasive specimen types such as finger sticks (61) in order to 
reduce complexity of the testing process. In South Africa, which has multiple testing 
requirements for ART initiation and monitoring and more than 50% of patients attending an 
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ARV treatment clinic for routine monitoring require three or more tests per clinic visit, this 
creates unique challenges. Subsequently, the feasibility and acceptability of performing 
multiple finger sticks for multidisciplinary POCT was addressed in two further studies 
(Chapter 5.2 and 5.3). The first, investigated whether performing multiple POC tests (CD4, 
Hb, Cr and ALT), each on a separate finger stick, would be feasible for the nurse and 
acceptable to the patient. Not only was a dedicated nurse able to perform multiple finger 
sticks and the relevant POCT required on a patient easily and accurately, but the process 
could be simplified by performing all POC tests on a single finger slice (lancet designed for 
CD4 testing to prevent lymphocyte degradation). Interestingly, patients also preferred having 
even multiple finger sticks to having a venepuncture.  
This study provided important insight for POC platform developers in designing their assays 
and determining the maximum blood volume that could be collected from a single finger 
stick. As a direct consequence of this work, a collaboration was established with 
Northwestern University and NWGHF to initiate a second study to investigate maximum 
blood volumes from a single finger stick (Chapter 5.3). Findings have influenced the design 
of a blood collection device for a new POC VL platform under development by Northwestern, 
namely the Savanna POC VL (45).  
The CD4 venous and capillary performance evaluation (nurse versus laboratory) results from 
Chapter 5.2 have been included in a meta-analysis of the PIMA CD4 platform (62) and the 
PhD candidate is subsequently a member of the PIMA CD4 consortium. 
The feasibility of a nurse performing POC VL testing on a finger stick specimen within a busy 
ARV treatment clinic was later demonstrated to determine whether the technology has the 
potential to extend existing laboratory VL testing (presented in Chapter 5.4). In the field, the 
assay was easy to perform but showed greatly increased detection of VL specifically at the 
1000 copies/ml treatment failure threshold (70% misclassification); this effect was minimised 
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but still apparent when the threshold was brought up to 5000 copies/ml (41% 
misclassification). Again, this highlights the potential value of the assay for diagnosis of HIV 
in key populations, rather than use for treatment monitoring. 
7.1.5 POLICY DEVELOPMENT 
Much of the work presented by the candidate contributed towards the development of a draft 
National policy document (Chapter 6) in support of the national strategic plan for POCT for 
the management of HIV and TB in South Africa (63).  
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7.2 CONCLUSION 
Multidisciplinary POCT for HIV ART (initiation and monitoring) and TB (diagnosis) service 
integration is feasible and accurate, if performed in a well-managed clinic by dedicated, well-
trained staff. To achieve quality POCT results, appropriate training, quality and data 
management systems need to be in place. Although the current work details the laboratory 
and clinical evaluation of a few POC technologies, ultimately the choice of platform to 
implement will depend on the needs of the population in which they are intended as well as 
the ability of the technology supplier to meet testing demands. Ideally, the chosen POC 
technologies should be rapid and easy to perform, require minimal training and no 
specialized laboratory set up, and reagents should be stable and temperature independent, 
if possible. Few technologies currently meet these criteria and based on South Africa’s 
testing volume needs, a hybrid model that includes POCT to extend the existing laboratory 
service footprint, could help achieve the ‘90-90-90’ goals. Performance evaluations of new 
POCT technologies will need to be ongoing based on availability. Alternative models which 
will improve logistics around specimen collection and transport and mobile health (mHealth) 
solutions which utilise mobile phones to increase access to patients, are also providing 
promise as a strategy for health systems strengthening (64).  
Although the focus of the current work was on HIV and TB, in reality the life expectancy of 
HIV-positive individuals is increasing, but so too are the frequency of co-morbidities such as 
diabetes, non-AIDS defining cancers, cardiovascular and metabolic diseases (65, 66). These 
will also need to be taken into account when expanding and integrating the repertoire of POC 
tests to be implemented. 
Beyond the scope of the current work, the need for cost effectiveness and clinical 
effectiveness studies cannot be overlooked. Overall, POCT has been found to be more 
costly than laboratory testing (67), but answers as to whether the incremental costs of POCT 
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implementation will have added value requires measurement and comparison of patient 
outcomes and impact through clinical trials. 
In a country such as South Africa, which has unprecedented numbers of HIV and TB-positive 
persons, the ‘90-90-90’ goals will require multiple, integrated interventions and significant 
investment and innovations to reach the objectives by 2020. POCT will form ‘part of’ the plan, 
but will also require innovative strategies around linkage to care.  
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7.3 APPENDICES 
7.3.1 APPENDIX A 
The South African national adult pulmonary TB diagnostic algorithm and interpretation. 
Adapted from the National Tuberculosis Management guidelines 2014 (68). 
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7.3.2 APPENDIX B 
The national HCT algorithm according to the South African NDoH (adapted from (69)). 
HIV Rapid test 
Result: HIV 
Positive 
Confirm with a 2nd 
rapid  
test 
2nd test Positive 
(final result 
positive 
Patient gets a TB 
screen, CD4 
count, Cr and 
HBV test on same 
day 
2nd test negative 
(final result 
indeterminate 
HIV ELISA is 
performed to 
check 
Result: HIV 
Negative 
Repeat HIV rapid 
test in 3 months 
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7.3.3 APPENDIX C 
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7.3.4 APPENDIX D1 
An example of a quick reference chart developed for use of the PIMA CD4 at POC. 
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7.3.5 APPENDIX D2 
An example of a quick referecne chart deveopled for use of the HemoCue Hb at POC. 
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7.3.6 APPENDIX E1 
Ethical clearance certificates. 
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7.3.7 APPENDIX E2 
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7.3.8 APPENDIX E3 
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7.3.9 APPENDIX E4 
